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An estimated 1.67 million people died of tuberculosis (TB) in 2016 and it is a threat to human 
life on a global-scale. To shorten current treatments and battle drug resistant strains it is 
important to discover and develop new drugs against the causative agent, Mycobacterium 
tuberculosis. 
Phenotypic screens have delivered potent hit and lead molecules in the past but the need to 
target new pathways in M. tuberculosis metabolism to circumvent pre-existing drug 
resistance mechanisms. The decaprenyl-phosphorylarabinose (DPA) biosynthetic pathway 
produces irreplaceable building blocks of the unique mycobacterial cell wall structure. 
Decaprenyl-phosphorylribose (DPR) Epimerase sub-units 1 and 2 (DprE1 and DprE2) are 
essential enzymes of this pathway. Whilst DprE1 has received much attention, however 
DprE2 has been overlooked as a potential drug target. 
In this thesis the role of a small disordered region of DprE1 in ligand binding and 
physiological function has been investigated. This region appears to interact with the 
substrate and based on enzyme activity assays, physiological importance of specific residues 
was found to be in line with the level of conservation between species.  
In addition, a high-throughput screen against a DprE2 overexpressing M. bovis BCG strain 
has been utilised to discover new hit compounds against this target, coupled with the 
development of an enzymatic assay to evaluate specific DprE2 inhibition. The screen 
resulted nitrofuran hit compounds that probably act as prodrugs, which was indicated by 
spontaneous resistant mutants resembling the mutations necessary to activate new TB pro-
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1.1 Tuberculosis disease 
1.1.1 Current global status 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) 
and is the leading cause of death by a single infectious agent in the world (WHO, 2017). The 
incidence of tuberculosis was estimated to be 10.4 million cases globally in 2016, most of 
which were from South-East Asia and Africa (WHO, 2017). Current treatment failure rates 
are estimated to be around 17%, which can increase by infection with drug-resistant strains 
of MTB. Tuberculosis infection in 2016 resulted in over 1.67 million deaths, with TB now 
considered within the Sustainable Development Goals developed by the United Nations and 
specifically addressed in the End TB Strategy by the World Health Organisation (WHO, 
2017). 
 
Figure 1.1. Global trends in TB incidence and mortality rates in recent years. (WHO, 
2017)). Shaded areas represent uncertainty intervals. 
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Owing to global coordinated efforts, tuberculosis incidence is on the decline (see Figure 
1.1.). Current initiatives are focusing on speeding up this trend, among other means, by 
improving prevention, diagnosis, increasing financial contribution and resources, setting up 
a monitoring framework, addressing HIV co-infection, and specifically preventing an 
epidemic of drug-resistant TB (WHO, 2017). 
Drug-resistance of pathogenic bacteria is a worldwide and pressing matter. Inadequate drug 
treatment of tuberculosis has given rise to resistance against first-line drugs in tuberculosis 
therapy and led to multi-drug resistant (MDR) and extensively drug resistant (XDR) strains. 
MDR-TB refers to infections by strains that are isoniazid (INH) and rifampicin (RIF) 
resistant, while XDR-TB strains are resistant to both INH and RIF, and in addition resistant 
to a fluoroquinolone (like moxifloxacin), and at least on second-line injectable agent (Chan 
E.D. and Iseman M.D., 2008). In 2016, approximately 600 000 new cases of TB were RIF 
resistant and 490 000 cases were of MDR-TB. Approximately, 78% of global drug-resistant 
cases are estimated to never receive the required care and specific drug regimen (Chan E.D. 
and Iseman M.D., 2008).  
Drug resistant tuberculosis consequently has a worse treatment outcome than drug sensitive 
strains.  The current treatment against MDR and XDR-TB with second-line drugs has 
success rate of 52% for MDR-TB, and 28% for XDR-TB as determined by latest cohort data 
from 2013 by the World Health Organisation. A key issue is that the treatment is more time 
consuming. 
Clinically, another complication within the last 25 years is the frequency of TB co-infection 
with the human immunodeficiency virus (HIV), which requires special patient management 
(WHO, 2017). In immunocompromised patients with HIV infection a latent TB infection is 
more likely to progress into an active TB infection (Getahun et al., 2015). Furthermore, drug 
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interactions and toxicity are even more severe due to simultaneously administered TB drugs 
and anti-retroviral therapy. 
Another important comorbidity is caused by diabetes mellitus. Diabetes is listed among risk 
factors by the WHO in tuberculosis infections, along with unhealthy alcohol consumption, 
smoking and undernourishment (WHO, 2017). Diabetes is associated with increased risk of 
tuberculosis (Jeon and Murray, 2008). The interconnection of the two illnesses is not 
completely understood, but as a general expectation the increase in living standards and 
changes in dietary habits, the number of diabetics will rise in the future enhancing 
tuberculosis susceptibility on a global population level (Jeon et al., 2012). 
 
1.1.2 Historical background of TB 
 
Tuberculosis is an ancient disease. Based on tracking of genetic mutation markers the most 
recent common ancestor of the Mycobacterium tuberculosis complex (MTBC) emerged 
about 70,000 years ago in the upper paleolithic age in North-East Africa (Comas et al., 
2013). The group of MTBC species share an exceptional genetic similarity at the nucleotide 
level  and consist of eight obligate pathogens (Comas et al., 2013). MTB, Mycobacterium 
africanum and Mycobacterium canettii prefer a human host organism, while others like M. 
bovis prefer an animal host, however direct contact with these animals can transfer them to 
humans and develop symptoms (Kazda et al., 2009). 
According to the most recent evidence MTBC species evolved parallel to the human host 
and followed early human migration over the world (Hershkovitz et al., 2015). Furthermore, 
unlike HIV or Ebola, these human mycobacterial pathogens are not of zoonotic origin, 
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instead the animal pathogens, such as Mycobacterium bovis, delineated at a later point from 
ancestral bacteria than MTB (Smith et al., 2009). 
Many mycobacteria related to the MTBC are fast-growing saprophytes that are only 
opportunistic human pathogens, however, the slow-growing sub-cluster within the genus 
that includes MTBC, Mycobacterium leprae and Mycobacterium ulcerans are the etiological 
agents of leprosy and Buruli ulcer, respectively (Smith et al., 2009). 
Beyond phylogenomic analysis and predictions there is archaeological evidence of MTB 
infections in ancient times. The oldest human remains with definitive tuberculosis infection 
by MTBC, possibly MTB is dated 6200-5500 BC (Hershkovitz et al., 2015). Signs of 
tuberculosis infections have been found in Egyptian mummies and written about in ancient 
Sanskrit and Chinese medical literature (Galagan, 2014). Hippocrates used the term phthisis 
meaning ’wasting away’ in the 5th century BC (Galagan, 2014), which echoes with the later 
name of the disease, consumption, common symptom of weight loss during tuberculosis. In 
short, TB infections have been part of history for a long time. 
During the industrial revolution, tuberculosis was followed by the expansion of global 
population movements and became a pandemic. By the end of the 18th century it was 
responsible for one quarter of all fatalities in the UK according to Parish registers (Davis, 
2000). Diagnosis of tuberculosis was limited to pulmonary tuberculosis in most cases and 
often considered hereditary due to entire families being infected (Davis, 2000). 
Robert Koch, a Microbiologist and later Nobel Laurate published in 1882 that MTB was the 
causative agent of tuberculosis (Koch, 1884). In this article, he wrote that every seventh 
person in Berlin died of tuberculosis at the time, and not enough attention was given to the 
disease.  
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„If the importance of a disease for mankind is measured from the number of fatalities which 
are due to it, then tuberculosis must be considered much more important than those most 
feared infectious diseases, plague, cholera, and the like.” From re-print of the 1882 article. 
Based on the work of Jean-Antoine Villemin, who demonstrated transmissibility in rabbits 
and between human and rabbit, it became evident that tuberculosis is contagious (Villemin, 
2015). These results led Koch to identify the microbe and to write a list of criteria applied 
for general pathogenic bacterial identification called Koch’s postulates (Koch, 1884). 
Koch also developed the tuberculin detection reagent, which is a skin test to detect people 
infected by tuberculosis (Koch, 1890)(WHO, 2017). Moreover, his visualisation technique 
was improved by Ziehl and Neelsen and became standard for acid fast bacilli staining 
(Neelsen, 1892). These tests are over 100 years old and yet are still the first-line diagnostic 
tools in use today (WHO, 2017). 
Following the realisation that tuberculosis is a contagious disease, isolation of patients into 
sanatoria became common practice for those who could afford treatment (Davis, 2000). 
Aside from the beneficial impact of fresh air, rest and sufficient nutrition on the patient’s 
health, isolation prevented further contact and chance of transmitting the disease. The 
tuberculosis epidemic was mitigated before Koch and antibiotics by improvements in 
sanitation and living standards in the 19th century (Fairchild and Oppenheimer, 1998). 
Addressing poverty and malnutrition are historically effective methods in lowering 
tuberculosis burden (Fairchild and Oppenheimer, 1998).  
Diagnostics for tuberculosis improved at the turn of the century. The sputum smear test with 
Ziehl-Neelsen staining however practical, it is mostly reliable in advanced stages of TB 
infection. A positive sputum smear test indicates 70% mortality if patients are not treated 
(Tiemersma et al., 2011). Therefore, the development of medical radiography in the early 
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1900s was an important new tool in non-invasive tuberculosis diagnosis. X-rays, since their 
discovery in 1895 by Wilhelm Röntgen, have been considered for clinical use and by the 
middle of the century mass-screening of the population became routine test for tuberculosis 
(Davis, 2000). 
The BCG (Bacillus Calmette-Guérin) vaccine was introduced in France in 1921 for the 
immunisation of children (Davis, 2000). BCG is an attenuated variant of M. bovis which was 
continuously passaged for 13 years on bile potato to decrease virulence (Calmette, 1931). 
Mass-vaccination with BCG is in place since the 1930s and in non-randomised human 
studies efficacy varies between 0-80% (Andersen and Doherty, 2005). 
The microbiologist Paul Ehrlich at the end of the 19th century postulated the existence of 
compounds, a ’magic bullet’, that would kill a microorganism without harming the human 
host (Murray et al., 2015). He synthesised arsphenamine (Salvarsan) in 1910, the first drug 
active against syphilis, later in 1929 penicillin was discovered by Alexander Fleming 
(Fleming, 1929). However, none of these compounds were potent against MTB. 
Anti-mycobacterial drugs were discovered in the 1940s and the following three decades (see 
Figure 1.2. for chronology). Most of the early antitubercular drugs (e.g. streptomycin,  
STM) were discovered using animal models infected with the M. tuberculosis (Murray et 
al., 2015). Aside from the cost and ethical issue, animal studies were very efficient in 
discovering drugs like pyrazinamide (PZA), a potent drug in vivo, whose efficacy cannot be 
easily reproduced in vitro and today most likely it would evade discovery with current drug 
discovery strategies (Zhang and Mitchison, 2003). 
 
 




Figure 1.2. Important events in TB drug discovery in the 20th century. Yellow boxes 
represent pre-chemotherapy era, green boxes stand for first-line drug development, blue 
boxes display the re-emergence of TB. Next to therapy descriptions the length of treatment 
is indicated in months (m). DOT is directly observed therapy, DOTS directly observed 
therapy short-course, BMRC is British Medical Research Council. Images show a chest X-
ray of a TB patient (with permission from Radiological Society of North America); molecule 
structures of the first-line drugs, and bedaquilin (Sirturo), the first Federal Drug 
Administration-approved TB drug in 40 years. Dates from (Murray et al., 2015) and (Iseman, 
2002). 
Historically, anti-tuberculosis drugs have been discovered by different approaches. STM and 
RIF discovery was based on the idea that soil microorganisms other than Penicillium moulds 
could also use antibiotic compounds in their natural environment to compete with other 
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bacteria and fungi (Murray et al., 2015). Meanwhile, para-aminosalicylic acid (PAS) was 
hypothesised to be a toxic alternative substrate for MTB, based on structural similarity to 
salicylic acid (Lehmann, 1946). In the case of PZA, it was observed that vitamin B3 inhibited 
MTB growth. Modification of nicotinamide (amide derivative of niacin, vitamin B3) lead to 
the discovery of PZA, then INH and ethionamide (ETH), structures illustrated in Figure 1.3. 
(Zhang and Mitchison, 2003). 
 
Figure 1.3. Structures of related first and second-line antituberculotic drugs. Nicotinamide 
is the amide of vitamin B3, INH is isoniazide, PZA is pyrazinamide, ETH is ethionamide. 
 
1.1.3 Pathobiology of tuberculosis with implications to drug development 
 
TB is an infectious disease with special pathological characteristics which affect drug 
development. The most notable features are dormancy, emerging resistance against existing 
drugs and the unique barriers of the microenvironment that limit drug access to the target. 
During drug development we need to assess compound activity against all of these 
distinctive populations, dormant, resistant, secluded populations in order to forecast 
precisely compound efficacy. 
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1.1.3.1 Latent TB infection 
Tuberculosis infections remain latent in most cases (see Figure 1.4.) (WHO, 2017), which 
causes no symptoms and tends to be sub-clinical. According to the WHO, approximately 
one third of the global population has latent tuberculosis (WHO, 2017). It can reactivate with 
a probability of 5-15% later in life thus developing secondary tuberculosis (Getahun et al., 
2015). The probability of reactivation depends mostly on elapsed time. Reactivation events 
which happen within the first five years following primary infection account for 85% of all 
reactivations, and 95% develop within the first ten years (Salgame et al., 2015). Besides 
reactivation, secondary tuberculosis may develop by reinfection as well, especially in high 
tuberculosis burden environments (Salgame et al., 2015).  
 
Figure 1.4. Overview of TB transmission and possible course of infection. Percentages show 
probabilities of that step based on data from 2015 (WHO, 2017). 
 
Latent tuberculosis is identified by immunological tests using tuberculin skin test or 
interferon gamma release assays (WHO, 2017). However, these tests are only indicative of 
prior M. tuberculosis exposure. The tuberculin skin test shows false positive for individuals 
vaccinated with M. bovis BCG and false negative with immunocompromised patients 
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(Getahun et al., 2015). Therefore, the WHO guidelines do not limit latent tuberculosis 
treatment pending a positive tuberculin skin test, but instead recommend nine months of 
prophylactic INH treatment if latent tuberculosis risk is high (WHO, 2017). 
M. tuberculosis in latent tuberculosis displays an altered phenotype termed dormant or non-
replicating (Alnimr, 2015). Although, this phenotype is not exclusively observable in latent 
tuberculosis infections, there is a logical connection between delayed active disease and 
dormant bacilli. M. tuberculosis in the non-replicating persistence (NRP) state grows slower 
in vitro, is not culturable on solid media, stains differently and shows altered susceptibility 
to antimycobacterial drugs (Alnimr, 2015). Due to the metabolically altered NRP state bacilli 
have higher tolerance to cell-wall targeting drugs, like INH (Mitchison and Davies, 2012) 
and need “sterilising” drugs to get eliminated, such as PZA (Zhang and Mitchison, 2003). 
There are specialised in vitro and in vivo models particularly directed at testing drug efficacy 
against NRP M. tuberculosis (Alnimr, 2015).  
1.1.3.2 Unique environmental niches 
M. tuberculosis is an obligate human parasite with no scientifically proven environmental 
reservoir. Tuberculosis is an airborne infection, yet unlike other bacteria infecting the lungs, 
it targets specifically the lower lungs (Cambier et al., 2014). Avoiding large bacterial 
competition and often highly active immune responses in the upper respiratory tract, it is 
transmitted most efficiently by small droplets directed to the pulmonary alveoli (Cambier et 
al., 2014). 
M. tuberculosis is a facultative intracellular pathogen targeting primarily (but no 
exclusively) alveolar macrophages (Ganbat et al., 2016). During its intracellular state 
M. tuberculosis endures various environmental conditions. It survives acidic conditions and 
lytic enzymes of the phagolysosome, nitric oxide and reactive oxygen species all aimed at 
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eliminating the bacterium (Ehrt and Rhee, 2013). Yet interestingly, M. tuberculosis seems 
to override endocytic pathways, prevents lysosome and phagosome fusion, and overcomes 
resource scarcity, such as iron or oxygen, and starts replicating to the level where the host 
cell undergoes necrosis (Baer et al., 2015)(Cambier et al., 2014). 
Granuloma, an aggregation of macrophages and other cells, is the hallmark formation of 
tuberculosis infection (Cambier et al., 2014). In this structure macrophages are increasingly 
microbicidal and the intracellular environment is hostile towards M. tuberculosis (Cambier 
et al., 2014). The pathogen is present extracellularly outside the granuloma, intracellularly 
and inside the granuloma caseum – all of which result in phenotypically different sub-
populations of M. tuberculosis (Baer et al., 2015) (see Figure 1.5. granuloma). 
In primary tuberculosis the characteristic lesion is the caseating granuloma (Monin and 
Khader, 2014). It has a lipid-rich necrotic centre, surrounded by foamy and epithelioid 
macrophages and lymphocytes. This structure does not incorporate blood vessels in the 
centre, hence the centre of the granuloma is hypoxic and isolated from nutrient sources (see 
Figure 1.5.). Primary granulomas grow up to 2-3 cm in size and this is the ‘tubercle’ 
structure the disease has been named after. 
Primary granulomas can undergo fibrosis and calcification and they can remain contained 
indefinitely, although in cases of infection with high bacillary load the granuloma can 
progress into a dysregulated inflammatory granuloma (Monin and Khader, 2014). These 
structures incorporate a large number of neutrophils and are the centres of unrestricted 
inflammation that impairs respiratory function (Monin and Khader, 2014), which is a typical 
symptom that leads patients to seek clinical help. 
The stressful milieu of the granuloma leads to drug-tolerance in M. tuberculosis (Dartois, 
2014; Baer et al., 2015). Replication slows down, generation time is prolonged from 24 hours 
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to more than 96 hours (Baer et al., 2015) and drugs targeting cell wall synthesis (INH, EMB) 
become ineffective. Especially in the caseum of the granuloma, persisting bacteria become 
phenotypically tolerant to most drugs, except towards RIF, PZA, bedaquiline and 
fluoroquinolones that inhibit metabolic processes still active in this phenotype (Baer et al., 
2015). In general, accessing and effectively killing all these different subpopulations of 
M. tuberculosis is a complex problem of chemotherapy and is currently only possible with a 
multitude of drugs administered in combination. 
To sum up, Figure 1.5. illustrates typical barriers that a drug compound needs to cross from 
the absorption or intravenous injection to reach the molecular drug target within the 
bacterium, all of which need a relevant model in laboratory testing. Animal models are the 
most relevant in studies at the granuloma level, however the pathology of human 
tuberculosis may not be mimicked accurately in some of these models. For example mice, 
which are the most widely used animal model, infected with MTB depending on mice strain, 
can develop specific types of granulomas, without hypoxia or necrotic caseum for example 
(Myllymäki et al., 2015). Therefore, correct understanding and application of mice strains 
immensely influence these experiments (Kramnik and Beamer, 2016). Surprisingly, 
important studies concerning granuloma formation and innate immune responses have been 
performed in zebrafish models with Mycobacterium marinum, because the granulomas that 
develop in various organs of the fish are very much alike the human granulomas (Parikka et 
al., 2012). For the level of bacterium and molecular target engagement whole cell assays are 
routinely applied. This topic is elaborated upon in Chapter 1.5. 
 




Figure 1.5. Path of antituberculotic drugs from blood to molecular target (Dartois, 
2014). Orange rhombuses represent the drug compound. 
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1.2 Characteristics of the mycobacterial cell wall 
 
Acid-fast bacilli are different from Gram-positive and Gram-negative bacteria regarding cell 
envelope structure. Briefly, in mycobacteria peptidoglycan is covalently linked to the cell 
wall core termed mycolyl-arabinogalactan-peptidoglycan (mAGP) (Abrahams and Besra, 
2018). Glycolipids, like lipomannan (LM) and lipoarabinomannan (LAM) are integral parts 
of the cell wall (Abrahams and Besra, 2018). Covalently linked mycolic acids of mAGP 
together with free lipids and waxes form an outer membrane establishing a pseudo-
periplasmic space like Gram-negatives (see Figure 1.6. for comparison). The outer 
membrane is covered by a capsule-like material of polysaccharides and proteins (Abrahams 
and Besra, 2018).  
 
Figure 1.6. Comparison of bacterial cell walls (Brown et al., 2015). Capsule material is 
not illustrated. 
A unique cell wall structure also means highly distinguished set of biosynthetic enzymes – 
many of these enzymes are essential and have no homologues outside the Corynebacterium-
Mycobacterium-Nocardia branch of bacteria (Jankute et al., 2012). 




Figure 1.7. Simplified M. tuberculosis cell wall model highlighting discussed elements 
in the text, original picture (Jankute et al., 2015) with edited elements. AGP is 
arabinogalactan-peptidoglycan, MA mycolic acid, AG arabinogalactan, PG peptidoglycan, 
LM lipomannan, LAM lipoarabinomannan, AcPIM acylated phosphatidyl-myo-inositol 
mannoside. Extractable lipids: SGL sulfoglycolipid, PDIM phthiocerol dimycocerosate, 
PAT polyacyltrehalose, DAT diacyltrehalose. 
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1.2.1 Lipoarabinomannan (LAM), lipomannan (LM) and phosphatidyl-myo-
inositol mannosides (PIMs) 
By the latest cell wall models (Kaur et al., 2009; Minnikin et al., 2015) these structures are 
non-covalently immersed into the leaflets of both the cell membrane and the mycobacterial 
outer membrane (only the former represented in Figure 1.7.). In fact, PIMs modify the 
stability of the inner cell membrane so much, that it has been suggested to distinguish the 
structure as mycobacterial inner membrane (Minnikin et al., 2015). 
The anchor for all three listed macromolecules is phosphatidyl-myo-inositol. In PIMs the 
anchor is typically bound to two or six mannosyl residues (PIM2 and PIM6), while maximum 
two more acyl groups may be added, one to the myo-inositol and another to the 
mannopyranose part. In M. tuberculosis the most common acyl chains are palmitic acid and 
tuberculostearic acid substitutions (Jankute et al., 2015). 
LM and LAM are also linked to phosphatidyl-myo-inositol extended through a mannan 
homopolymer (α(1→6) Manp), with species-dependent typical monomannose residues 
bound to the main polymer chain (α(1→2) Manp), in total containing 20-30 mannosides 
(Jankute et al., 2015). The difference between LM and LAM is the addition of an arabinan 
chain (α(1→5) Araf), approximately 50-70 residues in LAM, which is also branched 
(α(3→5) Araf) with a tetra-arabinoside or a (further branched and succinylated) hexa-
arabinoside (Jankute et al., 2015). These sidechains are frequently capped with dimannoside 
residues (or mono and tri-mannosides less frequently), forming ManLAM (Jankute et al., 
2012). This mannoside capping motif of LAM has an important role in immune reactions, 
however results in this topic are contradictory and need further assessment (the effect of 
purified ManLAM as model for cell wall component ManLAM has been questioned (Kaur 
et al., 2009)). 
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Synthesis of these three molecules are similar until tri- or tetra-acylated-PIM2 synthesis, 
aided by PimA and PimB (Rv2188c) (Guerin et al., 2009). These two enzymes utilize GDP-
Manp as the sugar donor, but interestingly, the enzyme Ppm1 synthesises a polyprenyl-
phosphorylmannose, which is utilised by transmembrane glycotransferases (Rana et al., 
2012). C50 isoprenyl carriers involved in this reaction are similar to the prenyl chain of 
decaprenyl-phosphorylarabinose (DPA), the substrate of Mt-DprE1 (discussed in Chapter 
1.4.). Also, these polyprenyl substrate utilising steps take place in the periplasm (similar to 
DPA synthesis (Brecik et al., 2015)). 
Enzymes MptA and MptB synthesise the linear mannan polymer chain, MptC finishing the 
mannan side chains of LM (Abrahams and Besra, 2018). LAM arabinan side chain is 
synthesised by some of the enzymes involved in arabinan synthesis of AG (see Chapter 
1.2.3.), involving AftB, AftC, EmbC (Alderwick et al., 2005, 2006; Escuyer et al., 2001), 
however several enzymes of the pathway have not yet been determined. 
1.2.2 Peptidoglycan (PG) 
PG is part of the mAGP, it is a rigid biopolymer responsible for the structural integrity of 
the cell wall (Minnikin et al., 2015). It is located on the outer side of the cell membrane and 
it is considered to be similar to other bacterial PGs (Brennan and Nikaido, 1995). The 
polymer has a backbone structure of alternating N-acetylglucosamine and N-acetyl or N-
glycolyl-muramic acid residues (β(1→4) linkage), which are highly cross-linked (70-80%) 
by tetra-peptide chains (Alderwick et al., 2015). 
The synthesis of PG starts with the formation of uridine-diphosphate-N-acetylglucosamine 
(UDP-GlcNAc), which is modified by a sequence of Mur ligases to form Park’s nucleotide, 
a soluble building block that is than coupled to decaprenyl-phosphate and anchored to the 
cell membrane (Jankute et al., 2015). This structure is called Lipid I and reacts with another 
Chapter 1 Introduction 
18 
 
UDP-GlcNAc molecule to form Lipid II, which is the base component of this polymer. Lipid 
II is flipped to the outer surface of the cell membrane, and penicillin binding proteins (PBPs, 
the targets of β-lactam antibiotics), which are transglycosylases and transpeptidases, link the 
moieties to form the PG polymer.  
Several TB drugs target the PG pathway. D-cycloserine prevents Park’s nucleotide 
formation, capuramycins block the formation of Lipid I (Muramatsu et al., 2003), 
vancomycin prevents polymer crosslinking (Meadow et al., 1964). It is important to point 
out that vancomycin and β-lactams are not potent against MTB on their own, instead only 
have an effect if the cell wall structure is already compromised by other drugs (Soetaert et 
al., 2015). 
1.2.3 Arabinogalactan (AG) 
AG is the central component of mAGP and it is formed of galactose and arabinose 
homopolymers (Jankute et al., 2012). About 10-12% of N-glycolylmuramic acid 
(MurNGlyc) of PG is covalently linked to AG. According to the latest model by Minnikin 
et al. (2015), AG adopts a helical structure. The model featured in Figure 1.7. shows PG 
helices interspersed by the galactan part of AG. Other models consider PG as a web-like 
base layer below AG (Kaur et al., 2009). The terminal hexa-arabinoside of AG arabinan is 
covalently linked to mycolic acids, which forms the basis of the inner leaflet of the outer 
membrane (Alderwick et al., 2015). 
AG biosynthesis starts with the formation of a linker unit, which is a disaccharide consisting 
of GlcNAc and L-rhamnose, shown as green and black spheres in Figure 1.7. GlcNAc of 
the linker unit is added by WecA, while rhamnose by WbbL (Jin et al., 2010; Mills et al., 
2004). Galactose monomers are added on the cytosolic side of the membrane by enzymes 
Glft1 and Glft2, with alternating β(1→5) and (β1→6) linkages (Mikušová et al., 2006). 
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Meanwhile, the synthesis of the arabinan chain is expected to take place on the periplasmic 
side (Jankute et al., 2012). AftA primes the galactan with the initial arabinose and the chain 
is elongated by the Emb proteins, while Aft proteins catalyse branch additions of Araf 
(Alderwick et al., 2006; Escuyer et al., 2001). The arabinan part of AG is further decorated 
with galactosamine and succinic acid (see in Figure 1.7.). Ultimately, the synthesised 
macromolecule is ligated to PG by the enzyme Lcp1 (Harrison et al., 2016). 
GlcNAc of the linker unit is anchored to the membrane by decaprenyl-phosphate, while the 
L-rhamnose is transferred from desoxythymidine diphosphate rhamnopyranose (dTDP-
Rhap) (McNeil et al., 1990; Jin et al., 2010). The donor for galactose is the soluble uridine-
diphosphate-galactofuranose (UDP-Galf)(Weston et al., 1997), while arabinose residues are 
transferred from decaprenyl-phosphorylarabinose (DPA)(Mikušová et al., 2005).  
Inhibition of the AG synthesis has been highlighted by the discovery of several compound 
classes. Currently, the enzyme WecA involved in this synthesis steps is the target of the 
experimental drug CPZEN-45 (capramycins) (Clinical pipeline, 2018). DPA formation is 
prevented by Mt-DprE1 inhibitors, such as benzathiazinones and dinitrobenzamides in pre-
clinical studies (Makarov et al., 2009; Christophe et al., 2009). The front-line drug EMB 
targets the Emb proteins of AG biosynthesis (Telenti et al., 1997). 
1.2.4 The outer membrane of M. tuberculosis 
Mycolic acids are long chain fatty acids (C70-C90) mostly located attached to AG or unbound 
as free trehalose-mycolates (Jankute et al., 2012). Together with other trehalose derivatives 
they form the basis of the mycobacterial outer membrane (see Figure 1.7. in various colours, 
names not listed for simplification). These molecules render M. tuberculosis with its 
hydrophobic outer membrane and result in exceptionally low permeability against staining, 
drugs and endurance in the intracellular microenvironment (Angala et al., 2014).  
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The “free lipids” of the outer membrane are not covalently bound and can be extracted and 
separated with the use of different organic solvents (Minnikin et al., 1985). (In Figure 1.7. 
sulfoglycolipid, phthiocerol dimycocerosate and the trehalose-derivateives, 
polyacyltrehalose and diacyltrehalose are shown with the sulfur-containing sulfoglycolipid. 
Trehalose dimycolate termed the ‘cord factor’ is exceedingly important in immune 
responses, particularly in causing inflammation (Angala et al., 2014). The transport of 
hydrophilic molecules is possible via porin proteins immersed in this outer membrane 
structure (not shown on Figure 1.7.) (Angala et al., 2014). 
Trehalose is a non-reducing disaccharide absent from human cells, yet mycobacteria possess 
three different biosynthetic pathways for its synthesis (Kaur et al., 2009). Mycolic acids are 
synthesised in the cytoplasm via the fatty acid synthase pathways FAS-I and FAS-II 
(Quémard, 2016). Enzymes of the FAS-II cycle in mycolic acid synthesis are especially 
favourable targets because this pathway is completely absent from humans (Chetty et al., 
2017). Due to the abundance of enzymes involved in their synthesis, here only proteins 
relevant to drug mechanism of action are discussed further. 
The front-line drug INH is activated by KatG and targets InhA (Islam et al., 2017), which is 
also the target of ethionamide and prothionamide (Marcinkeviciene et al., 1995). InhA is an 
enzyme in FAS-II (Abrahams and Besra, 2018). Pks13 participates in one of the final steps 
of mycolic acid synthesis and it is the target of some preclinical drugs (Islam et al., 2017). 
MmpL3 is a transport protein which is through to transport mycolic acids to the periplasm, 
which operates under the control of proton motive force (Li et al., 2014). Therefore, 
structurally diverse inhibitors e.g. delamanid and SQ109 (Islam et al., 2017) have one 
common feature: they disrupt the electrochemical gradient which drives MmpL3 (Cole, 
2016). The most promising such inhibitor, SQ109 is in phase 2 clinical trials (Clinical 
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pipeline, 2018). Finally, the antigen 85 complex, which is responsible for linking mycolates 
to AG and catalysing cord factor synthesis, is the target of preclinical drug I3-AG85 (Warrier 
et al., 2012). 
1.2.5 Capsule material 
The outer layer of the M. tuberculosis is a composite of polysaccharides and proteins, and 
its extension is highly variable and dependent on the growth environment of the bacilli 
(Angala et al., 2014). 70% of capsular material is α-D-glucan, a polymer of glucose similar 
to glycogen (Ortalo-Magne et al., 1995). In addition, D-mannan and D-arabinomannan are 
components of this structure, which are identical to the relevant features of LM and LAM, 
sharing enzymes in the biosynthetic pathway. Enzymes of the capsule synthesis may be 
interesting drug targets, for example GlgE (Rv1327c) maltose-transferase needed for α-
glucan synthesis has been validated as potential drug target (Kalscheuer et al., 2010). 
 
1.3 Present state of tuberculosis treatment 
1.3.1 Current set of anti-tuberculosis drugs 
Modern tuberculosis therapy applies exclusively drugs in combinations to minimise the risk 
of drug-resistance. Combinational chemotherapy has been advised since 1948 because STM 
and PAS resistance occurred quite frequently when administered in monotherapy (Fox et al., 
1999). Some elements of the regimen were replaced because other drugs were more effective 
in lower dosages (PAS replaced by EMB), and some were held back for severe side-effects, 
such as STM was replaced by PZA, thioacetazone was withdrawn (Murray et al., 2015). 
Some of these unfavourable drugs are still second-line alternatives in tuberculosis therapy.  
Currently, drug-susceptible tuberculosis treatment is according to the directly observed 
therapy short-course (DOTS) programme (Iseman, 2002). In the initial two months the 
Chapter 1 Introduction 
22 
 
combination of four front-line drugs is administered (INH/RIF/PZA/EMB), followed by four 
months of treatment with INH and RIF only. This 6-months course is the shortest treatment 
period with acceptable relapse rates (Fox et al., 1999).  
For drug resistant tuberculosis therapy, the earlier WHO guidelines (WHO, 2010) required 
four and the latest guidelines  a minimum of five effective drugs administered in combination 
in the intensive phase (8 months). The WHO 2016 guidelines (WHO, 2016) regrouped drugs 
involved in MDR-TB therapy and also introduced the ‘shorter MDR-TB regimen’. This is a 
standardised treatment based on the Bangladesh regimen (TBfacts.org, 2018) for pulmonary 
TB with suspected/confirmed drug resistance, regardless of the HIV status of the patient and 
it may be concluded in only 9 months. 
1.3.2 Adjunct therapies in TB treatment 
Host directed therapies (HDTs) follow an often overlooked approach in tuberculosis 
research: they explore the possibility to improve the reaction of the human host to the 
disease. This may be achieved by either enhancing adequate defensive immune reactions, 
lowering negative immunological mechanisms such as inflammation, and hindering 
interactions and processes in the host that are exploited by the bacterium (Palucci and 
Delogu, 2018). The containment of the infection and an optimal immune response is 
important both in primary infection, and also in the case of reactivation of the active disease 
from a latent phase (see Figure 1.4.). The main problem with modulating the immune 
response is the consequences that it may hold for TB patients with HIV-coinfection or 
diabetes, who could react negatively to these drugs or simply show no improvement (Lee et 
al., 2018). With co-morbidities present, it is also more and more difficult to weigh the cost-
benefit of these drugs added to the treatment and how they would interact with each other. 
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Similarly, compounds targeting the virulence of the microbe may improve anti-tuberculosis 
chemotherapy. M. tuberculosis is known for its ability of forming biofilms with altered drug 
susceptibility (Ojha et al., 2008). Also, increased transcription and presence of drug efflux 
pumps have been shown to cause drug resistance during early drug treatment in vivo, which 
was suppressed by the inhibition of these efflux pumps by reserpine for example (Adams et 
al., 2011). 
1.3.3 Typical drug targets of M. tuberculosis 
TB drugs target various physiological processes of M. tuberculosis. Nevertheless, it is not 
without precedent that the mechanism of action of a drug is poorly understood, yet it gains 
approval for clinical use, such as clofazimine (Yano et al., 2011). In general, TB drugs can 
be grouped into three categories: nucleic acid synthesis inhibitors, protein synthesis 
inhibitors or other mechanism of actions. 
Nucleic acid synthesis inhibitors include the front-line drug RIF (and derivatives rifapentine, 
rifabutin) that inhibit RNA polymerisation (Chetty et al., 2017). Fluoroquinolons 
(ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin) that inhibit DNA 
replication and supercoiling (Chetty et al., 2017).  
Numerous TB drugs target protein synthesis. PZA, although it has multiple mechanisms to 
kill MTB (for example causes intracellular acidification) also hinders protein translation 
(Zhang and Mitchison, 2003). STM and aminoglycosides (kanamycin, amikacin) target the 
30S ribosomal subunit in translation, just like the experimental compound, spectinamide 
1599 (Lee et al., 2014). Macrolids (like clarithromycin) and oxazolidinones (sutezolid and 
linezolid (Chetty et al., 2017; Islam et al., 2017) and the compound delpazolid (LCB01-
0371) (Kaul et al., 2018)) all target the 50S subunit (Chetty et al., 2017). Capreomycin and 
Chapter 1 Introduction 
24 
 
viomycin are cyclic peptides that also inhibit protein synthesis, they impede the interaction 
between the two ribosomal subunits (Chetty et al., 2017). 
Many compounds in development attempt to inhibit novel pathways, that clinically approved 
drugs do not exploit. Q203, an imidazopyridine amide in phase 1 clinical trials, targets the 
protein QcrB of the cytochrome bc1 complex, essential to ATP synthesis (Pethe et al., 2013). 
Meanwhile, compound GSK 070 (GSK 3036656) is in phase 1 clinical studies targets leucyl-
tRNA synthetase to attack protein synthesis from a different angle (Chetty et al., 2017). 
Several clinically approved drugs target the cell wall – proteins involved in cell wall 
synthesis (some discussed in Chapter 1.2.), or because they are located in the cell wall. The 
front-line drugs INH and EMB both target mycolic acid and AG synthesis (Marcinkeviciene 
et al., 1995; Telenti et al., 1997), while bedaquiline targets transmembrane ATP synthase 
AtpE (Goldman, 2013). QcrB is also located in the cell membrane, since the electron 
transport chain complexes of prokaryotic cells are situated there (instead of the 
mitochondrion). 
One of the reasons why cell wall targets are widely studied is that they have appeared in 
multiple phenotypic screens (Cole, 2016). It is yet to be explained why they are highly 
druggable, but several proteins of the cell wall are promiscuous targets and they can be 
inhibited by different chemical scaffolds unrelated to each other. QcrB is one of these 
proteins, among MmpL3 (both integral membrane proteins) and DprE1 (Cole, 2016).  
Another reason for drugs targeting membrane proteins is the hydrophobic nature of both 
compounds and the cell wall. Even highly hydrophobic compounds can reach their target in 
the lipid-rich environment, while hydrophilic compounds may never reach their intracellular 
target exactly because of this lipid-rich, acid-fast mycobacterial cell wall. 





1.4 Drug targets Mt-DprE1 and Mt-DprE2 
 
1.4.1 Mt-DprE1, validated drug target 
1.4.1.1 Physiological function of DprE1/2 
M. tuberculosis has one arabinose donor in cell wall synthesis, DPA (Wolucka et al., 1994). 
It is used as substrate by the arabinofuranosetransferase families Aft and Emb to synthesise 
AG, LAM (see Chapter 1.2.). Enzymes involved in DPA synthesis (see Figure 1.8.) are 
essential except for Rv3807c (Kolly et al., 2014). DprE epimerase subunits 1 and 2 (DprE1 
and DprE2) catalyse the final steps of DPA biosynthesis (Mikušová et al., 2005). 
Although, the biosynthetic pathway of DPA is essential for M. tuberculosis, the related 
species Corynebacterium glutamicum does not need arabinan to grow (Alderwick et al., 
2005). Viable mutants that lack ubiA have been produced that have no arabinan incorporated 
into the cell wall. This has been best explained by Grover et al. as dprE1 is a vulnerable drug 
target not because of the essentiality of arabinan, but because DPR accumulates in toxic 
levels inside the cell without dprE1. Furthermore, other biological processes which would 
use the same prenyl-carrier as ribose in DPR,  are limited due to the withdrawal of the carrier 
molecule (Grover et al., 2014). 




Figure 1.8. The DPA biosynthetic pathway. The blue boxes show the long name of 
intermediate sugar moieties, yellow boxes indicate the enzyme catalysing each step. Pink 
highlight signals the molecular changes in the structure at each step (Jankute et al., 2015; 
Abrahams and Besra, 2018) 
The glycotransferases that utilise prenylated sugar donors were postulated to operate on the 
extracellular side of the membrane, while nucleotide diphosphate-bound sugar reactions take 
place on the intracellular side of the membrane (Berg et al., 2007). The prenyl-sugar moiety 
is immersed in the membrane, and most enzymes that use them as substrate, are also integral 
membrane proteins (Berg et al., 2007; Abrahams and Besra, 2018). 
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The epimerisation reaction of DPR to DPA is a two-step reaction. Firstly, DprE1 oxidises 
DPR to the intermediate decaprenylphosphoryl-2-keto-β-D-erythro-pentofuranose (DPX), 
which is made possible by the concomitant reduction of a non-covalently bound FAD co-
factor (Batt et al., 2012; Mikušová et al., 2005). Secondly, DprE2 reduces DPX to DPA with 
the assistance of reduced nicotinamide adenine dinucleotide (NADH) or nicotinamide 
adenine dinucleotide phosphate (NADPH) as a co-factor (Trefzer et al., 2012). Both enzymes 
are reported to be periplasmic, membrane associated but not integrated, therefore possibly 
this epimerisation reaction takes place on the periplasmic side of the cell membrane (Brecik 
et al., 2015). 
1.4.1.2 Structure and inhibition of Mt-DprE1 
Mt-DprE1 belongs to the vanillyl alcohol oxidase/para-cresol methylhydroxylase family of 
proteins (Ewing et al., 2017). These proteins are structurally similar, all possessing an FAD-
binding domain, some bind the co-factor covalently (Ewing et al., 2017). Mt-DprE1 does 
not, however, in the absence of the co-factor it is structurally unstable that has been an issue 
during early purification studies of the protein, before the use of chaperons and codon-
optimised plasmids (Batt et al., 2012). Earlier, FAD was added in excess during the 
purification process to keep the protein folded (Neres et al., 2012). Also, members of this 
protein family often form homodimers or octamers (Ewing et al., 2017), but pure 
recombinant Mt-DprE1 is monomeric in solution (Batt et al., 2012). 
Mt-DprE1 has a highly conserved DNA sequence among related taxa (Batt et al., 2012). 
Indeed, Mt-DprE1 (gene rv3790) shares 82% sequence identity with DprE1 in M. smegmatis 
(gene MSMEG_6382) on the amino acid level. As a surrogate the protein the M. smegmatis 
protein has been used in inhibitor studies with encouraging results (de Jesus Lopes Ribeiro 
et al., 2011). Mycobacterium avium and Mycobacterium aurum however are poor models: 
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they are intrinsically resistant to covalent inhibitors (like benzothiazinones) because their 
Cys387 is substituted with other amino acids (de Jesus Lopes Ribeiro et al., 2011), the target 
residue of these compounds. Mt-DprE1 is a validated drug target and got to the centre of 
attention due to its high druggability and known 3D structure (Batt et al., 2012). So far 15 
different compound classes have been identified to inhibit Mt-DprE1 specifically (Piton et 
al., 2017). 
 
Figure 1.9. Three-dimensional structure of Mt-DprE1. Surface and gray cartoon shows 
Mt-DprE1 (pdb:4P8L) with the short and large loop region highlighted in blue and pink 
(316-330, 269-297) respectively. The ligand is Ty36C (Neres et al., 2015) in green spheres, 
FAD is in yellow sticks. Made in PyMol Version 2.0.6. (DeLano, 2002) 
The most notable covalent inhibitors are benzothiazinones (BTZs) (Makarov et al., 2009) 
and dinitrobenzamides (Christophe et al., 2009). All covalent inhibitors are aromatic nitro-
compounds that are activated via FADH by reducing the nitro-group to the active nitroso 
form (Trefzer et al., 2012) and form an adduct with Cys387 of Mt-DprE1. Nitro compounds 
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are prone to mutagenicity (Piton et al., 2017) which makes optimisation difficult, but 
PBTZ169 which is a clinical candidate molecule, recently termed macozinone (Clinical 
pipeline, 2018) is in phase 2 clinical studies with one of the lowest minimal inhibitory 
concentrations in the field (0.6 nM) (Makarov et al., 2014; Piton et al., 2017). 
 
Figure 1.10. Mt-DprE1 binding a covalent and non-covalent inhibitor example. (A-C) 
showcase covalent inhibitor PBTZ169, (D-F) the non-covalent inhibitor TCA1. (A) and (D) 
show compound structure, (B) and (E) are interaction maps by Piton et al. (2017), (C) and 
(F) the same interaction excerpt in 3D model, with the ligand coloured by element. FAD in 
yellow sticks. In C) the green ball represents the water molecule that interacts with both 
PBTZ169 and L115. 
Non-covalent inhibitors without nitro-groups, like TCA1 (Wang et al., 2013) or azaindoles 
(Shirude et al., 2014) offer a safer but less potent alternative to covalent inhibitors. Lead 
compounds of the different classes usually have an MIC below 1 µM (Piton et al., 2017). 
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The azaindole TBA-7371 is in the most advanced stage of clinical studies among these 
compounds (in phase 1) (Clinical pipeline, 2018). The number of inhibitors is still rising 
with the help of docking studies with the solved crystal structures and the development of in 
vitro enzymatic assay (Batt et al., 2016; Neres et al., 2012). 
Difference between covalent and non-covalent binding is illustrated in Figure 1.10. The 
involvement of Cys387 is less in binding with non-covalent inhibitors, also different amino 
acid side chains interact with the ligand. For example, the involvement of Tyr60 in TCA1 
binding, but not with PBTZ169 (Piton et al., 2017). The colouring in Figure 1.10. follows 
the example of Piton et al. (2017) with recognising a more constant, hydrophobic surface 
(residues in blue) interacting with various ligands. Other residues join the interaction only 
with certain ligands and with van der Waals bonds (in pink) or with hydrogen bonds (in 
green). These interactions are more difficult to predict based on in silico docking studies 
because these residues include more flexible elements. 
Mt-DprE1 has two loop regions, a long (amino acids 269-297) and a short disordered region 
(amino acids 316-329) as shown in Figure 1.9. These structures do not appear on apo 
enzyme crystal structures, because of their flexibility and have been a topic of speculation 
as to their function and importance in protein-ligand interactions. Co-crystals with inhibitors 
have demonstrated that certain ligands can stabilise one or both of these loops (Piton et al., 
2017).  
The short disordered region is placed over the active site of the protein (see Figure 1.10.), 
and became ordered in the presence of ligand CT319 (BTZ derivative), while Ty36c and 
QN129 (2-carboxyquinoxalines) stabilised both loops (Neres et al., 2015).  
Azaindoles, TCA1, pyrazolopyridones and aminoquinolones resistant strains can be cross-
resistant due to a common Tyr314His mutation (Piton et al., 2017). This residue is near the 
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short loop and in direct interaction with these inhibitors, but even these mutant strains 
remained susceptible to BTZs (Piton et al., 2017). Besides different point mutations, BTZ 
resistance was also demonstrated in M. smegmatis by overexpression of the nitroreductase 
NfnB (Manina et al., 2010). This enzyme has no confirmed homologue in MTB, but similar 
mechanisms are possible with similar inactivating enzymes. 
1.4.1.3 Biochemical assay of Mt-DprE1 
Enzyme activity of Mt-DprE1 was first monitored with radiolabelled substrates (Mikušová 
et al., 2005). The method used the membrane fraction of M. smegmatis incorporating an 
active enzyme mixture and p[14C]Rpp, the substrate of UbiA (see Figure 1.7.). Radioactive 
products DPR, DPA and DPX were separated by thin layer chromatography. 
A big step towards miniaturisation and screening was to introduce farnesyl-phosphorylribose 
(FPR), a truncated form of DPR to perform enzymatic reactions in solutions. The reaction 
could be followed by oxidising the reduced co-factor, FAD (Makarov et al., 2009). FAD can 
be re-oxidised by Amplex Red or dichlorophenolindophenol (DCPIP) electron acceptors 
(Neres et al., 2012) or resazurin (Batt et al., 2016) (illustrated in Figure 2.3. in Chapter 2). 
This assay type is useful in that it can be used to measure enzyme kinetics and to test 
inhibitors. It has been found that DprE1 exhibits allosteric enzyme kinetics (Neres et al., 
2012; Batt et al., 2012), a phenomenon yet to be explained. 
1.4.2 Mt-DprE2, potential drug target 
Mt-DprE2 is an essential enzyme (Kolly et al., 2014) in M. tuberculosis and as most enzymes 
of the DPA synthetic pathway (Figure 1.8.), it is a potential drug target. 
Mt-DprE2 is located in the same genetic cluster as Mt-DprE1 on the mycobacterial 
chromosome. Upstream of dprE1 (rv3790) is rv3789 coding Mt-GtrA, that has been 
identified as a transmembrane protein with suggested flippase (Larrouy-Maumus et al., 
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2012) and/or recruiting function for AftA (Kolly et al., 2015). dprE2 (rv3791) is just 
downstream of dpre1, followed by aftA and the Emb operon (see Figure 1.11.) (Kolly et al., 
2015). AftA is the transmembrane enzyme that primes the galactan polymer of AG with the 
first arabinofuranose residue (Alderwick et al., 2006), while the EmbCAB proteins are 
glycotransferases that participate in arabinan biosynthesis (Jankute et al., 2012). 
 
 
Figure 1.11. dprE1/2 locus in M. tuberculosis by Kolly et al. (2015). The genes rv3789, 
dpre1, dpre2 and aftA are co-transcribed to the same mRNA (Kolly et al., 2015). 
 
DprE2 has a wider interactome than DprE1 based on bacterial two-hybrid system 
experiments in C. glutamicum. While DprE1 was indicated to bind itself and DprE2, DprE2 
was reported to bind DprE1, DprE2, AftA, AftB, AftC and GlfT1 (Jankute et al., 2014). This 
implicates further that DprE2 inhibition could impair severely MTB physiology. 
The solution structure of Mt-DprE2 has not yet been solved, but an ab initio computer model 
based on amino acid sequence has been produced (Bhutani et al., 2015). The model predicts 
that the protein belongs to the short-chain dehydrogenase/reductase family performing 
NAD(P)H-dependent redox catalysis. Presumably, Mt-DprE2 takes the form of a typical 
Rossmann fold and has three disordered regions (Bhutani et al., 2015). The only enzymatic 
assay established to date for Mt-DprE2 is a radiolabelled assay developed by Trefzer et al. 
(Trefzer et al., 2012). It has been applied to confirm NAD(P)H-dependence and to prove that 
BTZs do not inhibit Mt-DprE2 (Trefzer et al., 2012). 
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1.5 Phenotypic screens in TB early stage drug discovery 
 
1.5.1  Early stage drug discovery 
Early stage drug discovery focuses on finding new compounds active against M. tuberculosis 
that can be improved in potency and physicochemical properties to become drug candidates 
in the future. It is an iterative process of constantly re-evaluating each derivative compound 
in the general setting of the 4Ms: compounds tested with the Molecular target, at whole-cell 
level for MIC, in Mice and finally in Man (Ballell et al., 2013). The compound as it 
progresses signifies higher and higher financial investment which makes it crucial to identify 
and eliminate unsuitable molecules as early as possible. Compounds follow the typical 
evolution to drug illustrated in Figure 1.12. 
 
Figure 1.12. The progression of a compound in early stage drug discovery. ID – 
identification; MOA – mechanism-of-action; SAR – structure-activity relationship; ADMET 
– absorption, distribution, metabolism, excretion, toxicity; IND – investigational new drug. 
 
Drug attrition is high in most antibiotic discovery projects – it has been estimated that about 
2066 high-throughput screens deliver one antibiotic with a new mechanism of action (So et 
al., 2011). As R. H. Baltz stated “the success of pharmaceutical discovery programs is 
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dependent on two things: (1) having appropriate high quality screens… and (2) having 
adequate numbers of high quality compounds to screen.” 
From the beginning of the drug development process some projects lean towards target-to-
drug, while others to the drug-to-target approach. The target-to-drug strategy focuses on the 
potential target first, a vulnerable pathway or enzyme, develops an assay to test inhibition of 
this isolated target and screens compounds for inhibition or binding. Meanwhile, the drug-
to-target approach firstly identifies an antimicrobial compound, then identifies and validates 
its target and proceeds with lead optimisation (Sala and Hartkoorn, 2011). Both have their 
short-comings, but the most crucial one is that target-to-drug hit compounds are prone to 
inactivity in vivo because they never engage their target through the numerous barriers (see 
Figure 1.5.), an issue not addressed in assays with purified targets. Purely target-to-drug 
concepts are considered a failure and have never delivered any drug candidate against M. 
tuberculosis to date (Cole, 2016). 
Minimal inhibitory concentrations (MICs) are the most important initial indicators of 
phenotypic screens in the drug-to-target approach. It is often specified as MIC50 or MIC99 
referring to the level of growth reduction (by 50% or 99%) caused by the compound 
(Franzblau et al., 2012), and it is a preliminary reporter on compound potency. 
Although, drug-to-target approach dominates in M. tuberculosis research, it is possible to 
include some aspects from the target-to-drug approach in screening. Hypomorph bacteria, 
that express less of a protein by repressing the promoter with the TET-OFF system for 
example (Sala and Hartkoorn, 2011) have an increased sensitivity towards inhibitors of that 
enzyme or pathway (Cole, 2016). Overexpression of a target results in the opposite effect 
and cells become tolerant to inhibitors of that specific target. This phenomenon is called the 
MIC shift. Mt-DprE1 overexpressing M. bovis BCG in high-throughput screens (HTS) has 
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identified a new inhibitor solely based on the shift in MIC comparing overexpressor and wild 
type strains (Batt et al., 2016), an exemplary strategy conducted in this work. 
1.5.2 Whole cell screening design in TB drug development 
1.5.2.1 Basic assay requirements 
The phenotypic whole cell assay measures M. tuberculosis growth inhibition in the presence 
of a compound. Therefore, essentially the assay requires a suitable bacterium, a medium that 
promotes cell growth, and a test compound. 
The choice of tested strain is an important determinant of whole cell screens. The laboratory 
strain MTB H37Rv is a widely applied standard and it has its whole genome sequenced (Cole 
et al., 1998). Unfortunately, it is a slow growing mycobacterium species with an average 
generation time 24 hours (Cole et al., 1998) that needs handling at biosafety level 3. Clinical 
isolates require similar treatment and may exhibit unique phenotypes. On the other hand, it 
may have its benefits to screen against drug resistant strains to narrow down the active 
compounds that are unaffected by prior resistance mechanisms. To standardise and 
rationalise, surrogate organisms are often opted to lower the hazard and to speed up culture 
growth. M. bovis BCG has a cell wall structure and similar antibiotic-susceptibility profile 
that mimics M. tuberculosis and needs only biosafety level 2, but unfortunately another slow 
growing species. M. smegmatis and M. aurum are fast growing mycobacteria and often 
substitute M. tuberculosis in research, but their sensitivity results are often different from M. 
tuberculosis and M. bovis BCG (Franzblau et al., 2012).  
Whole cell M. tuberculosis screens vary greatly in assay properties depending on which 
pathophysiological niche is simulated. M. tuberculosis survival can be assessed aerobically, 
which models the actively growing bacteria, while oxygen-depleted and nutrient-starved 
models aim to model susceptibility in the dormant/NRP subpopulations (Sala and Hartkoorn, 
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2011).  Macrophage assays carry M. tuberculosis intracellularly to imitate the 
microenvironment and drug-permeation in that stage of infection, however the additional 
advantage of it compared to the extracellular assays is uncertain (Franzblau et al., 2012). 
HTS assay media are typically liquid and based on Middlebrook 7H9 with supplements 
(Franzblau et al., 2012), however solid medium may be used as well. Supplements may be 
glycerol (0.2%), oleic acid, palmitic acid, albumin, dextrose and Tween-80, amongst others 
(Franzblau et al., 2012). The surfactant Tween-80 is added to prevent clumping of the cells 
and keep the culture in planktonic solution. However, it has been shown that Tween-80 can 
attenuate or even potentiate compounds (Franzblau et al., 2012). The same is true for the 
carbon source – glycerol is a common supplement, but false positive hits can emerge which 
are not potent in vivo, only due to an artefact of the active glycerol metabolism pathway, 
which is not the real target of these molecules (Franzblau et al., 2012). Therefore, alternative 
carbon sources (oleic acid, palmitic acid, acetate) are recommended to supplement the 
growth medium. 
Screening compounds are usually stem from compound libraries. Such libraries are the 
property of the Molecular Libraries Screening Center Network, the National Institute of 
Allergy and Infectious Disease, and private pharmaceutical companies like GVKbio (Ekins 
et al., 2010) or GlaxoSmithKline (GSK). Their libraries are curated by medicinal chemists 
that assess compounds by physicochemical factors (logP, Lipinski rule of 5, molecular 
weight) and biological data at service (MICs against different species, models etc.), and also 
weed out compounds that are typically false hits like the pan assay interference compound 
structures (Ekins et al., 2010). TB drugs tend to differ from other small drug compounds 
setting off alarms of usual filters, therefore special evaluation is required. 
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Current methods attempt to minimise compound amount necessary to assess potency and to 
speed up the assay process. Therefore, microtiter plates with low culture volumes are 
generally implemented. For precision compound dispensing special technologies, like the 
inkjet technology (like HP D300 Dispenser) or acoustic dispensing (like Labcyte Echo) are 
used for HTS (Marx, 2014). The former is cheaper, but cannot aliquot aqueous solutions or 
heat sensitive samples (Marx, 2014). 
Finally, an often overlooked aspect of assay design is the format in which the HTS is 
conducted. Assay miniaturisation is desired for little compound and reagent consumption 
and assaying a multitude of compounds simultaneously. However, MIC values can be 
different depending on the culture volume and format. In the case of this work the MICs 
seemed higher in small volumes than in slightly larger format (see Chapter 4). Solid and 
liquid media produce inherently different MICs as well (substance diffusion is different) 
therefore they cannot be directly compared. 
1.5.2.2 Indicators of cell viability 
As to the read-out of the whole cell assay, there are various options to determine cell growth. 
Absorbance, redox reactions and ATP assays are the most common (Franzblau et al., 2012). 
Optical density measurements need no reagent addition but have low signal to noise ratio. 
Redox reagents like resazurin and Alamar Blue have a higher redox potential than FAD, 
NAD+, NADP+ or even the respiratory chain enzymes so any of them can reduce the blue, 
barely fluorescent oxidised forms to a reduced, highly fluorescent and pink coloured form 
(Primm and Franzblau, 2007). Tetrazolium dyes, like MTT ((3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide), are applicable in HTS but do not offer any advantage 
compared to resazurin, however water-soluble ones are more expensive. Due to their larger 
size compared to resazurin they need a shuttle for electron transport as well, like menadione 
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or phenazine methyl sulphate (Primm and Franzblau, 2007). For intracellular ATP 
measurement commercial kits are available, such as BacTiter-GloTM, which is considered to 
be sensitive and has the shortest incubation time needed for reading (5 minutes compared to 
24 hours with resazurin) (Sala and Hartkoorn, 2011). The limiting factor of this reagent is 
its price. 
Reporter genes (like green fluorescent protein expression) can be used for real-time 
monitoring of M. tuberculosis survival (Franzblau et al., 2012). It has the additional benefit 
to produce a reliable signal in the intracellular macrophage assay as well and indicate 
inhibition kinetics. 
Another special read-out method is the combination of resazurin read-out with solid media, 
called charcoal agar resazurin assay (CARA), developed to HTS application (Gold et al., 
2015). This method uniquely distinguishes bacteriostatic and bactericidal compounds, and 
despite the solid media platform, it can be performed in 96-well microplates. The idea is to 
incubate bacteria cells in liquid culture with the tested compounds, but only part of the test 
volume is assessed via resazurin addition (or optical density). Another part of the culture is 
transferred to charcoal agar which adsorbs the compound from the culture and allows 
renewed cell growth if the compound was only bacteriostatic. 
1.5.3 Biological hit compound characterisation 
1.5.3.1 Toxicity screening of hit compounds 
In addition to activity studies hit compounds are early on tested for toxicity. To prevent drug 
attrition at an early stage of the drug development process hit compounds are profiled in 
vitro against a number of targets that are indicative of adverse drug reactions in the future 
(Bowes et al., 2012). If a hazard is identified, then the hit can get eliminated or the hazard 
circumvented during the lead optimisation process and drive hit to lead selection (see Figure 
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1.12. for evolution of a compound in the process). Furthermore, in vitro diagnostics can 
identify specific issues related to human physiology which could pass unnoticed even in 
animal models. 
In vitro toxicity profiling is usually required at the lead optimisation phase. The panel is 
different for each pharmaceutical research organisation, but Bowes et al. summarized a list 
of 44 targets that should be a minimum requirement for compound safety measurement 
(Bowes et al., 2012). These targets are receptors, ion channels and transporters. For example, 
the enzyme monoamine oxidase (MAO) is part of most panels because MAO inhibitors can 
cause hypertensive crisis and serotonin syndrome.  
1.5.3.2 Target validation 
A novel mechanism of action is highly desirable from a new drug candidate and target 
validation can help with lead prioritisation during development. A biochemical assay can 
confirm that the compound inhibits a specific enzyme function, or spontaneous mutation 
against the hit occurring in the target gene can indicate target of the inhibitor. Transcription 
profiling is another option to identify the pathway or pathways affected by the compound. 
For example, in the elucidation of mechanism of action of BTZ it was helpful to conduct 
comparative transcriptome studies. They resembled the transcriptome profile during EMB 
exposure and narrowed down the possible targets to the cell wall arabinan synthesis 
(Makarov et al., 2009). 
It is also possible to label the inhibitor and locate it within the cell by fluorescence or to 
purify the target in a pull-down method. However, without a known SAR it cannot be 
excluded that the label will change the protein-inhibitor binding. BTZ043 and PBTZ169 has 
been linked to the red fluorescent dye TAMRA and was used to verify cell penetration of 
the compound and target engagement (Neres et al., 2012). Moreover, it was also the basis to 
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determine the periplasmic localisation of Mt-DprE1 and classify it as a highly vulnerable 
drug target (Brecik et al., 2015). 
1.6 Aims 
 
This thesis aims to support drug development research and basic research of Mycobacterium 
tuberculosis physiology.  
The first goal is to gain more information about the drug target Mt-DprE1, in particular how 
it interacts with substrates and inhibitors. The question is whether the short disordered region 
of Mt-DprE1 is involved in inhibitor or substrate binding? To this end, a systematic approach 
was used to substitute the residues of the shorter disordered region and observe the 
alterations caused in enzyme activity and inhibitor binding. This can be achieved by applying 
available biochemical assay methods and implement them with novel Mt-DprE1 muteins. 
Also, in ligand binding experiments by intrinsic tryptophan fluorescence decay 
measurements. Studying disordered regions is a follow-up to the observation that certain 
inhibitors showed higher potency in biochemical assays yet interact nearly identically with 
Mt-DprE1 based on X-ray co-crystallography data. 
The second goal is to gain more information about drug target Mt-DprE2. There is no 
available crystallographic data about the structure of Mt-DprE2, and purification of the 
enzyme has been challenging. Crystallisation experiments failed mainly because of 
aggregation, especially in highly concentrated protein solutions which are generally used for 
crystal growth. Io overcome these problems a ‘tag-fusion’ – developing a 6xHis-SUMO-
tagged and MBP-tagged fusion protein was generated of Mt-DprE2. Potential benefits can 
result from size exclusion chromatography (removing seeds of aggregation) and exploring 
mild concentration methods instead of high-pressure filtration. 
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The third goal, with Mt-DprE2 was to design a biochemical enzyme activity assay. Testing 
Mt-DprE2-targeted inhibitors is currently restricted to assays with radiolabelled substrates 
and membrane preparations from a surrogate organism (M. smegmatis). A direct biochemical 
assay could utilise absorbance changes of the co-factor NAD and measure inhibition in an 
end-point or kinetic manner. 
Finally, a whole cell high-throughput screen was performed against a compound library to 
find new hits targeting Mt-DprE2. For this a M. bovis BCG surrogate system was used and 
to test susceptibility towards the TB Box library of GlaxoSmithKline, a collection of 10 000 
compounds specifically selected against M. tuberculosis. 
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2 Biochemical studies with DprE1 site-specific mutants 
 
2.1 Introduction 
M. tuberculosis DprE1 (Mt-DprE1) is the target protein of intensive new drug development 
studies (Piton et al., 2017). A better understanding of the physiological function and 
interaction of the protein with inhibitors may be highly informative in evaluating hits and 
leads, and potentially improving their affinity to Mt-DprE1. Currently there are 19 crystal 
structures of M. tuberculosis (MTB) Mt-DprE1 deposited in the Protein Data Bank (PDB) 
(Protein Data Bank, n.d.). The most important protein-ligand co-crystals have recently been 
summarised by Piton et al. (2017). These models have also been implemented in digital 
docking studies (Pore et al., 2015; Haribabu et al., 2015), however in each case the authors 
acknowledged the issue of two loop regions, which are disordered and therefore do not 
appear in the electron density maps, only when certain ligands are also present that they 
stabilise these regions (see crystal structure in  Figure 1.9.).  
The two disordered regions of Mt-DprE1 are located above the active site, therefore they 
have the potential to influence protein-ligand interactions. Furthermore, the short disordered 
region, termed loop II by Piton et al. (2017) between amino acids 316 and 330 is highly 
conserved among mycobacteria (Batt et al., 2012), which might suggest that these residues 
are important to its physiological function.  
To test the exact extent of how these residues may affect enzyme function, in this thesis 
single-site directed mutants of Mt-DprE1 were constructed, focussing on the short 
disordered region, and the protein was characterised in enzymatic assays and in ligand 
binding studies. 
Chapter 2 DprE1 studies 
43 
 
2.2 Materials and methods 
 
2.2.1 Site-specific mutant generation 
Single amino acid substitutions were introduced into plasmid pCDFDuet-6xHis-Mt-DprE1  
via the Quikchange protocol (Agilent Technologies, 2011). Complementary mutagenesis 
primers carried the desired mutations in the central part of the DNA oligos, the plasmid in 
its whole was amplified by PCR, then the parental (non-mutant) plasmids were digested 
based on their methylation, leaving only the unmethylated newly synthesised strands. 
Finally, the mutations were confirmed by DNA sequencing with specific sequencing 
primers. All primer sequences are listed in the Appendix. 
2.2.1.1 Primer design 
Mutagenesis primers were designed based on the guidelines in the Quickchange II site-
directed mutagenesis kit instruction manual (Agilent Technologies, 2011). The guideline 
suggests using completely complementary primers, however some PCR failed due to high 
melting temperatures of the primer pair. Therefore, for some mutants (see example mutant 
N385A below) partially complementary primer pairs were designed and also the 
concentration ratio between the forward and reverse primers were altered to prevent primers 
annealing to each other. The nomenclature of primers and resulting plasmid constructs was 
based on which amino acid is replaced at which position and by which amino acid. 




Figure 2.1. Primer design for Mt-DprE1 N385A mutagenesis. Both primers (in purple) 
carry the substitution, but only partially overlap. Illustration made in SnapGene 1.1.3. 
Primer pairs for the mutagenesis were designed with the aid of online programs 
OligoAnalyzer 3.1 (OligoAnalyzer 3.1, n.d.) and  PrimerX (PrimerX, n.d.), and synthesized 
by Eurofin Genomics Ltd.  
2.2.1.2 Polymerase Chain Reaction 
PCR amplification was performed in sterile 200 µl tubes. The basic reaction composition 
worked in most cases, but troubleshooting was necessary, and a modified version 
implemented in some cases. For example, with DprE1 M319A mutagenesis asymmetric 
primer concentration ratio and a different polymerase resolved this issue.  
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Basic PCR composition  Modified PCR composition 
component final conc. volume  component final conc. volume 
template DNA 50 ng 0.1 μl  template DNA 15 ng 3 μl 
forward primer 1 μM 
2 μl  
forward primer 0.1 μM 
2.5 μl 
reverse primer 1 μM reverse primer 1 μM 
Pfu DNA 
polymerase 












10x Pfu buffer with 
MgSO4 
1x 2 μl  
5x Phusion GC 
buffer 
1x 5 μl 
- - -  DMSO 3% 0.75 μl 
MilliQ water up to final volume: 20 μl  MilliQ water up to final volume: 25 μl 
 
Table 2.1. Mt-DprE1 mutagenesis PCR conditions.  
 
2.2.1.3 Clone evaluation 
PCR products were visualised on agarose gel, then transformed into E. coli Top10 cells, 
based on Hanahan method, heat shock at 37 °C for 5 min (Green and Sambrook, 2012) and 
grown on Luria-Bertani (LB) solid and liquid media supplemented with 100 μg/ml 
spectinomycin. Plasmids were isolated using a Qiagen Miniprep Kit (Cat No./ID: 27106) 
and sent to Eurofin Genomics Ltd. for sequencing. The received DNA sequences were 
analysed with Vector NTI ContigExpress program (Invitrogen). 
2.2.2 Protein production of Mt-DprE1 and muteins 
Proteins were expressed and purified based on the protocol by Batt et al. (2012), which was 
optimised for the full length wild type (wt) protein. Modifications were introduced to avoid 
an additional dialysis step to shorten purification time and to prevent protein denaturation. 
The plasmid was heat transformed into E. coli BL21 (DE3) cells and co-transformed with 
chaperon-carrier plasmid pTrc99a-GroES-Cpn60.2 expressing a GroES chaperonin from E. 
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coli and a GroEL chaperonin encoded by M. tuberculosis (Batt et al., 2012).  Cells were 
grown as preculture overnight, then diluted 100-fold and grown to log phase (OD600 = 0.6) 
in Terrific Broth (Sigma, #T0918), supplemented with both 100 μg/ml ampicillin and 
spectinomycin, with constant shaking at 200 rpm. The cultures were then cooled to 20 °C 
and induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) and incubated overnight. 
Cells were harvested by centrifugation and washed with 0.85% saline solution and stored at 
-20 °C. Cells were then resuspended in ice cold lysis buffer (50 mM potassium phosphate 
pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 Roche EDTA-free cOmplete protease inhibitor 
tablet/40 ml solution) and sonicated on ice (10 cycles of 20 seconds of treatment and 40 
seconds pause between cycles). The soluble fraction was separated by centrifugation at 
21,800 g for 30 min at 4 °C, filtered through a 0.22 μm syringe filter disk where necessary. 
The supernatant was loaded on pre-equilibrated GE HisTrap FF nickel-sepharose column 
and washed with lysis buffer containing 50 mM imidazole. Then the buffer was changed to 
storage buffer (50 mM Tris-HCl pH 8.5, 20 mM NaCl, 10% glycerol) and at the same time 
connected to a GE Healthcare HiTrap DEAE FF weak anion exchanger column directly  
(pre-equilibration step for the second column). Mt-DprE1 was eluted from the HisTrap 
column to the HiTrap column by storage buffer containing 300 mM imidazole. The HiTrap 
column with the sample was further washed and fractions collected using the storage buffer 
with increasing saline content. Mt-DprE1 typically eluted around 100 mM NaCl 
concentration. Fractions were evaluated by SDS-PAGE and Mt-DprE1 fractions with 
acceptable contaminations were concentrated by filtration (Amicon Ultra centrifugal unit, 
MWCO 10 kDa) to about 10 mg/ml final protein concentration, measured by NanoDrop, ε 
= 63495 [1/M*cm] and estimated by ProtParam (ProtParam, n.d.) for the wild type protein 
sequence and stored at -20 °C. 
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2.2.3 Ligand binding studies with Mt-DprE1 muteins 
Ligand-protein interaction was monitored by intrinsic tryptophan fluorescence quenching. 
In this method the fluorescence signal is altered due to the ligand interacting with the protein 
and changing the microenvironment of the tryptophan and tyrosine residues (Callis, 2014). 
The protein in dialysis buffer was kept at 20 °C. Ligand in the same buffer (stock solutions 
of 50 or 75 µM ligand) were added stepwise to achieve a 0-18 µM final concentration. The 
quartz cuvette contained 600 µl protein solution at the start of the reaction, volume expansion 
was corrected for in the fluorescence intensity calculations. Since the ligand stock solutions 
are in pure DMSO, the working stock may contain DMSO up to 10 % (v/v). DMSO content 
and volume expansion were the limiting factors in the highest tested concentrations. 
Fluorescence spectra were recorded with a PTI QuantaMaster 40 spectrometer (Photon 
Technology International) set to 0.5 mm monochromator slits and 1 nm steps through 
reading. The excitation wavelength was fixed through the experiment to 280 nm, the 
absorbance maximum of tryptophan, and emission spectra scanned from 300 to 400 nm, 
excitation maximum of proteins usually ranges between 305 and 352 nm (Callis, 2014). 
Data of three independent repeat experiments were then analysed using GraphPad Prism 
(version 6.00 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com) and data plotted with non-linear regression, ’One-site – specific 
binding’, defining Kd and Bmax values. 
2.2.3.1 Selection of mathematical model for ligand binding 
Mt-DprE1 is a monomeric enzyme (Batt et al., 2012)  with one expected ligand binding site. 
Therefore, the expected binding was a specific binding mechanism of enzyme and ligand at 
a 1:1 molar ratio. 
Chapter 2 DprE1 studies 
48 
 
Calculation of the dissociation constant (Kd [µM]) and overall binding capacity (Bmax 
[relative fluorescence units]) were conducted in Microsoft Excel with the Solver extension, 
and were first modelled on the equation below (based on Langmuir isotherm and Lambert-
Beer law) (Epps et al., 1999): 




However, based on the results for Kd the assumption of this equation, that free ligand and 
total ligand concentrations are approximately the same, are incorrect, because the Kd value 
is comparable with the enzyme concentration. In this case, the more general quadratic 
formula for 1:1 complex formation is applicable (Van De Weert and Stella, 2011): 
∆𝐹𝑒𝑚𝑖𝑡 ~ [𝐸𝐿] =
[𝑃]𝑡 + [𝐿]𝑡 + 𝐾𝑑 − √([𝑃]𝑡 + [𝐿]𝑡 + 𝐾𝑑)2 − 4 ∗ [𝑃]𝑡 ∗ [𝐿]𝑡
2 ∗ [𝑃]𝑡
 
Both calculations were made for comparison, and in the end the simpler equation used for 
ease of calculation, better use in global analysis with GraphPad Prism, and because in most 
cases it gave a better fit (sum of square errors was lower) for the measurement points. To 
illustrate the little difference between the two methods considering the large standard 
deviation between measurements see Figure 2.2. below.  




Figure 2.2. Difference between the simplified Langmuir isotherm-based equation and 
the quadratic equation calculation. This example is with wt Mt-DprE1 binding 93a3. Blue 
dots are the averages of four independent measurements with standard deviation bars, green 
curve is the quadratic equation best fit, the relevant Kd [µM] as a red dot on the abscissa. 
Orange curve is for the Langmuir-based equation best fit, with the relevant Kd [µM] in light 
blue on the abscissa. SSE is sum of squared errors. (A) Linear concentration values, (B) with 
logarithmic concentration values to show that enough measurement points were taken, and 
(C) summarises characteristic values (Bmax is in [relative fluorescence units]). 
 
2.2.4 Enzyme activity assays with Mt-DprE1 muteins 
Mt-DprE1 is a FAD-dependent oxidase-dehydrogenase enzyme and its activity can be 
monitored by measuring the reoxidation of FADH2 coupled to the enzyme reaction. The 
reoxidation event is linked to the redox dye resazurin, illustrated in Figure 2.3. This assay 
was first published by Neres et al. (2012). The resazurin assay was further optimised and 
implemented in a high-throughput screening as an end-point inhibitor assay using the 
substrate GGPR in GSK Stevenage (unpublished work by Argyrides Argyrou).  
Initial efforts aimed to reproduce the assay using DCPIP as an electron acceptor (Neres et 
al., 2012), using a published protocol measuring Mt-DprE1 enzyme activity. However, this 
was not successful, as absorbance values were not indicative of any measurable reaction 
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taking place. DCPIP is expected to turn from blue, with absorbance maximum at 600 nm, to 
colourless by reduction. 
 
Figure 2.3. Coupling of the Mt-DprE1 enzyme activity to fluorescence read-out signal. 
Resazurin is blue and shows low fluorescence, while the reduced form resorufin is highly 
fluorescent and pink in colour. Colorimetric determination is also possible but results lower 
sensitivity. DPR – decaprenyl-phosphorylribose, DPX – keto-intermediate of the 
epimerisation reaction. 
The native substrate DPR is difficult to obtain, highly amphipathic and forms micelles in a 
single phase aqueous buffer. Instead, substrates with shorter prenyl chains, carrying the same 
phosphorylribose moiety as DPR were prepared and evaluated. The shortened prenyl chains 
were farnesyl (3 isoprenes) and geranylgeranyl (4 isoprenes), with geranylgeranyl being 
reported to be already long enough to anchor a protein to a membrane surface (Resh, 2015). 
Both substrate analogues were provided by GSK. 
Reaction protocols were based on the published protocol of Batt et al. (2016). The reaction 
volume was 50 μl in 96-well plate format (Greiner Bio-One, black flat-bottom microplate, 
M9936) in an assay buffer containing 50 mM HEPES pH 7.5, 100 mM NaCl, 1.5 v/v % 
DMSO, 50 μM Brij-35, 5 μM FAD, 50 μM resazurin, 4 μM bovine serum albumin, substrate 
and Milli-Q water. Substrates farnesyl- and geranylgeranyl-phosphorylribose (FPR and 
GGPR) were added from 0 to 1.1 mM and 0 to 180 μM respectively, with reactions 
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performed in triplicates on the same plate. The plates were then incubated for 15 minutes on 
37 °C before measurement, initiating the reaction by the addition of the enzyme, Mt-DprE1 
in 2 μM final concentration. 
The reaction mixture was incubated at 37 °C throughout and monitored for 35 minutes with 
GGPR and 40 minutes with FPR. The fluorescence signal was indicative of first order 
reaction with a linear correlation between signal and time usually in the first six minutes of 
the measurement. Since the enzyme was added manually with ten measurement points in 
triplicates with two control reactions, resulting in altogether 26 reactions, with the first 
approximately two minutes of the reaction not measured. 
Each assay included two control reactions, one without enzyme and with 85 μM GGPR or 
400 μM FPR concentration (negative controls), and a positive control with wild type Mt-
DprE1 and 150 μM GGPR or 700 μM FPR (positive controls). 
Data were analysed by Microsoft Excel to calculate reaction rates, and GraphPad Prism for 
non-linear regression to fit one-site specific binding Hill-slopes to the reaction rates and 
calculate Vmax and Khalf values. For assays where automatic fit was not possible (deemed 
ambiguous by the software), were processed manually in Microsoft Excel. The Hill equation 







V is reaction rate, vmax is maximal reaction rate, S substrate concentration, h the Hill slope, 
and Khalf the substrate concentration at which the reaction rate is half of the maximal reaction 
rate. 
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2.3 Results and discussion 
 
2.3.1 Ligand binding assays 
A total of 11 single-site mutants and wild type Mt-DprE1 were expressed and purified. 
Intrinsic tryptophan fluorescence quenching for these proteins with non-covalent ligands 
93a3 and 8287, which are unpublished inhibitor compounds by GSK and bind the active site 
of the enzyme, were also evaluated. These ligands were chosen because they are known 
inhibitors of Mt-DprE1 by overexpression MIC shift in whole cell assay (unpublished), and 
the crystal structure of the enzyme-inhibitor complexes are also solved (unpublished work 
by Sarah Batt and Klaus Fütterer, University of Birmingham). The inhibitors bind near the 
FAD co-factor, near the hypothetic substrate-binding site. If the amino acid substitutions 
affected the microenvironment of the aromatic sidechains of the protein, it would imply 
conformational changes (Callis, 2014), and calculate parameters from the quenching, such 
as Kd and Bmax values. An example of recorded fluorescence spectra is shown in Figure 2.4. 
  




Figure 2.4. Typical intrinsic tryptophan fluorescence spectra collected in ligand 
binding studies. In the example wt Mt-DprE1 is titrated with ligand 8287. Excitation 
wavelength: 280 nm, emission maximum at 330 nm. Highest emission curve (in grey) 
corresponds to the ligand-free Mt-DprE1, decreasing signals to the addition steps of the 
ligand. Buffer background signal can be seen in orange, near the baseline with the solvent 
Raman peak (emission maximum around 307 nm). 
 
An interesting observation was that the wavelength of the fluorescence emission peak (λmax) 
was mostly influenced by not the replacement of the tryptophan at position 323, but the 
mutants of methionine and phenylalanine at positions 319 and 320 (see Figure 2.5.). 
Tryptophans and tyrosines are considered to contribute the most to the fluorescence 
intensity, and their immediate environment to influence the most λmax (Callis, 2014). There 
are eight tryptophans and thirteen tyrosines in Mt-DprE1, and one of each in the short 
disordered region 316-329 (full enzyme sequence in Appendix).  




Figure 2.5. Maximum emission peak differences among wt and mutant Mt-DprE1. 
Bright yellow point labels the maximum value in all measurements. All proteins are 1 µM 
in the same buffer composition, before any ligand addition. 
 
Ligand titration experiments were analysed to decide if any of the mutations significantly 
changed ligand affinity of the enzyme. Two different ligands were tested, and only the wild 
type and Mt-DprE1 W323A with both ligands, in the rest of the experiments only one ligand 
was measured. The primary aim of the experiment was to identify mutants with significantly 
different Kd values from the wild type, which would suggest an active participation from 
that residue in ligand binding and indicate the importance of the short disordered region in 
ligand binding.  
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construct Kd Kd SE Bmax Bmax SE 
wt 1.28 0.39 580 63 
P316G 2.02 0.23 672 34 
L317A 1.02 0.24 504 41 
D318A 1.07 0.14 628 28 
M319A 0.93 0.13 590 26 
F320A 0.78 0.11 479 21 
E322A 0.91 0.14 495 26 
W323A 1.70 0.43 450 43 
 
Table 2.2. Ligand binding analysis for Mt-DprE1 carrying point mutations in the 
mobile loop straddling across the active site with 93a3. Data were analysed by GraphPad 
Prism one-site ligand binding regression. Kd is dissociation constant [μM], Bmax is maximal 
change in fluorescence [relative fluorescence unit], SE is standard error. 
 
construct Kd Kd SE Bmax Bmax SE 
wt 2.78 0.72 393 44 
W323A 1.94 1.02 314 66 
N324A 2.52 0.63 304 30 
Y327A 1.73 0.72 303 44 
G328P 4.87 - 362 - 
P329A 4.47 1.08 374 50 
 
Table 2.3. Ligand binding analysis for Mt-DprE1 carrying point mutations in the 
mobile loop straddling across the active site with 8287. Data were analysed by GraphPad 
Prism one-site ligand binding regression. Kd is dissociation constant in [μM], Bmax is 
maximal change in fluorescence [relative fluorescence unit], SE is standard error. 
The measurements revealed no obvious changes in affinity, the largest deviations were still 
within range of analytical error (three-times the standard error of the wild type Kd, which 
means a Kd greater than 2.45 µM for 93a3, and 4.94 µM for 8287). 
It can be deduced that between the two ligands 93a3 has a higher affinity to the enzyme 
(lower Kd values) than 8287, and it is possible, that the higher Bmax values indicate a larger 
change in protein conformation. Although the latter is a speculation, since the fluorescence 
quenching could be due to both spatial protein backbone changes, as well as other qualitative 
changes in the conformation. 
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2.3.2 Enzyme activity assays 
To test the importance of the short disordered region (residues 316-329) of Mt-DprE1 
enzyme function, an activity assay based on the published protocol of Batt et al. (2016) was 
used. The physiological substrate DPR, would form micelles in aqueous solution, and could 
only be examined in a well-controlled membrane-solution interface. Alternatively, the 
strategy pursued in these studies takes advantage of truncated substrates (FPR and GGPR). 
Mt-DprE1 catalytic activity does not follow Michaelis-Menten kinetics. Instead, it shows 
allosteric enzyme kinetics. This has been observed before by Neres et al. (2012), and also in 
our research laboratories in Birmingham and at GSK (Batt et al., 2016). 
With both substrates the enzyme kinetics shaped a sigmoidal curve (see Figure 2.6), 
however turnover of the two differed: GGPR added to the reaction seemed to result in much 
higher resorufin formation than FPR. However, when continuing the experiments with a 
second batch of FPR, there was an 8-fold increase in fluorescence values and change in Kd 
values as well between the FPR batches. Considering the scarcity of the substrates available 
(only one batch of GGPR, and two batches of FPR) fluorescence values were used in the 
data analysis (instead of calculating turn-over numbers), compared to enzyme characteristic 
values Khalf, Vmax and h only relative to the wild type values performed with the exact same 
substrate batch. 




Figure 2.6. Kinetic allosteric sigmoidal fit curves of FPR batch 1 with wt and mutant 
Mt-DprE1. Error bars are the standard errors for three repeat measurements. 
The mutants grouped into three categories regarding activity. Complete inactivation was an 
arbitrary distinction with more than a 90% decrease in Vmax and highlighted in red. Active 
mutants have Vmax more than 50% of Vmax of wt Mt-DprE1 and are highlighted in green, 
with others termed ‘low activity’ highlighted in yellow (Tables 2.4. and 2.5.). 




Table 2.4. Allosteric sigmoidal curve fit values with FPR batch 1 in GraphPad Prism. 
Vmax is maximal reaction rate [fluorescence intensity unit/second], Khalf is substrate 
concentration at 50% of active sites occupied [µM], h is unitless. Active enzymes were 
highlighted in green (Vmax > 1/2 of Vmax wt), inactive in red (Vmax < 1/10 of Vmax wt), and 
low enzyme activity in yellow (1/10 < Vmax <1/2 of wt). Khalf is highlighted for mutant 
M319A to emphasise the lower affinity to FPR compared to any other mutant. Mutant P316G 
was completely inactive. ‘Ambiguous’ labels curve fits that have very wide confidence 
intervals. 
 
Table 2.5. Allosteric sigmoidal curve fit values with FPR batch 2. Highlighting as in 
Table 2.4. Mutant R325A appears to have a high Vmax, but actual activity is very low. Active 
enzymes were highlighted in green (Vmax > 1/2 of Vmax wt), inactive in red (Vmax < 1/10 of 
Vmax wt), and low enzyme activity in yellow (1/10 < Vmax <1/2 of wt). 
In summary, all mutants are less active than the wild type (Vmax is lower) in the FPR assay, 
most of them are inactive. In the case of Mt-DprE1 M319A the Khalf shifted significantly, 
while this parameter is hardly comparable in most other cases, with curve fitting barely 
possible (R square measures were below 0.6 with 6 mutants). 
wt P316G L317A D318A M319A F320A E322A W323A
Best fit values * Ambiguous
Vmax 2406 27.92 12.62 2715 281.1 327.4 126.3
h 3.034 ~ 86,84 101 1.92 3.371 4.209 10.82
Khalf 347.9 ~ 407,9 446.3 1469 571.9 332 414.8
Std. Error
Vmax 136.2 18.85 10.58 3038 40.38 35.91 18.71
h 0.4207 ~ 2,898e+008 834367 0.6139 0.9258 2.571 11.83
Khalf 19.19 ~ 2,655e+007 407532 1445 72.5 39.75 40.43
Goodness of Fit
Degrees of Freedom 21 20 21 21 21 21 21
R square 0.9803 0.1205 0.1166 0.9271 0.9273 0.8106 0.6793
wt G321P N324A R325A Y327A G328P P329A
Best fit values Ambiguous Ambiguous Ambiguous
Vmax 19 316 ~ 1,794e+007 134.5 ~ 71 233 375.7 74.16 4 019
h 2.247 1.271 7.882 ~ 0.4192 3.041 ~ 100.7 2.636
Khalf 549.8 ~ 421 462 290.2 ~ 6.850e+007 796.1 ~ 400.4 473.4
Std. Error
Vmax 1720 ~ 2.227e+010 24.64 ~ 1.636e+007 266.9 12.93 278.7
h 0.2978 0.4852 19.23 ~ 0.6696 2.014 ~ 8.190e+009 0.3952
Khalf 54.5 ~ 4.125e+008 58.88 ~ 3.909e+010 439.6 ~ 2.870e+007 33.98
Goodness of Fit
Degr. of Freedom 21 21 21 21 21 21 21
R square 0.9848 0.9223 0.4952 0.5563 0.7509 0.5261 0.9788
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To confirm substrate inhibition by GGPR, a reaction with and without the addition of 
400 µM geranylgeranyl-pyrophosphate (GGPP) was set up, and reaction rates measured. It 
showed lower enzyme activity in presence of GGPP (see Figure 2.7.) 
 
Figure 2.7. The effect of additional GGPP on 6xHis-Mt-DprE1 activity reaction rates 
with GGPR. Single shot experiment, graph connects measurement values, not a fitted curve. 
FI is relative fluorescence intensity. The reagent GGPP was kindly provided by James 
Harrison, University of Birmingham. 
 
Reaction rates were also determined with GGPR. However, it is important to point out that 
GGPR due to its amphipathic character unfolds DprE1 above a certain concentration, about 
220 µM substrate concentration. (This could be further examined and confirmed with NMR 
experiments in the future.) Therefore, enzyme activities were only measured below this 
critical concentration range, only until 180 µM and Vmax, Khalf extrapolated from this data. 
This is a limitation to all the results of these characteristic values describing DprE1 in the 
GGPR assay, therefore the listed Vmax and Khalf are all apparent values true to these 
measurement conditions. 
 




Table 2.6. Allosteric sigmoidal curve fit values with GGPR in GraphPad Prism. Asterix 
signs that fitting was not possible with DprE1 R325A, the enzyme had low activity (but not 
inactive). Active enzymes were highlighted in green (Vmax > 1/2 of Vmax wt), inactive in red 
(Vmax < 1/10 of Vmax wt), and low enzyme activity in yellow (1/10 < Vmax <1/2 of wt). 
 
Accepting the limitations of the GGPR assay and considering its results comparable with the 
FPR assay reaction rates, we can observe that the wild type enzyme has higher affinity to 
GGPR than to FPR (lower Khalf values). However, Khalf values are to be handled here with 
caution, because based on the two FPR batches would have different affinities to wt Mt-
DprE1. Also, the fluorescence values are higher with GGPR than any of the FPR batches, 
which is difficult to elucidate theoretically, but as a more practical aspect the GGPR assay 
has a better signal-to-noise ratio than the FPR assay, which is advantageous in 
miniaturisation of the high-throughput screen.  
Another minor difference between FPR and GGPR enzyme activity tests is that with GGPR 
only five mutants were inactive, while with FPR there were eight (table 2.7.). This can be 
explained by the aforementioned better signal-to-noise ratio. Also, since the activity scale 
was arbitrarily chosen, other thresholds could possibly deliver the same activity results with 
the two substrates. 
In general, it seems that the GGPR assay is more robust, but it would be presumptuous to 
conclude that it is a more relevant model of the enzyme mechanism than the FPR assay. 
wt P316G L317A D318A M319A F320A G321P E322A W323A N324A R325A Y327A G328P P329A
Best-fit values *
Vmax 41 095 410.3 933.2 200.8 37 805 49 243 50 541 25 763 8 047 5 186 748 561.2 13 871
h 4.927 2.699 6.005 13.73 5.103 5.272 8.128 7.646 7.391 8.011 8.609 8.271 5.886
Khalf 101.5 69.41 97.07 73.89 92.96 139.2 117.6 72.89 131.4 102.1 100.7 96.16 108.4
Std. Error
Vmax 1965 92.69 71.42 21.59 807.1 3743 3044 555.8 456.6 304.3 31.41 37.98 643.3
h 0.587 1.548 1.539 11.2 0.332 0.474 1.479 1.074 0.835 1.732 1.433 2.291 0.698
Khalf 3.094 16.21 4.659 4.933 1.298 5.22 3.404 1.177 3.277 3.248 2.259 3.63 2.892
Goodness of Fit
Degr. of freedom 21 21 19 21 21 21 21 21 21 21 21 21 21 21
R square 0.9795 0.651 0.917 0.58 0.994 0.99 0.959 0.9815 0.9842 0.935 0.96 0.896 0.979
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However, for inhibitor testing it is preferable, because GGPR is more stable in buffer 
solutions, FPR once dissolved in buffer could not be frozen again or reused later, while 
GGPR could withstand many freeze-thaw cycles. 
To better understand the consequences of single amino-acid substitutions in Mt-DprE1 
Table 2.7 showcases the assigned enzyme activities – active, low activity, inactive with 
colour-scale with both substrates, along with the level of evolutionary conservation of the 
specific residues. 
 
Table 2.7. Similarities between enzyme activity results and residue conservation among 
example species of the order of Actinobacteria. Pseudomonas fluorescens is a Gram-
negative non-related species with a published probable dpre1. Below the name of the species 
UniProt (UniProt Consortium, 2018) accession numbers are shown. Highlighting as in 
Table 2.4. Grey colour depicts amino acids that are identical with the residues in M. 
tuberculosis. Active enzymes were highlighted in green (Vmax > 1/2 of Vmax wt), inactive in 
red (Vmax < 1/10 of Vmax wt), and low enzyme activity in yellow (1/10 < Vmax <1/2 of wt). 
It can be deduced that the substitutions in Mt-DprE1 that caused enzyme inactivation are the 
most conserved residues between related species. Also, since alanine 326 was not mutated 







P L D M F G E W N R A Y G P
M. smegmatis
A0R607
P L D M F G E W N R A Y G S
M. leprae
Q9CDA4




P L D L I G E W N R G Y G S
Rhodococcus sp. PBTS 2
A0A143QI70
P L D M F S E W N R A Y G S
Nocardia terpenica
A0A291RC15
P L D M M G E W N R G Y G S
Gordonia phthalatica
A0A0N9N880
P L D L F G N W N R A Y G S
Streptomyces regensis
A0A0J8AGH2




P L D R I E H W N R I Y G R
P316G L317A D318A M319A F320A G321P E322A W323A N324A R325A A326 Y327A G328P P329A
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maybe lower enzyme activity, but most likely it would not inactivate the enzyme, since some 
orthologs of Mt-DprE1 have that amino acid substitution. 
It is interesting to note, that in the case of proline 329, it is often replaced by other amino 
acids, even alanine in the orthologous enzymes (Table 2.7.), yet single amino acid 
substitution to alanine lowered enzyme activity significantly.  
In conclusion it can be said that there is a correlation between Mt-DprE1 mutant enzyme 
activity and evolutionary conservation in residues, but one does not strictly determine the 
other. 
A possible explanation to sigmoidal kinetics in monomeric enzymes is a gateway function 
of some flexible parts of the protein. A lid-like motion of mobile loops near the active site 
could limit active site access. When the time-scale of lid motion is comparable to the enzyme 
turn-over, it can without actual cooperativity exhibit allosteric enzyme kinetics (Porter and 
Miller, 2012). It is possible, that the short disordered region 316-329 limits enzyme activity 
in a lid-like manner, causing the sigmoidal substrate-response kinetic curve. Following this 
hypothesis, the enzyme activity results with single site mutants highlight two distinct hinge-
like parts to the “lid”, residues 316-318 and 327-328, which cannot be replaced without 
major hindrance of enzyme function. 
It is possible that the loop interacts with the prenyl-chain of the substrate, and that the 
geranylgeranyl group contributes to the interaction more like the native substrate than the 
farnesyl substrate. To this end, crystallisation trials were set up with inactive mutants Mt-
DprE1 K367A published as the inactive mutant of ortholog K425A DprE1 M. smegmatis 
(Neres et al., 2012) and Mt-DprE1 K418A (unpublished inactive mutant by Sarah M. Batt, 
Universityy of Birmingham) with GGPR. Unfortunately, the achieved crystals did not 
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diffract, but it is an experiment of interest that could be repeated or performed with other 
mutants in the future, that could give an insight into enzyme-substrate interaction. 
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3 Expression and purification of Mt-DprE2 
 
3.1 Introduction 
To characterise and perform enzymatic assays with Mt-DprE2, large quantities of 
enzymologically active, purified protein is needed. Literature on Mt-DprE2 reports genetic 
analyses (Sridhar et al., 2016), whole cell experiments (Kolly et al., 2014) and in silico 
modelling (Bhutani et al., 2015). However, the production of pure, enzymatically active 
recombinant Mt-DprE2 has not yet been reported. Attempts have been made to produce 
recombinant Mt-DprE2 in E. coli, but purified Mt-DprE2 forms large aggregates, as is 
evident from ultracentrifugation experiments, and it did not crystallise (unpublished work 
by Sarah M. Batt, University of Birmingham). This body of work aims at developing a 
biochemical assay reporting on Mt-DprE2 activity and identification of inhibitors. 




Commercially available pMal-p2x was inserted with Mt-dprE2 utilising XmnI and HindIII 
restriction endonuclease sites. The plasmid design utilises XmnI blunt-end cleaving 
restriction endonuclease, using any other site in the multicloning site would add additional 
amino acids into the overexpressed fusion protein between the Xa protease cleaving site in 
the MBP-tag and the target protein, Mt-DprE2. Therefore, the type IIS restriction enzyme 
SapI was used to create a sticky end at the N-terminus of the insert with the required amino 
acid code, producing the required blunt end by Klenow-fragment treatment. 
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Prior to inserting Mt-dprE2 in the pMal-p2x vector, the innate SapI recognition site was 
silenced in the pET-6xHis-SUMO-DprE2 vector by Quikchange mutagenesis (Agilent 
Technologies, 2011), then Mt-dprE2 gene was amplified by PCR. The amplicon was cleaved 
with SapI and purified using the QIAquick PCR Purification Kit (Qiagen, ID: 28106), then 
treated with Klenow-fragment of DNA polymerase according to manufacturer’s protocol 
(New England Biolabs, #M0210S). The amplicon was cleaved with HindIII and ligated with 
XmnI-HindIII double digested pMal-p2x vector with T4 DNA ligase (New England Biolabs, 
#M0202S). The cloning process is depicted in Figure 3.1. 
The final construct was transformed into E. coli Top10, isolated using the Qiagen Miniprep 
Kit (ID: 27106), performed diagnostic digest with HindIII and NdeI. Selected clone 
sequences were confirmed by Sanger sequencing by Eurofin Genomics Ltd. 
 
Figure 3.1. The cloning process of pMAL-p2x-MBP-Mt-DprE2 plasmid. A) The PCR 
amplicon of Mt-dprE2 gene. In blue frame forward and reverse primers (with 
complementary strands), enzyme recognition sites in grey, overhangs after enzyme cut are 
signalled in red. GTT base triplet of the SapI overhang is the first code of Mt-dprE2. B) 
Ligation of vector and insert. The final product does not contain any SapI or XmnI restriction 
endonuclease recognition sites. 




The gene Mt-dprE2 was amplified from pET-6xHis-Mt-DprE2 (construct made by Sarah M. 
Batt, University of Birmingham) and inserted into pET-6xHis-SUMO vector (modified 
plasmid provided by Dr. Patrick Moynihan, University of Birmingham) using the BamHI 
and HindIII restriction endonuclease sites. A two-step PCR was performed with 52 °C and 
63 °C annealing temperatures, both vector and insert digested and visualised on an agarose 
gel. Corresponding bands were extracted using the QIAquick Gel Extraction Kit (Qiagen, 
#28706) and ligated with T4 DNA ligase. The resulting plasmid was tested by restriction 
digest with NotI and verified by Sanger sequencing by Eurofin Genomics Ltd. 
3.2.1.3 Tag-free Mt-DprE2 
In order to perform co-expression studies with Mt-DprE1 from separate plasmids, tag-free 
Mt-DprE2 was required. Consideration of selectable markers suggested the use of a pET-
6xHis-SUMO-Mt-DprE2 vector, as it carries kanamycin resistance. The 6xHis-SUMO-tags 
were deleted by Quikchange mutagenesis (Agilent Technologies, 2011), primers are listed 
in Appendix. 
The resulting clone was digested with NotI and BglI restriction endonucleases and visualised 
on an agarose gel, clones confirmed by Sanger sequencing by Eurofin Genomics Ltd. 
3.2.2 Mt-DprE2 protein purification 
3.2.2.1 Periplasmic MBP-Mt-DprE2 
This experiment aimed at producing Mt-DprE2 with a chaperonin-like tag that could be 
separated from contaminating proteins in fewer steps than with cytosolic expression. This 
protocol is based on the periplasmic extraction described by Chen et al. (2004). A new 
transformation of pMAL-p2x-Mt-DprE2 plasmid into E. coli BL21 was performed, colonies 
selected on 100 µg/ml ampicillin supplemented LB agar. Bulk cultures (1 L) were inoculated 
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with a 10 ml overnight culture and grown to an OD600=0.8 at 37 °C while shaking at 180-
200 rpm. The cultures were than cooled to 18 °C and 0.3 mM final concentration of IPTG 
was added to induce overexpression and incubated overnight. Cells from a 1.25 L culture 
were harvested by centrifugation, washed with 0.85% ice-cold saline solution, and pellets 
stored at -20 °C until use. 
Pre-treatment of cells consisted of resuspension in 30 ml of ice-cold 5 mM CaCl2 solution, 
incubated on ice for 10 min, cells were pelleted by centrifugation and the supernatant 
discarded. Then in the high osmotic pressure step the pellet was resuspended in 40 ml 
shrinker buffer, 20 w/v% sucrose, 50 mM Tris-HCl pH 8.0, 5 mM 
ethylenediaminetetraacetic acid (EDTA), and incubated on ice for 10 min, cells were 
pelleted and the supernatant discarded. Finally, in the osmotic shock step the pellet was 
resuspended in 50 ml 5 mM MgSO4 solution and incubated on ice for 10 min. Cell debris 
was separated by high speed centrifugation (15,000 rpm, 4 °C, 30 min) and the supernatant 
kept, and the pellet discarded. The supernatant was adjusted to the column buffer 
composition, 50 mM Tris-HCl pH 7, 400 mM NaCl for affinity chromatography.  
An MBP-Trap column (GE Healthcare, #28-9187-78) was pre-equilibrated with column 
buffer and the sample loaded at 1 ml/min by a peristaltic pump. The column was washed 
with 40 ml buffer, 50 mM Tris-HCl pH 7.5, 200 mM NaCl, and the fusion protein eluted 
with 15 ml of wash buffer with 10 mM maltose, then dialysed to 50 mM Tris-HCl pH 7.8, 
150 mM NaCl, 10% glycerol using a 15 kDa dialysis tube (Sigma #D0530), and then 
concentrated to 1 ml through ultrafiltration (Amicon® Ultra-15 PLGC Ultracel-PL 
membrane, MWCO 10 kDa) and stored fat -20 °C. 
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3.2.2.2 6xHis-Mt-DprE2 production 
E. coli BL21 cells were heat-transformed with pET-6xHis-SUMO-Mt-DprE2 plasmid and 
grown overnight at 37 °C in LB broth supplemented with 50 µg/ml kanamycin. Bulk cultures 
(1 L) were inoculated with 10 ml overnight culture and grown at 37 °C with shaking to 
OD600=0.4-0.8. Then cultures were cooled to 20 °C, overexpression induced with 0.5 mM 
IPTG and continued overnight. Cells were harvested by centrifugation, washed with 0.85% 
saline solution, and pellets stored at -20 °C until further use. 
Protein was extracted from a 2.5 L culture cell pellet by resuspending in 60 ml of ice cold 
lysis buffer: 100 mM NaH2PO4 pH 8.0, 250 mM NaCl, 0.05% (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate, (CHAPS, Sigma #C3023), 
10 mM imidazole pH 8.0, 10 mM (tris(2-carboxyethyl)phosphine hydrochloride, (TCEP, 
Sigma #C4706), 1 tablet of cOmplete Mini Protease Inhibitor Cocktail (Roche 
#11836153001) and sonicated (10 s input, 20 s pause on ice, for 10 cycles). Following cell 
lysis all extraction steps were conducted on ice. Cell debris was separated by high-speed 
centrifugation (21,800 x g, 4 °C, 30 min), the supernatant collected and filtered through a 
0.22 μm syringe filter disk where necessary.  
A HisTrap column (1 ml, GE Healthcare #17524701) was pre-equilibrated with lysis buffer 
and loaded with the protein sample at 1 ml/min via a peristaltic pump. Alternatively, 1.5 ml 
of Talon resin slurry (Clontech, #635503) was used instead of a prepacked column, washing 
steps performed similarly, separating the resin from supernatant by low speed centrifugation. 
The column was washed with 20 ml of lysis buffer, followed by 20 ml of lysis buffer with 
40 mM imidazole, then the buffer changed to 20 ml of column buffer (100 mM Tris-HCl pH 
8.5, 200 mM NaCl, 5% glycerol) and eluted in approximately 15 ml of elution buffer 
(column buffer containing 300 mM imidazole, pH 8). Overnight dialysis was avoided to 
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prevent possible protein aggregation and/or degradation by eliminating imidazole by 
concentrating and diluting the sample repeatedly three times into storage buffer (50 mM 
Tris-HCl pH 8.5, 50 mM NaCl, 10% glycerol). The final volume was 1 ml to 1.5 ml, and the 
sample was stored at -20 °C until further use. A 2.5 L culture of bacteria yielded approx. 6-
10 mg of pure protein  using this methodology. 
It was observed that ultrafiltration partially precipitated the protein (visible aggregate 
membrane formed over the filter), therefore a possible alternative would be to elute the 
protein from Talon or a Ni-NTA bead resin in a small elution volume and replace the buffer 
by PD-10 desalting columns (GE Healthcare #17085101 or similar). 
For size exclusion chromatography (SEC) the eluted sample was dialysed (Sigma #D0530, 
MWCO 15 kDa) overnight at 4 °C in SEC buffer (60 mM Tris-HCl pH 8, 200 mM NaCl). 
Overnight dialysis with lower salt concentrations lead to a complete precipitation of the 
protein, repeatedly. 
3.2.2.3 Small-scale protein expression trials 
Small-scale trials were conducted to confirm protein expression levels and select preferable 
co-expression partners, for example whether to include chaperon proteins. Chemically 
competent E. coli cells were transformed by heat shock (Green and Sambrook, 2012) with 
selected plasmids. Clones were selected on LB agar supplemented with appropriate 
antibiotics (100 µg/ml of streptomycin or ampicillin, kanamycin at 50 µg/ml final 
concentration). Plates were incubated at 37 °C in a static thermostat, single colonies spotted 
and used for inoculation of 5 ml LB broth aliquots. These small batches were incubated at 
37 °C while shaking (180-200 rpm) until OD600 = 0.6, then overexpression induced with 
1 mM IPTG and continued at 18 °C overnight. 
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Cells were harvested by centrifugation and washed with ice cold 0.85% saline solution, then 
transferred to clean 2 ml test tubes. Cells were then pelleted and resuspended in base buffer 
(50 mM Tris-HCl pH 8, 50 mM NaCl, 5% glycerol). 0.5 g of glass beads were added, then 
cell lysis achieved using a bead beater FastPrep-24 (MP Biomedicals), with the 
recommended program for E. coli, the program repeated three times. Cell debris was 
separated via centrifugation at a maximum speed in a bench-top centrifuge (13,000 rpm, 
2 min, room temperature). 40 µl of a pre-equilibrated Ni2+ or Co2+-covered bead slurry was 
added (Ni-NTA agarose Qiagen #30210, Talon metal affinity resin Clonetech #635502) and 
samples were incubated on ice for 30 minutes with manual gentle mixing, periodically. After 
binding the beads were separated by centrifugation at low speed (5000 rpm, 2 minutes, room 
temperature) and washed with base buffer supplemented with 20 mM imidazole. The 
supernatant was removed and washing step repeated twice. Finally, the beads were collected 
at low speed centrifugation and all samples were kept on ice until use and analysed by SDS-
PAGE. 
The affinity chromatography resin beads were treated as regular protein samples for heating 
with loading dye and loaded onto a precast gel. The SDS content of the loading dye (Green 
and Sambrook, 2012) elutes the proteins from the beads. When loading on the gel, the 20 µl 
pipette tips needed to be cut with a scissor for enlarging the tip for the slurry. Beads were 
visible on the gel but remained in the pocket, however the bound proteins penetrated the 
acrylamide matrix for separation. 
3.2.2.4 Mt-DprE1-Mt-DprE2 co-purification 
Co-purification of Mt-DprE1 and Mt-DprE2 have been attempted in three different setups 
that are summarised in Table 3.1. All constructs share the principle of utilising the 6xHis-
tag fused to Mt-DprE1 and co-purify a tag-free Mt-DprE2 that associates with Mt-DprE1 as 
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hypothesised and observed elsewhere (two-hybrid system in C. glutamicum in (Jankute et 








 coding gene rv3790 rv3791 
groEL2 (MTB) 
groES (E. Coli) 
rv3789 
  plasmid that carries this protein: 
construct 1 pCDFDuet (2 cassettes) pTrc99a pET 
construct 2 pCDFDuet (2 cassettes) pTrc99a - 
construct 3 pCDFDuet pET pTrc99a - 
 
Table 3.1. Mt-DprE1-Mt-DprE2 co-expression constructs grouped by plasmids 
carrying targeted proteins. Plasmids are labelled by commercial vector name without 
inserted target protein. For pCDFDuet the selection marker is streptomycin/spectinomycin, 
for pET kanamycin, for pTrc99a ampicillin.  
 
3.2.3 Analytical size exclusion chromatography (SEC) 
Size exclusion chromatography was performed using a Superdex 16/600 200 pg (GE 
Healthcare, 28-9893-35), with column volume 120 ml and maximum recommended 
purification sample of 4 ml and 22 mg protein, according to manufacturer’s manual. The 
column was washed with one column volume MilliQ (doubly deionised) water and 
equilibrated with one column volume of buffer (40 mM Tris-HCl pH 8, 200 mM NaCl for 
6xHis-SUMO-Mt-DprE2, and 40 mM Tris-HCl pH 8.5, 20 mM NaCl, 10% glycerol for Mt-
DprE1-Mt-DprE2 co-expresssion). 
The size exclusion run used a ÄKTA pure chromatography system (GE Life Sciences). The 
sample was filtered (0.22 µm) before use and 3.6 ml injected in the sample loop, which was 
emptied with continuous pressure and 5 ml buffer onto the column. Flow rate was set to 
1 ml/min, the process took place in a cold room (4-6 °C). Fractions of 1.8 ml were collected 
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by the system in a deep well 96-well plate (after 0.15 CV delay for collection). Absorbance 
chromatograms were recorded at 280 nm (protein maximum absorbance) and 340 nm 
(NADH maximum absorbance). Fractions were supplemented with 0.2 ml of glycerol for 
cryoprotection and stored at -20 °C until use. 
Calibration of SEC measurement was performed with bovine serum albumin (Sigma 
#A3803). The mature protein is 66.463 kDa (UniProt Consortium, 2018) and in solution 
forms monomers and dimers (Levi and González Flecha, 2002). The void volume (Vvoid) 
was measured with blue dextran (Sigma #D5751, molecular weight approx. 2 MDa) and 
found to be 45 ml. Based on the manufacturers’ manual of the column, the relationship 
between apparent distribution coefficient (Kav) and the logarithm of the molecular weight of 





Velution is the volume at which a given protein sample elutes, thus every protein of a given 
size has a relevant Kav value. For better illustration the calibration curve is showcased in the 
results section (Figure 3.10.). 
3.2.4 Thermal shift assay (TSA) 
Also called differential scanning fluorimetry, thermal shift assay (TSA) is a technique that 
has been used to test protein stability in ligand-binding screens, including in high-throughput 
settings (Sorrell et al., 2010). This assay measures the protein melting temperature as a 
function of solvent composition. Protein unfolding in monitored by addition of a highly 
hydrophobic fluorescent dye, such as Sypro Orange. Melting temperature (Tm) is defined as 
the temperature at which 50% of the protein is unfolded. This method is favourable because 
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it requires small quantities of pure protein, inexpensive reagents and a real-time PCR thermal 
cycler. 
The measurements were performed on a Applied Biosciences 7500 Fast Real-Time PCR 
System, recorded on a 7500 Software v2.0.6, data collected from the TAMRA filter (‘Filter 
3’, emission peak around 580 nm) and data analysed with the freely available DMAN 
software (Wang et al., 2012). The reactions were set up in a MicroAmp Fast Optical 96-well 
reaction plate, sealed with MicroAmp Optical Adhesive Film (#4311971). The first and last 
row and end-columns on the plates contained only water to prevent evaporation of the 
reaction mixtures. The dye Sypro Orange used was from Sigma (#S5692-50UL), a 5000x 
stock solution in DMSO, always diluted freshly in MilliQ water to a 200-fold solution for 
the experiment. The final reaction volume was 20 µl that contained 0.5 µl dye (5x final 
concentration). Final protein concentration was approximately 0.2-0.5 mg/ml, all reactions 
were in triplicates on the same plate. 
3.2.5 Mt-DprE2 enzyme activity assay 
The assay is loosely based on the Mt-DprE1 enzyme activity assay developed in GSK. The 
main constituents of the general reaction mixture are the enzymes Mt-DprE1 and Mt-DprE2, 
either as a co-expressed and co-purified mixture, or added separately as 6xHis-Mt-DprE1 
and 6xHis-SUMO-Mt-DprE2. The reaction mixture contained the substrate GGPR, provided 
by GSK as a 10 mM stock solution in 50 mM HEPES pH 7.5. The assay buffer was kept 
near physiological pH, most experiments conducted in GSK utilised bis-tris propane (BTP), 
whereas experiments at the University of Birmingham were conducted in HEPES buffer for 
comparability with previous studies. A minimum of 40 mM NaCl was added to reactions for 
osmotic pressure. NADH (Sigma, #N8129) and NADPH (Sigma, #N0411-15VL) stock 
solutions were prepared in 20 mM Tris-HCl buffer pH 8.5 and small aliquots kept at -20 °C, 
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and freeze-thaw cycles limited to three. Final reaction volumes were 10 µl for each reaction, 
in a 384-well small volume microplates (Greiner, #784076). Exact reaction mixtures are 
always showcased with specific experiment in the results section.  
The assays at GSK were performed with SpectraMax M2 and SpectraMax M5e instruments, 
fluorescence measurements with a monochromator set to 340 nm excitation and 462 nm 
emission wavelength. The reaction mixture was kept at 26 °C for 5 min, before reaction was 
initiated with manual GGPR substrate addition. Assays were monitored as kinetic readout 
for 40-90 minutes, 20 reads/well, and 15 sec/cycle. 
The assay at the University of Birmingham was performed using a PHERAstar FS microtitre 
plate reader, with fixed fluorescence filters at 350/450 nm, and assays run for a minimum of 
50 minutes. 
Control reactions included buffer and salt solution, the co-factor in buffer and salt solution, 
at least one negative control lacking either GGPR or one of the enzymes and a positive 
control with all necessary reagents added for enzyme activity. 
3.3 Results 
 
3.3.1 Initial purification methods of recombinant Mt-DprE2 
Expression and purification of MBP-Mt-DprE2 has been attempted to the cytoplasm 
(unpublished work by Sarah M. Batt, University of Birmingham) and had no significant 
benefit to protein production. However, the plasmid that fuses MBP-tag to the target protein 
was also available with the signal peptide for periplasmic translocation, which had the 
prospect of purifying Mt-DprE2 in fewer steps from the periplasm of E. coli (without the 
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contaminating proteins within the cytoplasm), and a possible disadvantage of producing low 
amounts of protein. 
The purification of MBP-Mt-DprE2 from the periplasm was attempted twice and produced 
highly pure protein with possible contaminations only from the self-cleaved proteins (based 
on protein size by SDS-PAGE, Figure 3.2.). Unfortunately, out of 5 L of bacteria culture 
this method produced only a total of 1.5 mg protein, which assessed by ultracentrifugation 
sedimented as a large aggregate. Therefore, this protein production strategy was abandoned. 
 
Figure 3.2. SDS-PAGE analysis of MBP-Mt-DprE2 periplasmic protein purification. 
Sample 5 is eluted and concentrated, approximately 10 µg protein loaded on SDS-PAGE 
gel. The column binds both the fusion protein and spontaneously cleaved MBP-tag. Pellet 
sample 2 floated out of the well. MBP-Mt-DprE2 is 72.4 kDa, MBP-tag 42.9 kDa, Mt-
DprE2 27.5 kDa. 
The co-expression of His-Mt-DprE1 with Mt-DprE2, chaperons and Mt-GtrA (construct 1 
in Table 3.1.) was unsuccessful due to the low levels of target proteins observed after 
purification. As captured in Figure 3.3., the small-scale expression trial conducted with this 
set-up and also large scale purification attempts (not illustrated) produced insufficient 
amounts of Mt-DprE2 for further investigation. 




Figure 3.3. Small-scale purification trial with co-expression of 6xHis-Mt-DprE1, Mt-
DprE2, chaperones GroES/GroEL, and Mt-GtrA. Samples are 15 µl slurry samples of 
Ni-NTA beads and proteins bound to them after a 40 mM imidazole wash, different clones 
(1 to 5) of the same construct. Ctrl sample is large scale purified clone after metal affinity 
and ion exchange chromatography, reference sample from Luke Broadbent (University of 
Birmingham). Mt-GtrA is 13.3 kDa integral membrane protein, not expected in the purified 
samples. MM is 7 µl molecule marker (New England Biolabs, #P77065). 6xHis-Mt-DprE1 
is 51.8 kDa, Mt-DprE2 is 27.5 kDa. 
What was more concerning about the Mt-GtrA co-expression profile is that it produced high 
amounts of a protein with slightly higher size based on SDS-PAGE than Mt-DprE1, easily 
confused with Mt-DprE1 in SDS-PAGE analysis, complicating both identification and 
quantification of Mt-DprE1. As illustrated in Figure 3.4., co-expression of Mt-DprE1 with 
Mt-DprE2 and chaperons without Mt-GtrA did not produce this contaminant. Ion exchange 
chromatography was also implemented to separate Mt-DprE1 or more likely a complex of 
Mt-DprE1 and Mt-DprE2 from this abundant contaminating protein but was not successful 
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(see Figure 3.5.). The complex eluted at much higher salt concentration than 6xHis-Mt-
DprE1 alone and eluted together with the contaminant. 
 
Figure 3.4. Protein products of Mt-DprE1 alone and Mt-DprE1-Mt-DprE2 co-
expressions. IMAC is immobilised metal affinity chromatography, IEX is ion exchange 
chromatography. MM is 5 µl molecule marker (New England Biolabs, #P77065). 6xHis-Mt-
DprE1 is 51.8 kDa, Mt-DprE2 is 27.5 kDa. 
  




Figure 3.5. Ion exchange chromatography purification of Mt-DprE1 constructs. (A) 
6xHis-Mt-DprE1 with GroES/GroEL, (B) 6xHis-Mt-DprE1 co-expression with Mt-DprE2, 
GroES/GroEL, and Mt-GtrA. IMAC is immobilised affinity chromatography sample eluted 
from the HisTrap column, FT is flow-through (protein unbound to the anion exchange 
column), numbers depict NaCl concentration [mM] of the eluted sample. MM is 7 µl 
molecule marker (A) ThermoFisher #26616 and (B) New England Biolabs, #P77065. 15 µl 
samples loaded on the gel. 6xHis-Mt-DprE1 is 51.8 kDa, Mt-DprE2 is 27.5 kDa. 
 
3.3.2 6xHis-SUMO-Mt-DprE2 production 
6xHis-SUMO-Mt-DprE2 fusion protein expressed from a pET-based plasmid produced high 
amounts of protein via metal affinity chromatography (see Figure 3.6.).  
In order to enhance protein expression two additives were tested during protein expression. 
Benzyl-alcohol (BA) induces membrane fluidisation in E. coli and elicits increased native 
chaperone expression (De Marco et al., 2005). Together with the osmolyte betaine especially 
high levels of recombinant proteins have been achieved (De Marco et al., 2005). 




Figure 3.6. Additive optimisation of 6xHis-SUMO-Mt-DprE2 expression. BA is benzyl 
alcohol, TP total protein after cell lysis, S supernatant after centrifugation of lysed cells, W 
washing step with 50 mM imidazole, E elution step with 300 mM imidazole, MM molecule 
marker (ThermoFisher, #26619). 3 µl of TP and S, 15 µl of W and E samples were loaded 
on the gels. 6xHis-SUMO-Mt-DprE2 is 40.9 kDa. 
The chosen additives did not visibly alter expression levels of 6xHis-SUMO-Mt-DprE2 (see 
Figure 3.6.). However, as the osmotic stabiliser betaine is relatively inexpensive, it was 
included in the liquid broth during overexpression of this construct. 
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3.3.3 6xHis-Mt-DprE1 and Mt-DprE2 co-expression 
Co-expression of the two proteins, Mt-DprE1 and Mt-DprE2 was successful aided by 
chaperon proteins. In Figure 3.7. the expression levels are compared when including or 
omitting chaperon, co-expression with the chaperons showed increased levels of Mt-DprE1 
and consequently Mt-DprE2. 
 
Figure 3.7. Small-scale expression trials with 6xHis-Mt-DprE1 and Mt-DprE2 co-
expression assessing chaperone necessity. S signifies soluble fraction after lysis, B labels 
Ni-bead bound protein samples. Clones 1 to 5 were tested. MM is molecule marker (New 
England Biolabs, #P77065). Chaperons are GroES from E. coli and GroEL (groEL2) from 
M. tuberculosis. Mt-DprE2 is expressed from a pET plasmid, separate from 6xHis-Mt-
DprE1 (construct 3 in table 3.1.). 6xHis-Mt-DprE1 is 51.8 kDa, Mt-DprE2 is 27.5 kDa. 
It was tested whether ion exchange chromatography improved protein purity following metal 
affinity chromatography. Overall protein yields were low and Mt-DprE2 production barely 
visible on SDS-PAGE (Figure 3.8.). Hence, ion exchange chromatography was omitted in 
following studies. 




Figure 3.8. Ion exchange chromatography of Mt-DprE1-Mt-DprE2 co-expression. The 
construct co-expressed 6xHis-Mt-DprE1, Mt-DprE2 and GroES/GroEL proteins. ‘IMAC 
300’ is the sample after metal affinity chromatography, eluted in 300 mM imidazole and 
dialysed. FT is flow-through (proteins unbound to the anion exchange column), numbers 
label the NaCl concentration in [mM] in the eluted fraction from DEAE anion exchange 
column. ‘cc’ signifies that the sample was concentrated via filtration. MM is molecule 
marker, here ThermoFisher #26616 was compared to Amresco #J383, the latter producing 
unusual running pattern indicating higher protein size than true. 6xHis-Mt-DprE1 is 
51.8 kDa, Mt-DprE2 is 27.5 kDa. 
The expression of Mt-DprE2 from a separate plasmid (Table 3.1. construct 3) also produced 
Mt-DprE2, notably the highest relative Mt-DprE2 concentration compared to Mt-DprE1 (see 
Figure 3.9.). Based on the SDS-PAGE analysis this construct contained an approximately 
1:1 ratio of the two proteins. 




Figure 3.9. Co-expression of Mt-DprE1 and Mt-DprE2 transcribed from separate 
plasmids. The construct co-expressed 6xHis-Mt-DprE1, Mt-DprE2, GroES/GroEL 
(construct 3 in Table 3.1.). Soluble protein is sample after cell lysis and centrifugation, 
IMAC is immobilised metal affinity chromatography, FT is flow-through (proteins unbound 
to HisTrap column), numbers signify imidazole concentration in [mM] in eluted fraction. 
Ctrl is reference sample from Luke Broadbent (University of Birmingham). MM is molecule 
marker (New England Biolabs, #P77065). 6xHis-Mt-DprE1 is 51.8 kDa, Mt-DprE2 is 
27.5 kDa. 
 
3.3.4 Analytical size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) separates proteins or macromolecules by 
hydrodynamic radius. Here I analysed if SUMO-tag-fused Mt-DprE2 was prone to 
aggregation, furthermore if 6xHis-DprE1 formed a complex with DprE2. 
All SEC experiments with 6xHis-SUMO-Mt-DprE2 resulted in low concentration protein 
samples. This is due to the aggregation in the IMAC eluted sample, because concentration 
via ultrafiltration promotes aggregation on the filter, and aggregates need to be removed by 
filtration (0.22 µm) before loading onto a SEC column. Thus, the highest protein 
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concentration achieved was only 5 mg/ml (based on an absorption at 280 nm). Also, the 
column had a limit of 4 ml for loaded sample. These limits resulted in low protein 
concentration fractions after chromatography, that in biochemical assays performed more 
poorly than the more contaminated but concentrated sample before SEC purification. 
 
Figure 3.10. Calibration and size estimation of 6xHis-SUMO-Mt-DprE2 in SEC. 
(A) Calibration with bovine serum albumin (monomer and dimer) and blue dextran (void 
volume). Equation for linear regression and coefficient of determination (R2) is in box on 
top right. (B) Peaks of representative species from two SEC measurements (SEC_02 and 
SEC_03). Kav is apparent dissociation constant. 
The measurement was repeated three times with similar results. Most of the protein eluted 
as a large aggregate around 45 ml (void volume), while a small fraction of the protein eluted 
at near 70 ml elution volume. This fraction contained a 6xHis-SUMO-Mt-DprE2 oligomer 
with degrading contaminant according to the SDS-PAGE visualisation (see Figure 3.11.). 
Based on the calibration with bovine serum albumin, the oligomer is about 100 kDa in size. 
Since the fusion protein is 40.88 kDa, taken together with results of the repeat experiment, 
where the oligomer eluted as a double peak at 73 and 81 ml (calculated weights 84 and 
66 kDa, respectively, Figure 3.11.B), the oligomer is likely a dimer. This is reproduced in 
Figure 3.12., where a second small peak (see fraction eluting at 80.5 ml) also appeared, 
which was likely the degradation product of this dimer. The contaminant proteins present in 
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these samples are visualised on SDS-PAGE and appear to be also between 70 and 100 kDa, 
which further supports the conclusion of it being a dimer (see fraction eluting at 64 ml in 
Figure 3.11.C). 
It is worthy to note, that certain samples were sent for analysis to Cellzome GmbH, (GSK, 
Heidelberg) where Western blot with anti-His-tag antibody and mass spectrometry was 
performed for fractions eluting at 46.3, 48.1, 73.3 and 80.5 ml (shown in Figure 3.12.B). 
The presence of Mt-DprE2 amino-acid sequence was confirmed in all samples by mass 
spectrometry. Also, the His-tag was detected on some smaller size proteins, possible 
degradation products of the fusion protein in sample eluted at 80.5 ml (Figure 3.13.). 




Figure 3.11. Size exclusion chromatography of 6xHis-SUMO-Mt-DprE2. (A) Elution 
chromatogram at two absorbance wavelengths. (B) and (C) SDS-PAGE analysis of collected 
protein fractions labelled by elution volume in [ml], 20 µl samples loaded on SDS-PAGE 
gel. IMAC is the sample loaded on the SEC column, MM molecule marker (ThermoFisher, 
#26619). 6xHis-SUMO-Mt-DprE2 is 40.9 kDa (red arrows). 




Figure 3.12. Size exclusion chromatography of 6xHis-SUMO-Mt-DprE2 (repeat 
experiment). (A) Elution chromatogram at two absorbance wavelengths. (B) SDS-PAGE 
analysis of collected protein fractions labelled by elution volume in [ml], 20 µl samples 
loaded on gel. MM molecule marker (ThermoFisher, #26616), IMAC is the sample loaded 
on SEC column.  6xHis-SUMO-DprE2 is 40.9 kDa (red arrow). 
 
 
Figure 3.13. Western blot analysis of 6xHis-SUMO-Mt-DprE2. Samples are from size 
exclusion chromatography (Figure 3.12.), labels refer to elution volumes in [ml]. 1 µg 
proteins were loaded, Abcam anti-6xHis-tag antibody (ab9108) 1:500 applied. Fusion 
protein is 40.9 kDa, 6xHis-SUMO-tag 13.5 kDa, Mt-DprE2 27.3 kDa. Work performed by 
Sonja Ghidelli-Disse (Cellzome GmbH). 
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SEC of co-expressed 6xHis-Mt-DprE1 with Mt-DprE2 was performed following metal 
affinity chromatography. The buffer was similar to the published dialysis buffer for Mt-
DprE1 purification (40 mM Tris-HCl pH 8.5, 20 mM NaCl, 10% glycerol), which is higher 
pH and lower salt concentration than used for the fusion protein experiments. Once again, 
due to the necessary removal of aggregate proteins by filtration, only very low amounts of 
protein (approx. 2 mg/ml, 8 mg in total) were loaded on the column and resulted in diluted 
protein fractions after SEC. The elution volume at which the possible oligomers eluted, 
around 80 ml, corresponds to approx. 65 kDa with the bovine serum albumin calibration 
standard (Figure 3.10.A).  
There is a possible monomer species eluting at 127 ml, with a calculated size of 13 kDa 
(Figure 3.11.A), which is beyond the range of this size exclusion column to determine the 
size accurately, hence the difference of calculated (27.3 kDa) and measured size values.  
The oligomer could be the 1:1 complex of 6xHis-Mt-DprE1 and Mt-DprE2 (78 kDa), 
however the bands are not equally broad, Mt-DprE1 seems to be present at a higher 
concentration then Mt-DprE2 (see Figure 3.14.B fraction eluted at 82 ml). On the SDS-
PAGE analysis of these samples some faint bands of unknown proteins can be observed as 
well between the size of the suspected Mt-DprE1 and Mt-DprE2 species. Furthermore, the 
protein approximately at the size of Mt-DprE2 is present in both aggregate and oligomer 
fractions, however, run differently on SDS-PAGE (see Figure 3.14.B, fractions eluted at 46 
vs 80.2 ml). 




Figure 3.14. Size exclusion chromatography of His-Mt-DprE1 and Mt-DprE2 co-
expression. (A) Elution chromatogram, (B) SDS-PAGE analysis of representative peak 
fractions. IMAC is the sample that is loaded on the SEC column, labels correspond to elution 
volumes in [ml]. MM molecule marker (ThermoFisher, #26619). 6xHis-Mt-DprE1 is 
51.8 kDa, Mt-DprE2 is 27.5 kDa. Co-expressed in the presence of GroES/GroEL. 
 
3.3.5 Buffer optimisation with thermal shift assay 
To optimise the buffer for biochemical assay and protein purification, the pH preference was 
assessed with 6xHis-SUMO-Mt-DprE2 in a thermal shift assay. The fusion protein has a 
calculated isoelectric point of 6.33 calculated by ProtParam (ProtParam, n.d.). A high 
melting temperature (Tm) was achieved at around pH 7 (see Figure 3.15.). 




Figure 3.15. Buffer pH optimisation with 6xHis-SUMO-Mt-DprE2 in thermal shift 
assay. Error bars are standard deviations for duplicates measured on the same plate. Protein 
is 0.4 mg/ml of the 300 mM imidazole elution sample of betaine additive test (in 
Figure 3.6.A). 
In order to find the best buffer for both Mt-DprE2 and Mt-DprE1, buffer preferences for 
6xHis-Mt-DprE1 were evaluated. Interestingly, Mt-DprE1 had a much lower Tm than the 
fusion-protein, highest stability could be achieved by keeping the pH relatively high (pH 8.5) 
and adding higher salt concentrations than the published storage buffer which is 20 mM Tris-
HCl (pH 8.5), 10 mM NaCl and 10 v/v% glycerol (Batt et al., 2012). 
 
Figure 3.16. Thermal shift assay measurements with 6xHis-Mt-DprE1 for buffer 
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As a conclusion, for enzyme activity assay the pH 7.2 was chosen in BTP (bis-tris propane) 
and minimum 100 mM salt concentration.  
To evaluate additives that may prevent aggregation of Mt-DprE2, screening advice from 
Lebendiker et al. (2014) was folloed. Osmolytes and salts are reported to stabilise proteins 
in general (Lebendiker et al., 2014), also the putative native ligand, NADH or NADPH may 
increase the Tm in solution. GGPR was also assessed, but it decreased the Tm for the fusion 
protein already at 100 µM final concentration, which further implies that the substrate acts 
as a surfactant and may unfold the protein at higher concentrations (see Figure 2.7.). 
Among beneficial additives, the salt (NH4)2SO4 had the most stabilising effect. This salt has 
been used historically in high concentrations to reversibly precipitate proteins for 
purification purposes, but in these tested concentrations stabilised Mt-DprE2 in solution. 




Figure 3.17. Additive screen with 6xHis-SUMO-Mt-DprE2 in thermal shift assay. 
14 w/v % of both sugars relate to approx. 410 mM. Buffer for samples in (A) is Tris-HCl pH 
8.5, in (B) Na-phosphate buffer pH 8. The control ‘no additive’ has 50 mM NaCl from 
storage buffer. Error bars are standard deviations for triplicates from the same plate. Protein 
as in Figure 3.15. 
 
3.3.6 Storage conditions optimisation by enzyme activity assay 
Highly similar protein samples produced for expression improvement were utilised 
(Figure 3.6.) for testing the impact of different cryoprotectant additions. Based on the 
Lebendiker aggregation optimisation (Lebendiker et al., 2014), sucrose, glycerol, PEG-400  
and Tween-80 were used for testing. Sucrose is an osmolyte, glycerol a widely used 
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cryoprotectant in protein crystallography, hence possibly advantageous for freeze-thaw 
cycles to keep the protein soluble. PEG-400 is a polyol with protein stabilising properties, 
and Tween-80 is a detergent that lowers surface-induced aggregation that can bind 
hydrophobic parts of the protein, increasing water solubility (Lebendiker et al., 2014). 
Cryoprotectants were assessed by ability to keep the protein in solution after overnight 
freezing at -20 °C, compared to unfrozen samples without additive kept on 4 °C. In this 
experiment, as shown in Table 3.2. all additives performed similarly with the exception of 
PEG-400, which separated from the solution and most likely had a fluorescence absorption 
by itself at 280 nm, hence reporting false protein concentrations. Also, the overnight frozen 
samples were centrifuged at high speed to separate precipitated protein, which was the most 










ctrl (no additive) 0.9 0.81 7% sucrose 0.68 
BA 0.65 0.55 4% PEG-400 0.69* 




BA+betaine 1 0.85 10% glycerol 0.6 
 
Table 3.2. Additive test for protein cryoprotection. Protein samples as in Figure 3.6. 
Conc. is concentration, frozen and unfrozen samples measured at 280 nm absorbance with 
Nanodrop (ThermoFisher), given in [mg/ml]. Concentrations after volume expansion are 
calculated, dilution (volume expansion) was 10-15 v/v% in the frozen samples. Asterisk 
shows misleading concentration, most of the protein visibly precipitated in the sample. 
Furthermore, all these protein samples of 6xHis-SUMO-Mt-DprE2 were investigated in 
enzyme activity assay and compared unfrozen enzymes. PEG-400 and Tween-80 frozen 
samples had low enzyme activity, while glycerol and sucrose retained enzyme activity well 
(Figure 3.18.). 
 





   40 mM HEPES pH 7.5 (1 M) 
   100 mM NaCl (5 M) 
   180 μM NADH (3 mM) 
   10 μM DprE1 (7.2 mg/ml ≈ 113 μM) 
   0.4 mg/ml 6xHis-SUMO-DprE2 
   150 μM GGPR (1.5 mM) 
   MilliQ water addition to 10 μl 
 
Figure 3.18. Cryoprotectant testing with 6xHis-SUMO-Mt-DprE2 enzyme activity 
assay. Background is NADH-oxidation by Mt-DprE1 alone (no GGPR, no Mt-DprE2 
added). Frozen samples incubated at -20 °C overnight, unfrozen samples were kept at 4 °C 
(see table 3.2.). DprE2 was purified by IMAC only (without subsequent SEC purification). 
Control reaction lacked GGPR. All reaction samples were centrifuged before activity 
measurement. Single shot assay, stock solution concentrations listed in parentheses, RFU is 
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3.3.7 Enzyme activity assay optimisation 
 
Figure 3.19. Basis of Mt-DprE2 enzyme activity measurement: fluorescence-decrease 
by NADH oxidation. GGPR is geranylgeranyl phosphorylribose, GGPA geranylgeranyl 
phosphorylarabinose, GGPX the keto-intermediate. The fluorescent co-enzyme is 
highlighted in blue. 
To measure Mt-DprE2 activity it is plausible to measure the oxidation of NADH resulting 
in fluorescence signal decrease (Figure 3.19.). GGPX production and separation from 
GGPR and Mt-DprE1 was unsuccessful. Therefore, Mt-DprE1 also had to be present in the 
Mt-DprE2 activity assay supplying the substrate, GGPX. As a result, the Mt-DprE2 assay is 
a two-step coupled enzyme activity assay. 
NADH (and NADPH) reduction can be observed via change in intrinsic absorption or 
fluorescence of the molecule. However, none of the absorbance studies showed enzyme 
activity. Therefore, all biochemical assays presented here were monitored by fluorescence 
spectroscopy. 
Firstly, the fluorescence spectrum of NADH was measured and the range of measurement, 
where co-factor concentration is directly proportional to fluorescence signal, established. 
(See Figure 3.20.) With current setup the maximum NADH concentration was set to 300 µM 
or less to remain in the linear range, and the general emission wavelength for assays, to 
measure the highest signal, was 462 nm. 




Figure 3.20. NADH fluorescence signal test. (A) Linear range of signal to concentration 
with SpectraMax M5 spectrophotometer, in 10 µl final volume, on black small volume plates 
(Greiner #784076). Measurement in triplicates. (B) Fluorescence emission spectrum of 
sample 2.5 mM NADH, at excitation wavelength 340 nm. RFU is relative fluorescence unit. 
 
Addressing the question of whether NADH or NADPH may be better co-factor for the Mt-
DprE2 assay, assays with both in different protein construct assays were utilised. 
Interestingly, only NADH performed with tag-free and SUMO-tagged Mt-DprE2 similarly, 
with a slow constant decrease in background signal compared to pronounced signal drop in 
an active reaction. However, NADPH signal was undetectable with 6xHis-SUMO-Mt-
DprE2 (Figure 3.21.), while the Mt-DprE1-Mt-DprE2 co-expression construct expressed 
from separate plasmids (construct 3 in Table 3.1.) gave a solid signal with a prolonged linear 
phase in co-factor oxidation (Figure 3.22.). Previous studies (conducted by Alice Moorey, 
MRes thesis work in University of Birmingham) utilised co-expression of Mt-DprE1-Mt-
DprE2-GroES/GroEL-Mt-GtrA in which the assay monitored NADPH oxidation. 
Reproducing those results in this work of the same construct was unsuccessful, no 
enzymatically active preparation of the proteins was obtained. 




  buffer NAD(P)H ctrl all but GGPR active 
80 mM HEPES pH 7.5 (1M) + + + + 
100 mM NaCl (5M) + + + + 
160 μM NADH/NADPH (1 mM)   + + + 
22 μM DprE1 (7.2 mg/ml = 113 μM)     + + 
0.32 mg/ml SUMO-DprE2 (1 mg/ml)     + + 
150 μM GGPR (1.5 mM) + +   + 
MilliQ water addition for 10 μl + + + + 
 
Figure 3.21. Co-factor testing with 6xHis-SUMO-Mt-DprE2 enzyme activity assay. (A) 
NADH and (B) NADPH as co-factor in the same reaction settings. Stock solution 
concentrations in parentheses. DprE2 was purified with IMAC. 
 
It is important to note, that due to the different detectors and instruments there is a large 
difference in fluorescence values between experiments conducted in GlaxoSmithKline Tres 
Cantos DDW (as in Figure 3.21.) and University of Birmingham (as in Figure 3.22.). The 
former reactions usually started from 1000 fluorescence intensity units, while the latter well 
over 100,000 fluorescence intensity units.  




  buffer 
NAD(P)H 
ctrl 
GGPR ctrl 0 μM GGPR 
180 μM 
GGPR 
40 mM HEPES pH 7.25 (1M) + + + + + 
80 mM NaCl (2M) + + + + + 
300 μM NAD(P)H (5 mM)   + + + + 
7.2 mg/ml His-Mt-DprE1 
+Mt-DprE2 (10.8 mg/ml) 
      + + 
180 μM GGPR (1.5mM) +   +   + 
MilliQ addition for 15 μl + + + + + 
 
Figure 3.22. Co-factor testing with co-expressed 6xHis-Mt-DprE1 and Mt-DprE2 in 
enzyme activity assay. Expression as in construct 3 in Table 3.1. Enzymes purified with 
IMAC. (A) NADH and (B) NADPH in the similar reaction setup. RFU is relative 
fluorescence unit. 
Assays with purified 6xHis-SUMO-Mt-DprE2 required additional Mt-DprE1 for the 
coupled reaction to take place (see Figure 3.19.). As a general guideline, to minimise the 
effect of Mt-DprE1 limiting Mt-DprE2 activity, an excess of the first enzyme is needed. 
With an assay trial (Figure 3.23.) it was determined as minimum 10 µM DprE1 for reaction 
with 0.5 mg/ml 6xHis-SUMO-Mt-DprE1. 
Also, Mt-DprE1 oxidised NADH by itself in some reactions, therefore only fresh, 
exceptionally pure protein samples could be applied in the assay. Purity was enhanced by 
larger volumes in washing steps than usual. 
 




 Reaction mixture: 
 40 mM HEPES pH 7.5 (1M) 
 80 mM NaCl (5M) 
 150 μM NADH (3 mM) 
 Mt-DprE1 (2.24 mg/ml = 35.2 μM) 
 0.5 mg/ml 6xHis-SUMO-DprE2 (3 mg/ml) 
180 μM GGPR (2 mM) 
MilliQ water addition for 10 μl 
 
Figure 3.23. Optimisation of Mt-DprE1 concentration for enzyme activity assay with 
6xHis-SUMO-Mt-DprE2. DprE1 was purified with IMAC and IEX, while DprE2 only with 
IMAC. Stock solution concentrations in parentheses. RFU is relative fluorescence unit, error 
bars are standard deviations of triplicate measurements. Bright blue curve represents the non-
linear regression best fit of the Michaelis-Menten equation to the data, Vmax = 149 RFU/min, 
Km = 3.6 µM.  
Another rate limiting factor of the Mt-DprE2 enzyme activity assay is the concentration of 
GGPR. On the one hand, it has to be high to allow GGPX formation and supply excess 
substrate for Mt-DprE2 to measure accurate maximum reaction velocity. But also, it cannot 
be too high, because it would denature Mt-DprE1. Partial denaturation of Mt-DprE1 at 
GGPR concentrations above 200 µM were observed (Chapter 2.3.2.). 
Surprisingly, measurements even with the same enzyme and similar reaction mixture 
(different only in GGPR concentration) delivered highly different results (Figure 3.24.). The 
general Vmax value was less than 10 RFU/min, at a standard error of 1 RFU/min, while the 
coefficient of determination (R2) was 0.349 for global data. Consequently, this assay setup 
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does not have the sensitivity to report precise enzyme kinetic data, but it does indicate 
enzyme activity and inactivity with optimised conditions. 
 
Reaction mixture: 
  50 mM BTP pH 7.2 (0.5M) 
  100 mM (NH4)2SO4 (3.6M) 
  180 μM NADH (2 mM) 
  0.24 mg/ml 6xHis-DprE1+DprE2 (0.6 mg/ml) 
  varying GGPR (0.5 mM) 
  MilliQ water addition for 10 μl 
Michaelis-Menten global curve fit 
    Standard Error 
  Vmax  9.276  1.065 
  Km  29.7  15.39 
  Degrees of Freedom  54  
  R square  0.359  
 
Figure 3.24. GGPR dependence of enzyme activity assay with co-expressed 6xHis-Mt-
DprE1 and Mt-DprE2. Enzymes were co-purified with IMAC. Yellow curve is the global 
fit for all data presented from assays 50-55. Dotted curves show the 95% confidence interval 
for the fit. Measurements over 300 µM GGPR showed decreased/no activity. Km in [µM], 
Vmax in [relative fluorescence unit / min]. 
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It is worthy to note that GGPR oxidises some NADH by itself (see Figure 3.22. assay 
‘GGPR ctrl’ versus ‘NADH’, ‘NADPH’ controls). This is likely due to hydrolysis of GGPR 
to ribose and prenylphosphate, with ribose capable of reacting with NAD(P)H. 
The addition of ammonium sulphate stabilised 6xHis-SUMO-Mt-DprE2 in the thermal shift 
assay (Figure 3.17.B). Enzyme activity assay observations confirmed that ammonium 
sulphate supported enzyme stability and hence enzyme activity increased. Both NaCl and 
ammonium sulphate delivered similar increase in reaction rates (Figure 3.25.). 
 
 Reaction mixture in (A)  Reaction mixture in (B) 
80 mM BTP pH 7 (0.5M) 40 mM HEPES pH 7.5 (1M) 
ammonium sulphate (4M) NaCl (1M) 
50 mM NaCl (2M) 50 mM NaCl (2M) 
180 μM NADH (3 mM) 180 μM NADH (3 mM) 
12 µM 6xHis-Mt-DprE1 (7.2 mg/ml = 
113 µM) 
10 µM 6xHis-Mt-DprE1 (7.2 mg/ml = 113 
µM) 
0.34 mg/ml 6xHis-SUMO-Mt-DprE2 
(1 mg/ml) 
0.75 mg/ml 6xHis-SUMO-Mt-DprE2 
(3 mg/ml) 
150 μM GGPR (2.5 mM) 150 μM GGPR (1.5mM) 
MilliQ water addition for 10 μl MilliQ water addition for 10 μl 
 
Figure 3.25. Salt addition testing in enzyme activity assay with 6xHis-SUMO-Mt-
DprE2. (A) With ammonium sulphate and (B) with NaCl. Concentrations of stock solutions 
in parentheses. RFU is relative fluorescence unit. DprE1 was purified with IMAC and IEX, 
while DprE2 with IMAC. 
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Potential benefit of other additives was tested similarly to the salt addition tests. Detergents, 
salts, osmolytes are known for stabilising certain proteins, keeping them in solution and 
hinder aggregation (Lebendiker et al., 2014). This screen was different to the storage 
condition experiments (Chapter 3.3.6.) in the way that no freeze-thaw of the protein was 
conducted, only the possible benefit of additives in the 6xHis-SUMO-Mt-DprE2 enzyme 
activity assay was evaluated. 
 
 Reaction mixture: 
40 mM HEPES pH 7.5 (1M) 
80 mM NaCl (1M) 
180 μM NADH (3 mM) 
10 µM 6xHis-DprE1 (7.2 mg/ml = 113 µM) 
0.75mg/ml 6xHis-SUMO-DprE2 3 mg/ml) 
150 μM GGPR (2.5 mM) 
+ additive from stock: 
     Brij-35 (0.012%=1 mM) (Sigma, #B4184) 
     betaine (100 mM) (Sigma, #B2629) 
     PEG-20 (4%) (Sigma, #81300) 
     Gdn-HCl pH 7.5 (0.5M) (Sigma, #50950) 
     CHAPS (0.1%) (Sigma, #C3023) 
MilliQ water addition for 10 μl 
 
Figure 3.26. Additive screen in 6xHis-SUMO-Mt-DprE2 enzyme activity assay. Stock 
solutions concentration and product numbers in parentheses. RFU is relative fluorescence 
unit. DprE1 was purified with IMAC and IEX, while DprE2 with IMAC. 
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The results show (Figure 3.26.) that salt addition and the osmolyte betaine increased the rate 
of reaction, detergents Brij-35 and CHAPS lowered it. PEG-20 had no additional benefit. 
Guanidine hydrochloride (Gdn-HCl) lowered enzyme activity as expected and it served in 
the experiment as a negative control. 
3.3.8 Evaluation of SEC fractions in enzyme activity assay 
 
 Reaction mixture: 
40 mM HEPES pH 7.5 (1M) 
80 mM NaCl (1M) 
180 μM NADH (3 mM) 
10 µM 6xHis-DprE1 (7.2 mg/ml = 113 µM) 
5 µl of SEC fraction sample 
180 μM GGPR (2 mM) 
MilliQ water addition for 10 µl 
 
Storage buffer of SEC samples: 
     55 mM HEPES pH 8 
     180 mM NaCl 
     10% glycerol 
 
Figure 3.27. Enzyme activity measurement of 6xHis-SUMO-Mt-DprE2 size exclusion 
chromatography fractions. ‘IMAC’ is protein sample after IMAC purification, before 
loaded on SEC column, A280 = 5. Controls contain only that one enzyme from the coupled 
reaction. RFU is relative fluorescence unit. 
SEC of both 6xHis-SUMO-Mt-DprE2 and Mt-DprE1-Mt-DprE2 co-expression produced 
very pure, low concentration preparations of the target protein(s) (Chapter 3.3.4.).  
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SEC fractions of 6xHis-SUMO-Mt-DprE2 were used in enzyme activity assay and showed 
that the aggregate protein fraction was active (see Figure 3.27.), but lower than the 
preparation before the SEC purification, which is best explained by the low concentration of 
the protein present in pure SEC fractions. 
Samples of the size exclusion chromatography fractions with 6xHis-Mt-DprE1 and Mt-
DprE2 co-expression were tested in enzyme activity assay but were all inactive, likely due 
to low protein concentrations. 
3.4 Discussion 
 
3.4.1 Overcoming aggregation of Mt-DprE2 
Previous experiments purifying Mt-DprE2 from E. coli cell extracts provided only an 
amount of protein insufficient for crystallography. His-tagged Mt-DprE2 fusion protein 
expressed from a pET vector aggregated during purification and required high 
concentrations of glycerol for stabilisation (unpublished work by Sarah M. Batt, University 
of Birmingham). 
In this thesis we have explored the possibilities of using other tags for both purification and 
chaperon-like purposes. ‘Maltose binding protein’ (MBP) and ‘small ubiquitin-like 
modifier’ (SUMO) proteins have been reported to enhance soluble expression levels of 
certain proteins (Arbing et al., 2013; Peroutka Iii et al., 2011). Both are commercially 
available, also their protein constructs are designed to be cleavable by proteases, Factor Xa 
and SUMO protease respectably, so the tags are removable after purification. 
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The fusion of Mt-DprE2 with 6xHis-SUMO was successful in a way that it overexpressed 
the protein in sufficient concentrations for enzyme activity assay, studies by size exclusion 
chromatography and thermal shift assays.  
The size exclusion chromatography demonstrated that most of the protein formed an 
aggregate (Figure 3.11.), which was despite aggregation enzymatically active 
(Figure 3.27.). Fractions attributed to an oligomer, most likely a dimer, were active as well, 
performing with worse reaction rates due to lower enzyme concentrations. These 
experiments indicate that the tag-fusion with 6xHis-SUMO did not prevent aggregation 
altogether, however, the obtained enzyme aggregate has the potential to report on enzyme 
activity and therefore to be applied in inhibition assays. 
Another strategy revolved around the idea that Mt-DprE1, as a part of Mt-DprE2 interactome 
(Jankute et al., 2014), may stabilise the structure of Mt-DprE2. Therefore, co-expression and 
co-purification of Mt-DprE2 with Mt-DprE1 could prove to be beneficial. Similar work has 
been done with the result of low-level expression of either of the proteins (unpublished work 
by Sarah M. Batt, University of Birmingham). Also, it has been further investigated with the 
co-expression of Mt-GtrA protein (rv3789), which is part of the same operon as dprE1 and 
dprE2 (see Figure 1.11.). It has been reported that Mt-GtrA is likely to act as an anchor for 
AftA, advancing DPA incorporation into the cell wall (Kolly et al., 2015) and/or as a DPA 
flippase (Larrouy-Maumus et al., 2012) .  
In this work the co-expression experiment and also compared to a new construct producing 
Mt-DprE2, His-Mt-DprE1 and chaperon proteins in the same cell simultaneously, but from 
separate plasmids (see constructs in Table 3.1.). 
Both co-expression of five target proteins in the same cell (construct 1 in Table 3.1.) and the 
MBP-tagged periplasmic expression failed for the reason of resulting in excessively small 
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amounts of Mt-DprE2 (see Chapter 3.3.1.). This result was anticipated since periplasmic 
extractions are prognosed to result in one tenth of the amount of MBP-fusion protein 
expressed cytoplasmically (Inc, n.d.). Logically, fine tuning of expressions levels of five 
different proteins is also a difficult task that was expected as a set-back in Mt-DprE2 
production. 
Simplification of the co-expression construct, omitting Mt-GtrA, lead to the production of 
sufficient amounts of protein for further studies. Mt-DprE2 was observed to co-purify with 
the His-tagged Mt-DprE1 in affinity chromatography (Figure 3.7.) and samples were active 
in enzymatic assay (Figure 3.22.). Size exclusion chromatography of the proteins 
(Figure 3.14.) showed that the aggregate and the oligomer (65 kDa in size, suspected 1:1 
complex of 6xHis-Mt-DprE1 and Mt-DprE2) contained different additional protein species. 
In fact, the oligomer on SDS-PAGE showcased two unidentified bands at molecular weight 
between the suspected Mt-DprE1 and Mt-DprE2 proteins (Figure 3.14.). Unfortunately, all 
fractions were so diluted that enzyme activity assessment or further studies were not rational 
to pursue. Repeat experiments resulted also in small protein quantities. Therefore, it remains 
to be solved how Mt-DprE1 forms a complex with Mt-DprE2, to confirm that it is Mt-DprE2 
in the complex and to identify the co-eluting proteins. 
Co-expression of 6xHis-Mt-DprE1 and Mt-DprE2 are yet the physiologically most relevant 
preparations since only a small peptide (6xHis-tag is 841 Da) is fused to Mt-DprE1, and Mt-
DprE2 is produced in its physiological amino acid sequence. However, even in the presence 
of chaperons (Figure 3.7.) the co-expression produced low levels of the heterologous 
proteins, along with typical contaminating proteins that are co-purified in metal affinity 
chromatography with the construct in high abundance (Figure 3.9.). This is detrimental to 
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the yield of Mt-DprE2 and constrains additional protein separation steps to gain homogenous 
protein. 
One observation with implication for further studies is that the 6xHis-SUMO-fused Mt-
DprE2 protein in size exclusion chromatography displayed an array of degradation products 
(Figure 3.11.), which retained the His-tag on their N-terminus (Figure 3.13.). Although, 
since a high molecular weight protein band was also labelled with the anti-His antibody in 
the Western blot, one cannot rule out that these are not exclusively degradation products, but 
also include some non-specifically detected proteins by the antibody. But if the C-terminus 
of the protein is prone to degradation, it can be truncated or fused to a tag in future studies 
to prevent degradation. 
Another finding of the 6xHis-SUMO-Mt-DprE2 experiments was that the oligomer state did 
not contain NADH/NADPH based on absorbance at 340 nm (see size exclusion 
chromatogram in Figure 3.11.A). This could be due to loss of co-factor during purification. 
Taken together with the results of the thermal shift assay in which NADH and NADPH did 
not stabilise the protein (Figure 3.17.), and the findings of Chapter 4, which resulted in 
spontaneous resistant mutants of DprE2 hit compounds affecting F420 co-factor production, 
it cannot be ruled out that F420 is an alternative or native co-factor of Mt-DprE2. This co-
factor is not present in the E. coli expression system, and should be investigated in alternative 
expression systems, such as M. smegmatis that natively produce and utilise F420.  
In conclusion, none of the assessed methods in this work prevented completely the 
aggregation of Mt-DprE2, therefore for protein crystallography, in the future the focus of 
research has to be on producing high amounts of protein and attempt to concentrate the 
sample with minimal additional aggregation in the process. Unfortunately, it is also possible 
that further chromatography steps would be necessary to eliminate the contaminating 
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proteins remaining after metal affinity chromatography. A concentrated, but soluble pure 
preparation may be subjected to size exclusion chromatography and oligomeric fractions 
may be used for crystal growth. This purification step separating oligomers or a complex 
with Mt-DprE1 from large aggregates seems to be the next milestone towards protein 
preparations for crystallography. 
3.4.2 Analysis of enzyme activity assays 
The enzyme activity assay was optimised regarding several factors. The conditions 
supporting the highest reaction rate were pH value near 7, 80 mM or higher salt 
concentrations, either NaCl or Li2SO4 resulted a reaction stable and a well distinguishable 
signal difference between active and inactive reaction (see Figures 3.15., 3.17., 3.25., 
respectively). The reaction tolerated glycerol well up to 10% (Figure 3.18.). For the 
instruments range of signal linearity was established. Furthermore, GGPR reaction substrate 
concentration maximum was investigated and found to be similar to the one observed in the 
Mt-DprE1 assay studies (Figures 3.24. and 2.7.). The 6xHis-SUMO-Mt-DprE2 at 0.5 mg/ml 
protein preparation required approx. 0.65 mg/ml = 10 µM 6xHis-Mt-DprE1 to reach optimal 
reaction rate (Figure 3.23.).  
An unexpected finding of the enzyme activity assays was the high variability and differences 
between the performance of enzyme preparations. One reason for this phenomenon was the 
varying Mt-DprE2 content in Mt-DprE1-Mt-DprE2 co-expression studies, where Mt-DprE2 
could appear to be present in a 1:1 ratio to Mt-DprE1 (Figure 3.9.) or even barely noticeable 
on SDS-PAGE analysis (Figure 3.14.). This unpredictability poses a huge problem for 
enzyme activity assays intended for large sample sizes (like an HTS campaign). One option 
to ensure active enzymes for assays is to produce large amounts of enzyme at the same time 
and run a quality test enzyme activity assay, after which smaller aliquots could be frozen in 
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the explored preferable storage buffers, that contained high osmotic pressure agents, such as 
sucrose, trehalose or glycerol (Chapter 3.3.6.). This way a standard enzyme preparation 
could be ensured for a limited number of assays. 
An additional concern about the enzyme activity assay originates in its lack of refinement in 
GGPR dependence. GGPR is the substrate of the coupled reaction of Mt-DprE1-Mt-DprE2, 
and results showed that even with the same enzyme preparation and set-up significant 
deviations are common between re-runs (Figure 3.24.). The apparent Km of the co-expressed 
protein activity assay was measured as 30 µM±15 µM with DprE1-DprE2 co-expressed 
preparation. In general, it is recommended (Acker and Auld, 2014) that inhibitor screens 
should be performed with a set substrate concentration near the Km to detect competitive and 
uncompetitive inhibitors without bias. Lower substrate concentrations are biased to 
recognise competitive inhibitors that bind to the active site and compete with the substrate, 
and miss uncompetitive inhibitors, which bind to the enzyme-substrate complex. 
Meanwhile, higher substrate concentrations achieve the opposite effect (Acker and Auld, 
2014). With the current low signal-to-noise ratio between active and inactive reaction even 
at higher substrate concentrations (approx. 200 µM), it is unwise to lower the GGPR 
concentration to the Km value. Consequently, a high enough GGPR concentration that 
produces a good signal also favours uncompetitive inhibitors and may underrepresent 
competitive inhibitors. Non-competitive inhibitors, that bind allosteric sites of the enzyme, 
are unaffected by the substrate concentration in the reaction. 
Another matter that needs to be addressed at the level of assay design is that the read-out of 
the developed enzyme activity assay in this work is fluorescence based with excitation at 
340 and emission at 460 nm. The compounds of interest need to be tested for fluorescence 
at these values to rule out false results in the screen, which may be challenging with large 
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compound libraries and render the assay not applicable for compounds that are fluorescent 
or quench at the same wavelength ranges. 
As for the different preference of enzyme constructs towards co-factors, 6xHis-SUMO-Mt-
DprE2 was found to perform only with NADH, while tag-free Mt-DprE2 had a better signal-
to-noise ratio with NADPH, although it could utilise NADH as well (Figures 3.21 and 
3.22.). This imposes a difference of the 6xHis-SUMO fusion protein compared to the tag-
free protein. For lack of 3D conformational data, it is impossible to tell how and at what 
extent does the tag fusion affect enzyme function. Therefore, Mt-DprE1-Mt-DprE2 co-
purifications are to be promoted to be used in inhibitor assays until the fusion protein is not 
proven to function equally. 
Finally, a flaw in assay design regarding inhibitor screens is that Mt-DprE1 inhibitors are 
not distinguished from Mt-DprE2 in the assay read-out. Results have to be compared to Mt-
DprE1 enzyme activity assays with the same compounds for reliable reporting.  
Considering all these results, and the low success rate of target-based enzyme activity assays 
in drug discovery (Cole, 2016), it can be concluded that the enzyme activity assay developed 
herein is only meaningful and applicable as an auxiliary assay for a Mt-DprE2 targeting 
whole-cell assay to test potential hits against Mt-DprE2, because it is limited by many 
constraints. 
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The protein Mt-DprE2 is an essential enzyme of M. tuberculosis (Kolly et al., 2014) and a 
potential target of new drugs against mycobacteria. In this Chapter a target-focused whole-
cell screen against the TB box compound library (unpublished set by GSK), a library of 
11,096 compounds with activity against mycobacterial species was performed to identify 
potential hit molecules. 
The set-up of the experiment is based on the approach that both strategies of target-based 
and phenotypic-based discovery could be implemented simultaneously, combining their 
advantages. The approach of selecting compounds with activity against mycobacteria and 
screening for activity against strains that overexpress a particular target aims to minimise  
compound attrition due to inactivity (failure to penetrate the cell wall for example). Target 
overexpression at the same time gives an early indication whether the inhibitor targets 
specifically Mt-DprE2. When there is a shift in cell growth during compound exposure due 
to target overexpression it may be due to the enhanced target concentration in the cell. The 
shift is further confirmed as a shift in MIC in a larger assay format thereby validating target 
engagement, with selected hit compounds further tested in thermal shift assays and in a Mt-
DprE2 enzyme activity assay, which was developed in Chapter 3. This set of experiments 
has the potential to select among whole-cell active compounds those that target Mt-DprE2. 
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4.2 Materials and methods 
 
4.2.1 Bacterial cultures 
M. bovis BCG was grown at 37°C in 5% CO2 atmosphere, in Middlebrook 7H9 broth with 
0.025% Tween-80 and 10% albumin-dextrose-catalase (ADC) supplement, or on 
Middlebrook 7H10 plates with 10% oleic acid-ADC (OADC) enrichment. Both media were 
supplemented with kanamycin at a 25 µg/ml final concentration. Liquid cultures were 
passaged for a maximum of two months, then started a new from frozen stocks (1 ml aliquot 
of liquid culture with 30% glycerol cryoprotectant, stored at -80 °C). 
Overexpression of Mt-DprE2 was achieved by transforming M. bovis BCG cells with 
plasmid pMV261-Mt-DprE2 (Parish and Roberts, 2015). The plasmid was cloned and kindly 
provided by Sarah M. Batt, University of Birmingham. Plasmid pMV261 is a shuttle vector 
stably maintained in both E. coli and mycobacteria in vivo, which can constitutively express 
proteins in excess from an extrachromosomal copy of the selected gene, under the control of 
hsp60 stress protein regulatory region, with a kanamycin-resistance selection marker (Stover 
et al., 1991). 
4.2.2 Primary screening 
The collection of TB Box compounds was requested from GSK Harlow UK in a 384-well 
plate format (Greiner, #781091) in two concentrations and in duplicate. Selected screening 
concentrations were 1 and 5 µM (50 nl and 250 nl compound/well). On each plate column 6 
served as live cell control (only DMSO normalisation), and column 18 as a dead cell control 
by adding rifampicin (same as in Figure 4.1.). The plates were stored overnight at -80 °C 
before the screen to confirm sterilisation. 
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M. bovis BCG transformed with pMV261 (control, ctrl) and pMV261-Mt-DprE2 
(overexpressor, oe) were grown to mid-log phase (OD600 = 0.4-0.8), diluted to 10
5 CFU/ml 
(considered OD600 = 0.125 equal to 10
7 CFU/ml). 50 µl of culture was aliquoted to each well 
by MultiDrop Combi (Thermo Scientific), covered with a sterile lid without condensation 
rings (#656161 Greiner), wrapped in parafilm and aluminium foil, packed in plastic boxes 
along with tissue soaked into water to ensure humidity, and kept at 37 °C in a 5% CO2 
incubator for 7 days.  
After incubation with compounds the published REMA protocol (Sharma et al., 2014) was 
followed and scaled down to small volume plates. In short, a 1:1 ratio of 0.02% resazurin (in 
MilliQ water) and 10% Tween-80 was mixed and filter-sterilised, then 10 µl added to each 
well on the plate by MultiDrop Combi. Plates were sealed with the lid and wrapped in 
aluminium foil and incubated overnight at 37 °C in a 5% CO2 incubator. Plates were sealed 
with adhesive film (A5596 EASYSeal) and read with EnVision spectrophotometer (Perkin 
Elmer), with fluorescence filters at 531/595 nm (excitation/emission wavelength). Collected 
data were analysed in Microsoft Excel. 
The complete screen with the TB Box was performed twice, because the Z’ values of the 
first screen were very low. 
4.2.3 Secondary screening 
Initial hits were tested again in a 384-well plate format, only in a dose-response manner as a 
2-fold dilution series from 100 to 0.098 µM. Each plate contained the dilution series of 32 
different compounds, column 6 and 18 dedicated to live and dead cell controls, respectively 
(Figure 4.1.) with DMSO content normalised to 1%. 
Two repeats were tested against each strain, replicas were on different plates. These plates 
were dispensed and shipped from GSK Harlow, UK. Assay protocol exactly as in HTS. 




Figure 4.1. The plate layout for dose-response testing in 384-well plate format. 
Concentration values in [µM]. Orange and green colouring depicts the two different 
compounds in the same row. 
Hits that reproduced an MIC shift in a 2-fold dilution series in 50 µl in 384-well plate format 
were further evaluated in a 96-well format with 100 µl culture volume. Compounds were 
distributed as 2-fold dilution series by hand from 10-fold master plates or by HP D300 
Digital Dispenser, leaving an evaporation frame empty of compound all around the plate 
(first and last row, first and last column on the plate). DMSO concentration was maximised 
at 2.8% to avoid cell toxicity by the compound solvent. The cell growth inhibition 
experiment protocol was very similar to the HTS above, only scaled up based on the REMA 
protocol (Taneja and Tyagi, 2007). The main difference was that for 100 µl of culture a 30 µl 
mixture of 0.02% resazurin and 12.5 µL 10% Tween-80 were added, and the plate readings 
were performed using a SpectraMax spectrophotometer, with monochromators set to 530 nm 
excitation and 590 nm emission wavelength. 
4.2.4 Data evaluation 
Firstly, raw fluorescence data were imported from raw data files and plate layouts annotated 
manually in Microsoft Excel. Then fluorescence data were converted to percentage of 
inhibition (%inh): 
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𝐹𝐼 − 𝑑𝑒𝑎𝑑 𝑐𝑡𝑟𝑙
𝑙𝑖𝑣𝑒 𝑐𝑡𝑟𝑙 − 𝑑𝑒𝑎𝑑 𝑐𝑡𝑟𝑙
∗ 100 
where FI is fluorescence intensity of the sample well. Standards for dead and live cell in 
384-well plate layouts data evaluation controls were taken from the same row on the plate 
as the analysed sample well to compensate for the extensive edge effect. In 96-well plate 
layouts, where evaporation frames were included, the average of dead and live control values 
was calculated and applied in the formula.  
As quality assessment to each plate the Z’ value (Zhang et al., 1999) was calculated (also 
called Zprime or Z-factor): 
𝑍′ = 1 −
3 ∗ 𝑆𝐷 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑡𝑟𝑙 + 3 ∗ 𝑆𝐷 𝑜𝑓 𝑑𝑒𝑎𝑑 𝑐𝑡𝑟𝑙
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑡𝑟𝑙 − 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑑𝑒𝑎𝑑 𝑐𝑡𝑟𝑙
 
where SD is standard deviation. Based on guidelines adopted at GSK this value should be 
above the significance threshold 0.4, or else a repeat measurement is recommended. For 
better representation the Z’ calculations of two examples are portrayed in Figure 4.2. 
MICs recorded in liquid culture assays were MIC50 values, where values refer to the 
compound concentration that elicited 50% percentage of growth inhibition (%inh=50%). 
However, on solid media this value is not measurable, hence the concentration of compound 
that allowed no colony growth was taken as MIC. This concentration value does not directly 
translate to percentage of inhibition, but sometimes in literature is referred to as MIC95 
(%inh=95%) (Blanco-Ruano et al., 2015). 
4.2.5 Mt-DprE2 inhibition assay 
In order to assay enzymatic activity of purified Mt-DprE2, oxidation of the redox co-factor 
NAD(P)H was monitored by measuring fluorescence. The co-enzyme was exclusively 
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NADH in GSK experiments, and NADH and NADPH in University of Birmingham. Exact 
reagent mixtures are portrayed along specific reported reaction curves. 
The general inhibitor assays in GSK DDW contained 50 mM bis-tris propane at pH 7.0, 
100 mM ammonium-sulfate, 50 µM Brij-35 surfactant, 180-250 µM NADH, 100 µM 
compound or 3% DMSO and MilliQ water. Reaction mixtures were split from the master 
mix to wells of a small-volume microplate (Greiner, #784076), and enzymes were added to 
the mixture at maximum 50% of the assay volume (total assay volume 10 µl). His-Mt-DprE1 
and Mt-DprE2 co-purification samples were used, also 6xHis-SUMO-Mt-DprE2 
purification samples (see Chapter 3 for detailed method), in which case His-Mt-DprE1 was 
added in excess. Plates were kept at room temperature (25-26°C) for 5 minutes inside the 
spectrophotometer. The substrate GGPR was added last and initiated the reaction which was 
monitored by fluorescence measurement at 340/462 nm using a SpectraMax M5 
spectrophotometer, with measurement points taken at every 15 or 30 seconds for 50 minutes. 
The general inhibitor assays in University of Birmingham contained enzyme at 50% assay 
volume (approx. 7.5 mg/ml total protein concentration of Mt-DprE1-Mt-DprE2 co-
purification), 40 mM HEPES pH 7.5, 80 mM NaCl, 400 µM NADPH, 333 µM inhibitor or 
3.3% DMSO, 280 µM GGPR added last to initiate reaction. The reaction was performed in 
a 15 µl volume, kept at 25 °C, and fluorescence monitored at 350/450 nm using a 
PHERAstar FS microtiter plate reader for 50 minutes, with signal linearity in the first 
12 minutes.  
4.2.6 Spontaneous resistant mutant generation 
Previous attempts for mutant generation have failed against hit compound 15 (in Table 4.3., 
hit compound of PhD thesis work by Giacomo Chiodarelli, University of Birmingham). No 
colonies were observed on 7H10-OADC solid media supplemented with compound 15 at 5-
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10-times the MIC95 (unpublished). A liquid culture-based protocol was performed, where 
cells are first grown in liquid culture at near MIC concentrations before plating on 
compound-containing plates, which did not deliver any mutant colonies either. 
A different approach on the other hand generated mutants against certain derivatives of 
compound 15 and other hits of the Mt-DprE2 HTS. This method is based on the serial 
passaging technique of Leeds et al. (2014) scaled to the 24-well SPOTi assay format (Gupta 
and Bhakta, 2012).  
Firstly, 24-well plates (Corning, #CLS3524) were made for solid MIC measurement as in 
the SPOTi assay, but instead of the generally applied 2-fold dilution series, I opted for 1.25-
fold and 1.5-fold dilution series. Therefore, cells were exposed to several near-MIC 
concentrations of the compounds. Each well contained 1 ml of Middlebrook 7H10 solid 
media with 10% OADC supplement, 0.5% glycerol, 0.025% Tween-80 and the tested 
compound (stock solution in neat DMSO, 0.1% DMSO final concentration in solid media), 
live control contained 2% DMSO. Made three replicate plates of each layout (plate 1, plate 
2 and plate 3), and kept the unused plates at 4 °C until handling. 
Compounds were selected from the HTS hits (see Chapter 4.3.2. for selection criteria) based 
on the highest shift of MIC50 in the dose response experiments. Derivatives of compound 
15 were selected based on solubility and potency in dose response assay (compound series 
generated by Giacomo Chiodarelli, University of Birmingham). 
 
 




Table 4.1. Example of mutant generation layout in 24-well plate format. 1.5-fold 
dilution series, concentration values are in [µM]. 
Liquid culture of wild type M. bovis BCG was grown in Middlebrook 7H9 broth with 10% 
ADC supplement, 0.5% glycerol and 0.025% Tween-80 to log phase (OD600=0.4-0.8), then 
2 µl of culture were spotted on each well. Plate lids were sealed with parafilm and aluminium 
foil, and plates kept at 37 °C in a 5% CO2 incubator. The first aggregate colonies normally 
appeared after two weeks on the plate at the location of the spot, then MICs could be 
determined. Cells growing at the highest concentration with the given compounds were then 
inoculated from plate 1, and grown in compound-free liquid media to log phase. 
At this stage plate 1 was still not discarded, colony appearance was observed up to 6 weeks 
after incubation. With some compounds already from plate 1 single colonies were found on 
higher than MIC conditions, these were also inoculated and grown in liquid media. If there 
was a mutant with high compound tolerance, then that culture was spotted on to plate 2. If 
there was no mutant colony, then the culture with the highest tolerated concentration from 
plate 1 was spotted on the relevant compound series. This strategy was repeated from plate 
2 to plate 3 in a similar manner. 
Mutant strains were archived to -80 °C in a 30% glycerol stock, and four mutant genomic 
DNA samples were sent for whole genome sequencing to Genomic Facilities of University 
of Birmingham. 
1 2 3 4 5 6
0.09 0.14 0.21 0.31 0.47 0.70
MIC
1.05 1.58 2.37 3.56 5.33 8.00
0.17 0.26 0.39 0.59 0.88 1.32
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4.2.7 Genomic DNA extraction 
50 ml of M. bovis BCG culture was grown to log phase (OD600=0.4-0.8) in Middlebrook 
7H9 broth with 10% ADC supplement, 0.5% glycerol and 0.025% Tween-80. The culture 
was pelleted by centrifugation on 4 °C, then resuspended in 450 µM Qiagen P1 buffer 
(#19051, 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNaseA (Qiagen, 2005)) 
supplemented with 50 µl 10 mg/ml lysozyme solution. Samples were incubated at 37 °C 
overnight, then 100 µl 10% SDS solution and 50 µl 20 mg/ml proteinase K was added for 
30 min incubation at 55 °C. After the addition of 200 µl 5M NaCl solution the samples were 
heated to 65 °C and kept for 15 min. A 1 ml of chloroform:isoamylalcohol (24:1) mixture 
was added and gently mixed. The aqueous layer was separated by centrifugation (10 min, 
room temperature, 13,000 rpm on a bench-top centrifuge), transferred to a sterile tube and 
the washing step with chloroform:isoamylalcohol repeated. Then the aqueous layer was 
transferred again to a sterile tube, and 700 µl ice-cold 100% isopropanol was added and 
gently mixed. DNA was then pelleted by centrifugation at 4 °C, 13,000 rpm for 1 hour, and 
the supernatant gently removed, the pellet washed with 700 µl of 70% ice-cold ethanol. The 
sample was pelleted again at 4 °C, 13,000 rpm for 1 hour. Ethanol was gently removed, and 
sample was left at room temperature in a fume hood until all the solvent evaporated. Finally, 
the pellet was resuspended in 25 µl MilliQ water and stored at -20 °C, while 1 µl of each 
gDNA preparation sample was loaded onto 0.8% agarose gel for visualisation. Samples with 
satisfactory amount of gDNA were sent for whole genome sequencing. 
4.2.8 Thermal Shift Assay 
As described in Chapter 3.2.4. with the difference, that in some cases Filter 4 output of the 
real time PCR thermocycler (recommended with ROX dye according to manufacturers’ 
manual) resulted in less noisy signal than with filter 3 (recommended with TAMRA dye). 
Therefore, filter 4 output data were analysed.  





4.3.1 Whole-cell screens against Mt-DprE2 in M. bovis BCG 
The first results from the HTS showed a much less robust screen than anticipated. Z’ values, 
that are expected to be 0.4 or higher for a successful screen, were well below this value. 
From the total of 132 plates only 67 passed this limit. As a lower limit when Z’>0 was 
accepted, then 94 plates passed the quality assessment, which means 29% of the plates failed 
even this permissive evaluation. See Figure 4.2. with examples for acceptable and 
unacceptable plates by Z’ analysis. Plates with failed Z’ values were not excluded from the 
hit selection process, but a high number of false positive hits were expected. 
Low Z’ values can be explained by the edge effect (Carralot et al., 2012). In this specific 
case, this observation may be explained by high evaporation with a typical central pattern 
on almost every plate. Since the 384-well plates are fitted with a lid without condensation 
rings, visible amounts of vapour accumulated in the central part of the plates, likely 
originating from the wells in the middle. As the protocol describes, these lids are discarded 
and replaced by sealing films for the read, and at this scale of experiment a few microliters 
of sample missing makes for a large impact on results.  




Figure 4.2. Examples for plate quality assessment by Z’ values. On the left two plate 
layouts with fluorescence intensities as gradients (yellow high, red low) are shown. Wells 
towards the plate edges retained more culture sample than the central, more evaporated 
wells. On the right histograms of control wells of the example plate are shown. (A) Plate 
with Z’ = 0.64 passes, (B) plate with Z’ = -0.23 fails HTS quality requirements. 
This pattern between central and peripherial wells lead to the decision of instead of using 
average values for dead and live controls when calculating the percentage of inhibition (and 
consequently the MIC shift) for each well, the single values of controls in the corresponding 
row were used. This gave systematic correction for the evaporation effect, but also simpler 
than other published method with systematic correction algorithm (Carralot et al., 2012). 
As an attempt to minimise evaporation, the entire HTS was repeated with more attention to 
slow heating from room temperature to 37 °C, and also incubated all plates in a different 
thermostat. This resulted in better quality of the screen, 94 plates passed the Z’>0.4 criterium 
(71%). However, a suspiciously low amount of hits emerged, and a disproportionate amount 
of the failed plates belonged to the overexpressing strain (for example at 1 µM compound 
concentration against overexpressing strain 23 plates out of 33 failed quality assessment). 
Therefore, it is likely that the bacteria cultures were not optimal for the screen and the second 
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HTS was only considered as a complement to the first HTS, and finally produced merely 8 
new preliminary hits to test in dose response. 
4.3.2 Hit compound selection process 
A compound was selected from the HTS for dose response testing in two scenarios. Either 
compounds that showed a shift or compounds that were too potent at the set compound 
concentrations. Compound causing a shift was defined as the compound that is potent against 
the control strain at 5 µM (at least 40% growth inhibition) and shows a shift of minimum 
40% in percentage of inhibition compared to the overexpressing strain on either 
concentration. A compound too potent for evaluation was defined as the compound by which 





cmps selection criteria cmps selection criteria 
11 096 TB Box 11 096 TB Box 
340 possible hit in HTS 8 
additional possible 
hits in HTS 
235 
available in 10 mM 
stock 
7 
available in 10 mM 
stock 
24 













reproducible in both 
laboratories 
N/A 
reproducible in both 
laboratories 
 
Table 4.2. Compound attrition during whole-cell screen and the influence of scale-up 
and location. Asterix labels two compounds that were questionable due to solubility issues. 
HTS2 hits were only confirmed in 96-well plate format. HTS is high-throughput screening, 
DS dose-response in 2-fold dilution series, DS rep means dose-response reproducibility, 
MIC50 minimum inhibitory concentration of growth by 50%, cmps compounds. N/A not 
applicable, HTS2 hits were tested in dose response in one laboratory only. 
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Initial dose response was performed in 384-well plates, then compounds with at least 2-fold 
MIC50 shift were selected from the 96-well plate (Corning, #CLS3896) repeat dose response 
experiment. Compounds with the largest shift were applied in enzymatic assay against Mt-
DprE2. 
During hit selection and confirmation, it was taken into account which compounds were 
reproducible in both laboratories, which resulted in surprisingly low number of hits 
(Tables 4.2. and 4.3.). 
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cmp MW Results in GSK Results in UoB 
    MIC50 shift MIC50 shift 
1 401.453 0.75 4-6x 6 no 
2 351.402 1 2-3x 3 reverse 
3 300.7 3 4x 9 no 
4 497.548 1.3 4x 8 ? 
5 415.46 3 large 2.5 4x 
6 364.249 0.375 large 3 reverse 
7 406.482 5 2x 4.5 no 
8 377.458 >16 ? 13 reverse 
9 552.917 10 reverse 10 no 
10 257.334 2.5 large unavailable 
11 262.354 >16 ? >100 ? 
12 403.439 12 small 12 2x 
13 349.32 4.5 small untested 
14 368.43 >16 ? >20 reverse 
15 425.39 0.6 8x 0.6 4x 
16 487.385 >16 ? 60 reverse 
17 317.7 3 2-3x 5-12 reverse 
18 442.554 1 large 6-8 no 
19 394.349 5 2x 9 no 
20 451.416 >16 ? 17 2x 
21 504.96 8 small 15-24 no 
22 297.18 10 ? 12-17 no 
23 506.62 15 reverse 15 reverse 
24 379.456 1 reverse 1 reverse 
25 336.429 - - 0.75 2x 
26 303.359 - - 6 reverse 
27 434.94 - - 0.75-2 large 
28 271.318 - - 2 reverse 
29 341.408 - - 11 no 
31 483.904 - - 0.7 large 
32 325.276 - - 0.75 4x 
 
Table 4.3. Refined hit selection of the HTS in various formats, on two locations. 
Compound 15 and 29 had different stock sources in UoB and GSK. Reverse shift means that 
overexpressing strain had lower MIC than control. Compounds 25-32 are from HTS2, all 
other from HTS1. MICs in [µM]. MW is molecular weight in [g/mol], ‘small’ shift means 
less than 2-fold, ‘large’ means over 8-fold shift in MIC. Question marks signal inconsistent 
dose response curves (possible solubility issue) and possible hit for compound 10. 
Yellow/green highlighting is for confirmed hits. 
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4.3.3 Proof of concept for Mt-DprE2 enzyme inhibition assay 
As proof of concept Mt-DprE1 enzyme inhibitors were cross-referenced in Mt-DprE2 
enzyme activity assay. By design, the Mt-DprE2 assay does not distinguish between Mt-
DprE1 and Mt-DprE2 inhibitors, since Mt-DprE1 activity is a prerequisite to DPX formation 
which is the substrate of Mt-DprE2. Attempts to separate DPX from DPA/DPRs have been 
unsuccessful. Therefore, all Mt-DprE1 inhibitors appear as false hits with the Mt-DprE2 
assay, that can be assorted by testing the false hits in Mt-DprE1 assay (Batt et al., 2016), 
where only Mt-DprE1 inhibitors would test positive.  
TCA1 (Wang et al., 2013) and 93a3 (studied in Chapter 2 Mt-DprE1 ligand binding studies) 
are highly potent Mt-DprE1 inhibitors and were selected for this experiment. TCA1 was 
tested with both enzyme preparations, 6xHis-SUMO-Mt-DprE2 and 6xHis-Mt-DprE1+Mt-
DprE2 co-expression preparations and exhibited the anticipated constant read-out 
fluorescence signal, instead of a decreasing signal indicative of active enzyme reaction 
(Figure 4.3.). 93a3 also functioned similarly with the co-expression protein preparation. 
Compounds were incubated for 20 min with the enzymes for these results. 
 




Figure 4.3. Mt-DprE2 inhibition assay proof-of-concept with TCA1 and (A) 6xHis-Mt-
DprE1 + Mt-DprE2 co-expression and (B) 6xHis-SUMO-Mt-DprE2. RFU is relative 












active TCA1 active TCA1 
  BTP pH 7.2 45 mM + + + + + + 
  100 mM ammonium sulfate  + + + + + + 
  180 µM NADH   + + + + + 
  DprE1 appr. 9.5 µM         + + 
  0.2 mg/ml 6xHis-SUMO-Mt-   DprE2          + + 
  0.3 mg/ml 6xHis-Mt-DprE1 + Mt-DprE2     + +     
  50 µM TCA1       +   + 
  180 µM GGPR + + + + + + 
MilliQ water addition for 10 µl + + + + + + 
 
Table 4.4. Reaction composition of assays in Figure 4.3. 




Figure 4.4. Mt-DprE2 inhibition assay proof-of-concept with 93a3 and 6xHis-Mt-
DprE1 and Mt-DprE2 co-expression. RFU is relative fluorescence unit. 
 
Reaction mixture: buffer +GGPR all but GGPR active ctrl 93a3 
40 mM HEPES pH 7.25  + + + + 
80 mM NaCl  + + + + 
400 µM NADPH   + + + 
333uM 93a3       + 
7 mg/ml 6xHis-DprE1 + DprE2   + + + 
280 µM GGPR +   + + 
MilliQ addition for 15 µl + + + + 
 
Table 4.5. Reaction mixture for Figure 4.4. 
 
4.3.4 DprE2 enzyme inhibition assays 
Compound 15 was the first Mt-DprE2 hit compound from the published collection of 177 
compounds (Ballell et al., 2013), with extensive reproducibility in whole-cell assays 
(Table 4.3.), hence evaluate in the Mt-DprE2 enzyme activity assay in the hope of 
developing the first Mt-DprE2 enzyme inhibitor control.  
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Unfortunately, compound 15 and four of its derivatives had no observable effect on enzyme 
activity. This result suggested that either compound 15 may be a pro-drug that is converted 
in vivo to the active form, or Mt-DprE2 is not the target of this compound series.  
 




Table 4.6. Reaction mixture of assays in Figure 4.5. Assays run in GSK. 
 
Hits form the HTS (see Table 4.3.) were tested in the Mt-DprE2 inhibition assay to explore 
if any of them directly inactivated Mt-DprE2. Since these compounds were not related in 






























GC14 GC43 GC65 GC67 93a3
DMSO 
ctrl
80 mM BTP pH 7 + + + + + + + + + +
50 mM NaCl + + + + + + + + + +
600 mM ammonium sulphate + + + + + + + + +
180 μM NADH + + + + + + + + +
12 μM DprE1 + + + + + + + + +
0.3 mg/ml 6xHis-SUMO-DprE2 + + + + + + + + +
50 μM inhibitor or 3% DMSO + + + + + + +
150 μM GGPR + + + + + + + + +
MilliQ water addition to 10 μl + + + + + + + + + +
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DprE2 without prior activation. Of the 18 from 34 compounds listed in Table 4.3. the 
following have been evaluated: compounds 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 15, 17, 18, 19, 20, 
27, 31, 32. 
Interestingly, none of the selected compounds inhibited enzyme activity similar to the Mt-
DprE1 inhibitor controls. Compound 3 oxidised NADH and NADPH without enzymes 
present, which gave a low starting level of fluorescence and little difference due to enzyme 
activity. Compound 20 gave a slightly prolonged reaction start compared to active ctrl 
reaction, which in coupled reactions may be an indication of low activity of the first enzyme, 
Mt-DprE1. This phenomenon could be repeated with lower substrate concentrations, at 
240 µM GGPR as well, hence the lag of the reaction was not caused by the relatively high 
GGPR concentration near the maximum limit of substrate tolerance of the assay 
(Figure 3.24.). 
 
Figure 4.6. Mt-DprE2 inhibition assay with compound 20 (Table 4.3) HTS hit 






















Table 4.7. Reaction mixture of assays in Figure 4.6. Assays run in University of 
Birmingham. 
 
4.3.5 Thermal shift assay (TSA) with 6xHis-SUMO-Mt-DprE2 and 
compound 15 
In theory, TSA is an adequate method to show enzyme-ligand interaction in cases when the 
bound ligand stabilises the enzyme protein conformation. With Mt-DprE1 several of these 
interactions have been investigated (in GSK DDW, unpublished) and as a general rule of 
thumb ligands that increased the melting temperature (Tm) of Mt-DprE1, were inhibitors, but 
not all inhibitors stabilised Mt-DprE1. For example, a well known inhibitor BTZ043 did not 
cause a Mt-DprE1 Tm increase. 
Fractions of 6xHis-SUMO-Mt-DprE2 with metal affinity chromatography followed by size 
exclusion chromatography purification seemed pure and concentrated enough to conduct 
ligand binding studies using TSA (Figure 4.7.). This technique requires only 0.2 mg/ml 
protein for detectable signal, but protein homogeneity is essential for sharp transition 
changes. 
Firstly, as proof-of-concept NADH co-factor was tried as a ligand. NADH is not supplied 
during protein purification in excess, therefore it is possible that some co-factor is lost in the 
Reaction mixture: buffer +GGPR no GGPR ctrl DMSO ctrl no GGPR cmp20 active cmp 20
40 mM HEPES pH 7.5 + + + + +
80 mM NaCl + + + + +
400 µM NADPH + + + +
333 µM inhibitor + +
3.3% DMSO + +
7 mg/ml coexpressed 
6xHis-DprE1+DprE2
+ + + +
280 µM GGPR + + +
MQ water to 15 µl + + + + +
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process that may be reincorporated in this assay. Interestingly, NADH addition did not 
impact Tm significantly (Table 4.8.). 
Compound 15 was tested in TSA with fraction and resulted the same small increase in Tm as 
the DMSO control (Table 4.9.). 
 Tm in °C SD 
no ligand 60.1 0.4 
+ 4 µM NADH 60.9 0.3 
+ 10 µM NADH 60.7 1.3 
 
Table 4.8. NADH as ligand of 6xHis-SUMO-Mt-DprE2 in thermal shift assay. Protein 
as ’75.1’ in Figure 4.7. Melting curves generated and analysed with filter 4 output data. 
 
 
Figure 4.7. SDS-PAGE analyses of protein fractions of 6xHis-SUMO-Mt-DprE2, after 
size exclusion chromatography, used in thermal shift assay. (A) ‘75.1’ fraction used in 
NADH binding. MM molecule marker Amresco #J383. (B) Fraction ‘73.3’ used in 
compound 15 binding TSA. IMAC sample is the protein before size exclusion 
chromatography. MM is molecule marker is ThermoFisher, #26616. Fraction labels refer to 
elution volumes in [ml]. 
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  Tm in °C SD 
no ligand 61.4 1.05 
+ 0.25% DMSO 64.8 0.52 
+1  µM cmp 15 65.2 0.56 
+ 5 µM cmp 15 63.5 0.29 
+ 10 µM cmp 15 64.5 0.92 
+ 15 µM cmp 15 63.7 0.36 
+ 25 µM cmp 15 62.0 1.33 
 
Table 4.9. Compound 15 titration study with 6xHis-SUMO-Mt-DprE2 in thermal shift 
assay. 0.25% DMSO is as the final DMSO concentration with 25 µM compound 15 addition. 
Protein as ’73.3’ in Figure 4.7. Melting curves generated and analysed with filter 4 output 
data. 
In conclusion, the thermal shift assays did not confirm that compound 15 binds DprE2, 
because there is no significant increase in melting temperature, but it does not exclude the 
possibility either, since this technique only measures the protein stability which might not 
be altered by the ligand. 
4.3.6 Spontaneous mutant generation against hit compounds 
Three compounds, the hit compound 15 and two derivatives, GC14 and GC46 (referred to 
as compound 20 and 31 in thesis work currently in publishing by Giacomo Chiodarelli, 
University of Birmingham) were tried in the modified mutant generation protocol, detailed 
in Chapter 4.2.6. Each mutagenesis delivered one clone that had a 5-fold higher MIC than 
wt M. bovis BCG (Table 4.10.). These clones were highly crossresistant to the other 
compounds with similar structures. Known structures are listen in table 4.12.  
  
solid MIC in 
SPOTi [μM] 
  liquid MIC90 [μM] 
clone: wt BCG Mt-DprE2 oe p1C6 p2A3 p4B5 
GC46 < 1.5 
  
2.99 9.14 16 16 N/A 
GC14 < 0.24 0.56 5.22 5.22 5.22 N/A 
cmp 15 < 0.6 0.56 1.71 2.99 2.99 2.99 
cmp 31 < 0.6 0.97 > 28 - - > 28 
 
Table 4.10. Cross-resistance shown as similar shift in MIC between generated 
spontaneous resistant mutant clones. Compounds labelled GC46 and GC14 are potent 
derivatives of compound 15 (produced by Giacomo Chiodarelli, University of Birmingham). 
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Resistant mutant ‘p1C6’ originates from mutagenesis against compound GC46, p2A3 
against compound GC14, p4B5 against compound 31. Mt-DprE2 oe labels the strain 
overexpressing Mt-DprE2.  
Four spontaneous mutants were subjected to whole genome sequencing (performed by 
Genomics Facilities at the University of Birmingham) and compared to wt M. bovis BCG 
genomic DNA sequence. Table 4.11. details which mutant colonies appeared against which 
compound during mutagenesis (see ‘highest tolerated concentration’). The results 
highlighted two key genes affected by mutation: fgd1 and fbiC. Mutant p1C6 and p2A3 had 
missense mutations in fgd1 leading to a L321R amino acid replacement, while p3A4 
acquired a missense mutation leading to a S196P change. The protein encoded by fgd1 is 
identical in both M. tuberculosis and M. bovis BCG on the amino acid level (P9WNE1 and 
A0A0H3M1G9 on UniProt (UniProt Consortium, 2018)). Mutant p4B5 had a missense 
mutation in fbiC that resulted in a R847H amino acid replacement. Again, this gene codes 
identical proteins in both species (P9WP77 and Q7U0G9 in M. tuberculosis and M. bovis 
BCG, respectively (UniProt Consortium, 2018)). 
compound comment wt MIC 
highest tolerated  
conc. 
mutant ID pointmutation 
cmp 15 initial hit 0.14 0.31 p3A4 fgd1 gene S196P 
GC46 derivatives of 
cmp 15 
< 1.54 4.69 p1C6 fgd1 gene L321R 
GC14 < 0.24 0.53 p2A3 fgd1 gene L321R 
cmp 31 
HTS hit, cmp 
15 derivative 
0.7 8 p4B5 fbiC gene R847H 
 
Table 4.11. Genomic sequencing results of resistant mutant M. bovis BCG clones. 
Concentration values in [µM]. 
In conclusion, these spontaneous mutations are suggestive of similarity to delamanid and 
pretomanid activation in the case of compound 15 and its derivatives, which is detailed in 
Chapter 4.4.  





The compound library ‘TB Box’ was investigated as a pool of potential Mt-DprE2 inhibitors 
in this HTS. Details about the library are not published, but it contains about 11,000 
compounds that in previous phenotypic assays inhibited MTB growth. The library excludes 
drugs with known mechanisms of action, furthermore only compounds with an acceptable 
level of cytotoxicity were included that were detailed in the TB Box subset ‘177 TB set’ 
published by Ballell et al. (2013).  
The compound concentrations of the single-shot HTS is a crucial decision in hit discovery. 
Earlier published (Cox et al., 2016) and unpublished screens explored in similar set-ups 
against other targets the concentration range between 0.5 to 20 µM. At the selected 1 and 
5 µM single-shot HTS in HTS1 986 compounds were potent (inhibited growth in ctrl strain 
by 40% or more), in HTS2 580 compounds (which is 11.3% and 5.2% of all compounds, 
respectively). This implies that the TB Box has a large pool of compounds that were beyond 
the reach of this screen and may be of interest to test at higher concentrations in the future. 
It is worth mentioning, that there are alternatives to single concentration testing. If there were 
information regarding MICs in whole-cell assays with similar assay conditions on each 
compound of the library, then it would be more informative to test each compound around 
its MIC or slightly above that value to observe elevated MICs. 
One of the most important findings of the HTS and following hit confirmation experiments 
was the unexpectedly high compound attrition rate (Figure 4.2.). In the case of preliminary 
hits not confirmed in dose response assay, it was an expected consequence of low initial 
screen quality. In the first screen (HTS1) 29% of the 384-well plates failed quality 
assessment by Z’ values (Chapter 4.3.1.), which could easily translate to several initial hits 
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resulting to be false positives. A more complex task was to interpret how the majority of 
384-well dose response screen results became irreproducible in 96-well plates. 
There are several differences between the two dose response assay formats. The 384-well 
plate format had 50 µl of bacteria culture grown and evaluated compared to the 100 µl 
reaction volume of the 96-well format. A larger bacterial culture may give more robust 
response to compound exposure, the survival of the cells is based on a larger statistical 
sample leading to a better average than with small cell numbers. Also, plate well geometry 
is different: the 384-well plates’ chimneys by Greiner are rectangular cuboids, while 96-well 
plates by Corning are cylindrical with a V-bottom (Figure 4.8.). Bacterial cells accumulate 
at the bottom of the well at rest, so from the aspect of oxygen diffusion, it is important how 
tall the liquid layer is above the cells. In the 384-well plate chimney well it is approximately 
4.6 mm, while in the V-bottom 96-well plate chimney approximately 3.1 mm (calculated 
with well parameters of the manufacturer’s brochure and reaction volumes). The relative 
surface area in contact with the culture is bigger in the case if 384-well plate format. MTB 
is known to be capable to form biofilms and that this feature confers higher drug tolerance 
to the cells (Sambandan et al., 2013). The detergent Tween-80 is included in the media 
precisely to prevent biofilm formation and cell clumping. Taken these information together 
it is likely, that the small size inoculum and the geometry more supportive of cell adherence, 
and hence deviance from average drug susceptibility for cell subpopulations adhered to the 
surface, the 384-well plate format is less robust than the 96-well plate format, more 
responsive to variation in controlled and uncontrolled factors. 




Figure 4.8. Well chimney geometry of (A) the Greiner 384-well plate used in HTS, (B) 
the Corning 96-well plate used in dose response measurements. Well parameters from 
the manufacturers’ brochures (Gbo.com, n.d.)(Corning, n.d.). 
Difficulties reproducing results between laboratories proved to be an issue as well with hit 
compounds. Out of 16 hit compounds investigated in GSK DDW only 2 were reproducible 
hits in University of Birmingham laboratories (Tables 4.2. and 4.3.). Experiments were 
conducted, with two exceptions (see Table 4.3.), from the same compound stock – two 
different aliqouts from the exact same compound preparation in GSK Harlow compound 
library. Compounds 1 to 8 were deposited in the same 96-well plate, in the same column 
during the GSK DDW experiments, but the cross-contamination of compounds in-between 
wells is unlikely for two reasons: if the only shift-causing compound among these, 
compound 5 was to spill to the surroundings, it makes no sense that it would affect only 
some neighbouring cells, but not others. Furthermore, the MIC50 values were not 
representative to compound 5, in GSK the compound 4 and 6 were more potent than 
compound 5 (Table 4.3.). Therefore, it is more likely that the differences in MIC values 
between laboratories was somehow the consequence of using different M. bovis BCG stocks. 
Only the plasmids were transferred between laboratories, locally available wild type M. 
bovis BCG bacteria were transformed with pMV261-Mt-DprE2 for overexpressing strain, 
and with pMV261 empty plasmid for control strain. These theoretically identical strains 
responded similarly to compound 15, the main hit compound, however with seven other hits 
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(compound 1, 2, 3, 4, 6, 17, 18 see Table 4.3.) the MIC values were equally high for the 
control strain, as it was only with the overexpressing strain in GSK. 
One of the most useful and pursuable outcome of the Mt-DprE2 screen were the few hit 
compounds, that proved to be reproducibly elicit a shift in MIC depending on Mt-DprE2 
overexpression in M. bovis BCG. These compounds are compound 5, 15, 27, 31, 32 and 
potentially compound 10 (which was not tested in University of Birmingham). Compound 
10 and 27 are unpublished structures of GSK, but the structures of compound 15, 31 and 32 
are not only published, but share structural similarities: they are all nitrofurans (Table 4.12.). 
Nitrofurans have been reported previously as potent inhibitors of M. tuberculosis 
(Tangallapally et al., 2007). Some derivatives demonstrated potency in the nanomolar range 
(Yempalla et al., 2015). The main challenge of compound optimisation was then to keep the 
compound metabolically stable.  
Also, erroneously the target of nitrofurans was firstly identified as Glf (Scherman et al., 
2003; Tangallapally et al., 2007), based on enzyme activity screens where whole cell screens 
indicated it as the target, but enzyme activity assays did not. Glf contributes to the 
arabinogalactan synthesis, as does Mt-DprE2, but is involved in the synthesis of the UDP-
Galf residue, the building block of the galactan homopolymer (Weston et al., 1997). To date 
no mechanism of action have been published to these compounds. 
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HTS hit compound 




HTS hit compound 




HTS hit compound 




HTS hit compound 
 
Table 4.12. Published compound structures with antimycobacterial activity, hits in the 
Mt-DprE2 screen against the TB Box compound library. Available from PubChem (Kim 
et al., 2016). 
 
The spontaneous mutant generation studies pointed to two genes that lead to resistance 
against Mt-DprE2 screen hit compounds: genes fgd1 and fbiC. These two genes have been 
previously reported to contribute to pretomanid (PA-824) (Haver et al., 2015) and delamanid 
resistance (Fujiwara et al., 2018), the latter is a WHO approved drug for treating MDR-TB 
since 2014 (WHO, 2017). These compounds are similar (Table 4.13.), both are 
nitroimidazoles and pro-drugs that require activation (Islam et al., 2017). Also, both 
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inhibitors have a complex mechanism of action. In the case of pretomanid, a combination of 
respiratory effects changing the redox status of the cell, releasing nitric oxide and hindering 
mycolic acid synthesis (Manjunatha et al., 2009). 
Delamanid 
 
MW = 534.492 g/mol 
 




MW = 359.261 g/mol 
 
in phase 3 clinical studies 
 
Table 4.13. Structures of delamanid and pretomanid, drugs in clinical testing. 
Why mutations within these two genes are often encountered against pretomanid and 
delamanid, is explained by the bioactivation of these compounds. The activator of delamanid 
is the protein deazaflavin-dependent nitroreductase (Ddn, Rv3547), however this enzyme 
functions only in the presence of the reduced F420 co-enzyme. The genes fbiA/B/C synthesise 
F420 while fgd1 codes a glucose-6-phosphate dehydrogenase which utilises the oxidised co-
factor and completes the catalytical cycle of F420 (Fujiwara et al., 2018) (Figure 4.9.). 
 
Figure 4.9. In vivo activation of delamanid by (Fujiwara et al., 2018). 
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Based on structure similarity and spontaneous mutations in these specific genes together 
suggest that compounds 15, 31 and 32 may be similar in bioactivation and mechanism of 
action to pretomanid and delamanid. That would explain the failure of Mt-DprE2 enzyme 
activity assay proving compound 15 inhibiting Mt-DprE2 (Chapter 4.3.4.). Firstly, if it is a 
pro-drug, then the activator is not included in the assay setup, unless it is Mt-DprE1. 
Secondly, Mt-DprE2 may not be a unique and/or specific target of these compounds. The 
latter could be elucidated in the future with in vitro bioactivation of compound 15 with Ddn 
protein and reduced F420 and subsequently preforming the Mt-DprE2 enzymatic assay. 
A further implication of similarities between hit compounds and other nitroimidazoles is that 
if their mechanism of action is similar, the hit compounds may also be highly active against 
dormant M. tuberculosis. Delamanid is a sterilising drug (Fujiwara et al., 2018). Pretomanid 
has been confirmed to inhibit M. tuberculosis growth by NO release, a phenomenon that is 
insufficient to kill aerobically grown bacteria, but gains importance in anaerobic conditions 
(Manjunatha et al., 2009). In the future it is worth looking into the potential sterilising 
qualities of the hit compounds (Table 4.12. and 4.3.) because it would influence the possible 
drug combinations in therapy and even their application in latent tuberculosis treatment and 
prophylaxis.  
Notwithstanding the distance between species, these compounds might be active even 
against parasites. Nitroimidazoles have been used against infectious agents unrelated to M. 
tuberculosis, in particular against trichomoniasis, leishmaniasis and Chagas-disease (Ang et 
al., 2017). These diseases are caused by kinetoplastid protozoa, eukaryotic species (Ang et 
al., 2017). If the Mt-DprE2 screen hit compounds could be repurposed for the treatment of 
these neglected diseases, it could be an interesting new area of investigation.
 





Experiments conducted in this thesis were all aimed at investigating the decaprenyl-
phosphorylribose epimerase subunits Mt-DprE1 and Mt-DprE2 proteins, that are both 
promising targets for developing new inhibitors against mycobacteria. Inhibitors directed 
against novel targets can limit proliferation of drug-resistant strains of M. tuberculosis, 
which is a prime ambition of new drug discovery research currently. 
Mt-DprE1 is an established and thoroughly studied drug target of mycobacterial cell wall 
synthesis. Mt-DprE1 has emerged as a target from several independent phenotypic screening 
campaigns, suggesting it is highly druggable, while the availability of various protein 
structures via crystallography make docking studies and structure activity relationship 
optimisation possible. The proximity of two disordered regions to the active site and frequent 
ligand binding site raised the question if these disordered regions participated in ligand 
binding. 
Results of ligand binding experiments with intrinsic tryptophan fluorescence measurement 
revealed that with two investigated ligands the affinity for binding did not change 
significantly by introducing pointmutations to the short disordered region. Therefore, from 
the drug developmental aspect, the lack of this disordered region in crystal structures causes 
a level of uncertainty to how ligands interact with the protein in solution, but in some cases 
(such as with these tested ligands) do not interfere with ligand affinity.  
Based on the enzyme activity assay studies with Mt-DprE1 muteins, it became clear that 
some amino acid residues in the short disordered region are vital for normal enzyme 
function. The enzyme follows an allosteric kinetics which is uncommon for monomeric 
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enzymes, together with the pattern in residue essentiality in the short loop corroborate the 
theory that the enzyme likely follows a lid-like enzyme dynamic (Porter and Miller, 2012). 
Mutations of the lid ‘hinges’, residues at both ends of the loop affect enzyme activity the 
most, and these are also evolutionally highly conserved amino acids. 
A notable observation of the enzyme activity assay with Mt-DprE1 was the direct 
comparison of the published assay with substrate FPR, and the not yet published assay of 
GSK with GGPR. Using the latter substrate analogue led to a much more robust and better 
signal-to-noise assay design which is beneficial to inhibitor testing at any scale. However, 
at higher concentrations GGPR appeared to inhibit enzyme activity, which makes enzyme 
characterisation with this substrate impossible beyond a certain concentration limit. 
With the generated Mt-DprE1 single site muteins in the future some interesting experiments 
can continue. The small disordered region may or may not interact with Mt-DprE2. Native 
Mt-DprE2 may be produced for example from 6xHis-SUMO-Mt-DprE2 expression and 
purification, followed by tag cleavage. Furthermore, the inactive muteins of Mt-DprE1 could 
also participate in crystallisation trials, since the substrate binding interaction with the 
enzyme has never been solved. 
The second main goal of this work was to produce pure, non-aggregated but concentrated 
Mt-DprE2. There is still no experimental protein structure solved for this potential drug 
target and there are no biochemical studies published to date due to the difficulty of obtaining 
non-aggregated protein. There are only whole cell, genetic or in silico modelling studies with 
it, because its purification has proven to be difficult. Crystallisation failed likely because the 
aggregation impedes protein crystal formation. It is undetermined, why Mt-DprE2 self-
associates so readily, perhaps it functions natively also as an oligomeric enzyme. The most 
similar protein structures listed in an in silico modelling study (Bhutani et al., 2015) 
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paralleled Mt-DprE2 to proteins that all form homo-tetramers. Multiple native protein-
protein interaction sites present in a highly concentrated protein solution may produce large 
aggregates, especially in the artificial environmental to which the protein is exposed to 
during purification, including large changes in pressure, the presence of a filtration 
membrane and shear by the solvent during ultrafiltration, which could further propagate 
aggregation (Kim et al., 1993). Nevertheless, it has been hypothesised that periplasmic 
proteins in E. coli are more resistant to aggregation, than other proteins of the cell (Liu et al., 
2004), which by similarity between species either adds to the unique properties of Mt-DprE2, 
or adds to the question whether it is located in the periplasm as reported (Brecik et al., 2015). 
In the third chapter various conditions have been explored to improve protein solubility and 
homogeneity in solution. Firstly, tag-fusion with 6xHis-SUMO improved enzyme quantities 
and led to enzymatically active, adequately pure preparations. However, protein degradation 
is likely taking place in fresh preparations already, and the fusion protein kept its tendency 
towards aggregation, as seen with size exclusion chromatography. Therefore, without 
solving the issue of protein concentration causing further aggregation by filtratioin, the 
method is not effective to produce protein preparation for crystallography. As for enzyme 
activity assay, the fusion protein did not show activity in combination with the redox co-
factor NADPH, the most probable co-factor of the enzyme, therefore its usefulness in 
inhibitor screening is ambiguous.  
Co-expression of Mt-DprE2 with His-tagged Mt-DprE1 lead to useful amounts (near 
1 mg/ml stock solutions) of the two proteins for enzyme activity measurements, especially 
when expressed from different plasmids. The preparation was enzymatically active with both 
NADH and NADPH, and activity was reversible by Mt-DprE1 inhibitors. The main concern 
regarding the assay that needs further assessment is the difficulty to standardise the enzyme 
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activity across batches. Each enzyme preparation had different activity profile which did not 
strictly correlate with total protein concentration. One clue to this behaviour is that when co-
expressing Mt-DprE2 with Mt-DprE1, the molar ratio was often distinctly less than one. 
Also, depending on the expression design, expressing the proteins from one single or two 
separate plasmids led to different types and amounts of characteristic contaminants co-
purified with the mixture. Therefore, in the future different purification techniques could be 
included in the protein production to achieve consistent ratio and eliminate the remaining 
contaminants. One main contaminating protein stood out, which has to be separated to 
measure precise concentrations. Since this contaminant was very similar in size on SDS-
PAGE, and ion exchange chromatography required unusually high salt concentrations for 
elution, it is sensible to replace the second chromatography step to hydrophobic interaction 
chromatography in the future. 
Size exclusion chromatography studies revealed, that Mt-DprE1 and Mt-DprE2 in solution 
form a complex. Interestingly, unidentified proteins were also present in the complex 
fraction of the experiment, which when reproduced with higher enzyme quantity, may be 
informative to assess in mass spectrometry. These complexes, if separated in higher 
concentration, could also serve as sample in crystallography. High salt concentrations helped 
both enzymes to stabilise in solution, which already led to improved crystallisation with 
difficult M. tuberculosis proteins in the past (Cohen-Gonsaud et al., 2002).  
High-throughput screening with Mt-DprE2 overexpressing M. bovis BCG aimed at 
identifying Mt-DprE2-specific inhibitor compounds in the TB Box compound library. The 
whole cell assay in 50 µl final volume and resazurin read-out lead to an unexpectedly low 
signal to noise ratio and a systematic error of edge effect. For this reason, sample location 
on a microplate greatly influenced the signal-to-noise ratio of the reaction and hit 
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identification of the compound. This issue was most reliably solved by doubling the assay 
volume to 100 µl, which in secondary screens delivered first approximately 16 hit 
compounds, followed by 5 more after the repeat of the total high-throughput screen. 
Interestingly, only seven compounds were confirmed in multi-laboratory testing (tested in 
both University of Birmingham and GSK DDW Tres Cantos), and none of the tested hit 
compounds inhibited the developed in Mt-DprE2 enzyme activity assay. Which also proves 
that they are not Mt-DprE1 inhibitors, since the enzyme activity assay is coupled to and 
dependent on Mt-DprE1 activity. 
One of the biggest successes of the Mt-DprE2 inhibitor screen was the generation of 
spontaneous resistant mutants against some potent inhibitors. As the negative result in 
enzyme activity assay suggested, none of the resistance-conferring mutations arose in dprE2. 
Instead, resistance was linked to point mutations in two enzymes, fbiC and fgd1, involved in 
co-enzyme F420 synthesis and recycling to its reduced form, respectively. These mutations 
are reminiscent of mutations that provided resistance against delamanid and pretomanid, 
nitroimidazole antituberculotic drugs in development and approved for drug resistant 
tuberculosis therapy. Spontaneous mutations against these drugs focus on the activator 
enzyme, Ddn, and enzymes producing the reduced co-factor of Ddn, the deazaflavin F420, in 
particular the enzymes FbiA, FbiB, FbiC and Fgd1 (Fujiwara et al., 2018). 
The screening revealed one specific chemical scaffold: 2-nitrofuran compounds were 
confirmed hits in several different derivatives. These compounds may be prodrugs similar 
to the nitroimidazoles, whose activation has been studied in detail. Pretomanid mechanism 
of action is complex, in aerobic environment it inhibits the mycolic acid synthesis (Stover et 
al., 2000), while anaerobically cell death is attributed to NO production (Manjunatha et al., 
2009), which hinders the function of multiple native enzymes. Mt-DpE2 may be one of 
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several targets impaired by reactive nitrogen species formed during the reduction of the hit 
compound. 
Target identification of the newly found hits is of paramount importance. Since Chapter 4 
elaborated on a phenotypic compound screen, a change in susceptibility due to 
overexpressing Mt-DprE2 may be only a minor contributor to compound resistance and may 
play a small part in the mechanism of action. To determine, if Mt-DprE2 is a direct target of 
an activated compound, in the future a fully functioning enzyme inhibition assay needed to 
be conducted. Assay reaction should include the activator enzyme, which could be Ddn-F420 
or a different enzyme, which has to be identified and then added to the assay reaction. Pull-
down methods may be beneficial as well in the search. Lastly, the identified activator either 
has to be expressed and purified in a system that uses F420, like M. smegmatis, or the co-
factor has to be added to the sample throughout purification and enzyme reaction.  
Involving the “omics” technologies in future experiments may help in narrowing down the 
group of potential targets of the hits. Transcriptome profiling for pretomanid elucidated how 
anaerobic environments propagated cell death by a different mechanism of action, through 
respiratory poisoning (Manjunatha et al., 2009). Metabolome profiling of pretomanid was 
informative regarding the diversified mechanism of action that did not resemble any 
compared clinical drugs (Baptista et al., 2018), which is advantageous in combinational drug 
therapy inhibiting multiple metabolic pathways to eliminate drug-resistant strains of M. 
tuberculosis.  
In conclusion, the high-throughput screen in search of new inhibitors of Mt-DprE2 resulted 
in compounds with a more complex mechanism of action than anticipated. Although Mt-
DprE2 may be only one of multiple targets of these new compounds, but this implies once 
more the vulnerability of the decaprenyl-phosphorylarabinose biosynthetic pathway of M. 
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tuberculosis, and encourages the study of other identified, essential enzymes involved in 
mycobacterial cell wall biosynthesis as drug targets.     
 
 





Abrahams, K.A. and Besra, G.S. (2018) Mycobacterial cell wall biosynthesis: A 
multifaceted antibiotic target. Parasitology. doi:10.1017/S0031182016002377. 
Acker, M.G. and Auld, D.S. (2014) Considerations for the design and reporting of enzyme 
assays in high-throughput screening applications. Perspectives in Science. 
doi:10.1016/j.pisc.2013.12.001. 
Adams, K.N., Takaki, K., Connolly, L.E., et al. (2011) Drug tolerance in replicating 
mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 
doi:10.1016/j.cell.2011.02.022. 
Agilent Technologies (2011) QuikChange II Site-Directed Mutagenesis Kit: Instruction 
Manual. Europe. doi:PMID:12449398. 
Alderwick, L.J., Harrison, J., Lloyd, G.S., et al. (2015) The mycobacterial cell wall—
peptidoglycan and arabinogalactan. Cold Spring Harbor Perspectives in Medicine. 
doi:10.1101/cshperspect.a021113. 
Alderwick, L.J., Radmacher, E., Seidel, M., et al. (2005) Deletion of Cg-emb in 
corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation 
of Cg-ubiA results in an Arabinan-deficient mutant with a cell wall galactan core. Journal 
of Biological Chemistry. doi:10.1074/jbc.M506339200. 
Alderwick, L.J., Seidel, M., Sahm, H., et al. (2006) Identification of a novel 
arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in 
Mycobacterium tuberculosis. Journal of Biological Chemistry. 
doi:10.1074/jbc.M600045200. 
Alnimr, A.M. (2015) Dormancy models for mycobacterium tuberculosis: A minireview. 
Brazilian Journal of Microbiology. doi:10.1590/S1517-838246320140507. 
Andersen, P. and Doherty, T.M. (2005) The success and failure of BCG - Implications for a 
novel tuberculosis vaccine. Nature Reviews Microbiology. doi:10.1038/nrmicro1211. 
Ang, C.W., Jarrad, A.M., Cooper, M.A., et al. (2017) Nitroimidazoles: Molecular Fireworks 
That Combat a Broad Spectrum of Infectious Diseases. Journal of Medicinal Chemistry. 
doi:10.1021/acs.jmedchem.7b00143. 
Angala, S.K., Belardinelli, J.M., Huc-Claustre, E., et al. (2014) The cell envelope 
glycoconjugates of Mycobacterium tuberculosis. Critical Reviews in Biochemistry and 
Molecular Biology. doi:10.3109/10409238.2014.925420. 
Arbing, M.A., Chan, S., Harris, L., et al. (2013) Heterologous expression of mycobacterial 
Esx complexes in Escherichia coli for structural studies is facilitated by the use of maltose 
binding protein fusions. PLoS ONE. doi:10.1371/journal.pone.0081753. 
Chapter 7 References 
148 
 
Baer, C.E., Rubin, E.J. and Sassetti, C.M. (2015) New insights into TB physiology suggest 
untapped therapeutic opportunities. Immunological Reviews. doi:10.1111/imr.12267. 
Ballell, L., Bates, R.H., Young, R.J., et al. (2013) Fueling Open-Source Drug Discovery: 
177 Small-Molecule Leads against Tuberculosis. ChemMedChem. 
doi:10.1002/cmdc.201200428. 
Baptista, R., Fazakerley, D.M., Beckmann, M., et al. (2018) Untargeted metabolomics 
reveals a new mode of action of pretomanid (PA-824). Scientific Reports. 
doi:10.1038/s41598-018-23110-1. 
Batt, S.M., Cacho Izquierdo, M., Castro Pichel, J., et al. (2016) Whole Cell Target 
Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis 
Decaprenylphosphoryl-β- d -ribose Oxidase. ACS Infectious Diseases. 
doi:10.1021/acsinfecdis.5b00065. 
Batt, S.M., Jabeen, T., Bhowruth, V., et al. (2012) Structural basis of inhibition of 
Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proceedings of the 
National Academy of Sciences. doi:10.1073/pnas.1205735109. 
Berg, S., Kaur, D., Jackson, M., et al. (2007) The glycosyltransferases of Mycobacterium 
tuberculosis - Roles in the synthesis of arabinogalactan, lipoarabinomannan, and other 
glycoconjugates. Glycobiology. doi:10.1093/glycob/cwm010. 
Bhutani, I., Loharch, S., Gupta, P., et al. (2015) Structure, dynamics, and interaction of 
Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, 
simulation, and electrostatic studies. PLoS ONE. doi:10.1371/journal.pone.0119771. 
Blanco-Ruano, D., Roberts, D.M., Gonzalez-Del-Rio, R., et al. (2015) Antimicrobial 
susceptibility testing for Mycobacterium sp. Methods in Molecular Biology. 
doi:10.1007/978-1-4939-2450-9_15. 
Bowes, J., Brown, A.J., Hamon, J., et al. (2012) Reducing safety-related drug attrition: The 
use of in vitro pharmacological profiling. Nature Reviews Drug Discovery. 
doi:10.1038/nrd3845. 
Brecik, M., Centárová, I., Mukherjee, R., et al. (2015) DprE1 Is a Vulnerable Tuberculosis 
Drug Target Due to Its Cell Wall Localization. ACS Chemical Biology. 
doi:10.1021/acschembio.5b00237. 
Brennan, P.J. and Nikaido, H. (1995) The Envelope of Mycobacteria. Annual Review of 
Biochemistry. doi:10.1146/annurev.bi.64.070195.000333. 
Brown, L., Wolf, J.M., Prados-Rosales, R., et al. (2015) Through the wall: Extracellular 
vesicles in Gram-positive bacteria, mycobacteria and fungi. Nature Reviews Microbiology. 
doi:10.1038/nrmicro3480. 
Callis, P.R. (2014) Binding phenomena and fluorescence quenching. II: Photophysics of 
aromatic residues and dependence of fluorescence spectra on protein conformation. Journal 
of Molecular Structure. doi:10.1016/j.molstruc.2014.04.051. 
Chapter 7 References 
149 
 
Calmette, A. (1931) Preventive Vaccination against Tuberculosis with BCG. Journal of the 
Royal Society of Medicine. doi:10.1177/003591573102401109. 
Cambier, C.J., Falkow, S. and Ramakrishnan, L. (2014) Host evasion and exploitation 
schemes of Mycobacterium tuberculosis. Cell. doi:10.1016/j.cell.2014.11.024. 
Carralot, J.-P., Ogier, A., Boese, A., et al. (2012) A novel specific edge effect correction 
method for RNA interference screenings. Bioinformatics. 
doi:10.1093/bioinformatics/btr648. 
Chan E.D. and Iseman M.D. (2008) Multidrug-resistant and extensively drug-resistant 
tuberculosis: A review. Current Opinion in Infectious Diseases. 
Chen, Y.C., Chen, L.A., Chen, S.J., et al. (2004) A modified osmotic shock for periplasmic 
release of a recombinant creatinase from Escherichia coli. Biochemical Engineering Journal. 
doi:10.1016/j.bej.2004.03.001. 
Chetty, S., Ramesh, M., Singh-Pillay, A., et al. (2017) Recent advancements in the 
development of anti-tuberculosis drugs. Bioorganic and Medicinal Chemistry Letters. 
doi:10.1016/j.bmcl.2016.11.084. 
Christophe, T., Jackson, M., Hee, K.J., et al. (2009) High content screening identifies 
decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial 
inhibitors. PLoS Pathogens. doi:10.1371/journal.ppat.1000645. 
Clinical pipeline (2018). 
Cohen-Gonsaud, M., Ducasse, S., Hoh, F., et al. (2002) Crystal structure of MabA from 
Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis. 
Journal of Molecular Biology. doi:10.1016/S0022-2836(02)00463-1. 
Cole, S.T. (2016) Inhibiting Mycobacterium tuberculosis within and without. Philosophical 
Transactions of the Royal Society B: Biological Sciences. doi:10.1098/rstb.2015.0506. 
Cole, S.T., Brosch, R., Parkhill, J., et al. (1998) Deciphering the biology of mycobacterium 
tuberculosis from the complete genome sequence. Nature. doi:10.1038/31159. 
Comas, I., Coscolla, M., Luo, T., et al. (2013) Out-of-Africa migration and Neolithic 
coexpansion of Mycobacterium tuberculosis with modern humans. Nature Genetics. 
doi:10.1038/ng.2744. 
Corning (n.d.) Microplates. 
Cox, J.A.G., Mugumbate, G., Del Peral, L.V.G., et al. (2016) Novel inhibitors of 
Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic 
screen. Scientific Reports. doi:10.1038/srep38986. 
Dartois, V. (2014) The path of anti-tuberculosis drugs: From blood to lesions to 
mycobacterial cells. Nature Reviews Microbiology. doi:10.1038/nrmicro3200. 
Davis, A.L. (2000) “A Historical Perspective on Tuberculosis and Its Control.” In Reichman, 
Chapter 7 References 
150 
 
L.B. and Hershfield, E.S. (eds.) Tuberculosis : A Comprehensive International Approach. 
DeLano, W.L. (2002) The PyMOL Molecular Graphics System. Schrödinger LLC 
wwwpymolorg. doi:citeulike-article-id:240061. 
Ehrt, S. and Rhee, K. (2013) Mycobacterium tuberculosis metabolism and host interaction: 
Mysteries and paradoxes. Current Topics in Microbiology and Immunology. doi:10.1007/82-
2012-299. 
Ekins, S., Kaneko, T., Lipinski, C.A., et al. (2010) Analysis and hit filtering of a very large 
library of compounds screened against Mycobacterium tuberculosis. Mol. BioSyst. 
doi:10.1039/C0MB00104J. 
Epps, D.E., Raub, T.J., Caiolfa, V., et al. (1999) Determination of the affinity of drugs 
toward serum albumin by measurement of the quenching of the intrinsic tryptophan 
fluorescence of the protein. The Journal of pharmacy and pharmacology. 
doi:10.1211/0022357991772079. 
Escuyer, V.E., Lety, M.A., Torrelles, J.B., et al. (2001) The Role of the embA and embB 
Gene Products in the Biosynthesis of the Terminal Hexaarabinofuranosyl Motif of 
Mycobacterium smegmatis Arabinogalactan. Journal of Biological Chemistry. 
doi:10.1074/jbc.M102272200. 
Ewing, T.A., Fraaije, M.W., Mattevi, A., et al. (2017) The VAO/PCMH flavoprotein family. 
Archives of Biochemistry and Biophysics. doi:10.1016/j.abb.2017.06.022. 
Fairchild, A.L. and Oppenheimer, G.M. (1998) Public health nihilism vs pragmatism: 
History, politics, and the control of tuberculosis. American Journal of Public Health. 
doi:10.2105/AJPH.88.7.1105. 
Fleming, A. (1929) On the antibacterial action of cultures of a penicillium, with special 
reference to their use in the isolation of B.influenzae. British journal of experimental 
pathology. doi:10.1038/146837a0. 
Fox, W., Ellard, G.A. and Mitchison, D.A. (1999) Studies on the treatment of tuberculosis 
undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with 
relevant subsequent publications. International Journal of Tuberculosis and Lung Disease. 
Franzblau, S.G., Degroote, M.A., Cho, S.H., et al. (2012) Comprehensive analysis of 
methods used for the evaluation of compounds against Mycobacterium tuberculosis. 
Tuberculosis. doi:10.1016/j.tube.2012.07.003. 
Fujiwara, M., Kawasaki, M., Hariguchi, N., et al. (2018) Mechanisms of resistance to 
delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis. 
doi:10.1016/j.tube.2017.12.006. 
Galagan, J.E. (2014) Genomic insights into tuberculosis. Nature Reviews Genetics. 
doi:10.1038/nrg3664. 
Ganbat, D., Seehase, S., Richter, E., et al. (2016) Mycobacteria infect different cell types in 
the human lung and cause species dependent cellular changes in infected cells. BMC 
Chapter 7 References 
151 
 
Pulmonary Medicine. doi:10.1186/s12890-016-0185-5. 
Gbo.com (n.d.) Greiner Bio-One Microplate Dimensions Guide. 
Getahun, H., Matteelli, A., Chaisson, R.E., et al. (2015) Latent Mycobacterium tuberculosis 
Infection. New England Journal of Medicine. doi:10.1056/NEJMra1405427. 
Gold, B., Roberts, J., Ling, Y., et al. (2015) Rapid, semiquantitative assay to discriminate 
among compounds with activity against replicating or nonreplicating Mycobacterium 
tuberculosis. Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.00803-15. 
Goldman, R.C. (2013) Why are membrane targets discovered by phenotypic screens and 
genome sequencing in Mycobacterium tuberculosis? Tuberculosis. 
doi:10.1016/j.tube.2013.09.003. 
Green, M. and Sambrook, J. (2012) Molecular cloning. doi:10.3724/SP.J.1141.2012.01075. 
Grover, S., Alderwick, L.J., Mishra, A.K., et al. (2014) Benzothiazinones mediate killing of 
Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall 
biosynthesis. Journal of Biological Chemistry. doi:10.1074/jbc.M113.522623. 
Guerin, M.E., Kaur, D., Somashekar, B.S., et al. (2009) New insights into the early steps of 
phosphatidylinositol mannoside biosynthesis in mycobacteria: PimB′ is an essential enzyme 
of Mycobacterium smegmatis. Journal of Biological Chemistry. 
doi:10.1074/jbc.M109.030593. 
Gupta, A. and Bhakta, S. (2012) An integrated surrogate model for screening of drugs against 
mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 
doi:10.1093/jac/dks056. 
Haribabu, J., Subhashree, G.R., Saranya, S., et al. (2015) Synthesis, crystal structure, and in 
vitro and in silico molecular docking of novel acyl thiourea derivatives. Journal of 
Molecular Structure. doi:10.1016/j.molstruc.2015.03.035. 
Harrison, J., Lloyd, G., Joe, M., et al. (2016) Lcp1 is a phosphotransferase responsible for 
ligating arabinogalactan to peptidoglycan in mycobacterium tuberculosis. mBio. 
doi:10.1128/mBio.00972-16. 
Haver, H.L., Chua, A., Ghode, P., et al. (2015) Mutations in Genes for the F 420 Biosynthetic 
Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in 
Spontaneous In Vitro -Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis. 
Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.00308-15. 
Hershkovitz, I., Donoghue, H.D., Minnikin, D.E., et al. (2015) Tuberculosis origin: The 
Neolithic scenario. Tuberculosis. doi:10.1016/j.tube.2015.02.021. 
Inc, N.E.B. (n.d.) pMALTM Protein Fusion and Purification System. In . Version 5. 
Iseman, M.D. (2002) Tuberculosis therapy: past, present and future. European Respiratory 
Journal. doi:10.1183/09031936.02.00309102. 
Chapter 7 References 
152 
 
Islam, M.M., Hameed, H.M.A., Mugweru, J., et al. (2017) Drug resistance mechanisms and 
novel drug targets for tuberculosis therapy. Journal of Genetics and Genomics. 
doi:10.1016/j.jgg.2016.10.002. 
Jankute, M., Byng, C. V., Alderwick, L.J., et al. (2014) Elucidation of a protein-protein 
interaction network involved in Corynebacterium glutamicum cell wall biosynthesis as 
determined by bacterial two-hybrid analysis. Glycoconjugate Journal. doi:10.1007/s10719-
014-9549-3. 
Jankute, M., Cox, J.A.G., Harrison, J., et al. (2015) Assembly of the Mycobacterial Cell 
Wall. Annual Review of Microbiology. doi:10.1146/annurev-micro-091014-104121. 
Jankute, M., Grover, S., Rana, A.K., et al. (2012) Arabinogalactan and lipoarabinomannan 
biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiology. 
doi:10.2217/fmb.11.123. 
Jeon, C.Y. and Murray, M.B. (2008) Diabetes mellitus increases the risk of active 
tuberculosis: A systematic review of 13 observational studies. PLoS Medicine. 
doi:10.1371/journal.pmed.0050152. 
Jeon, C.Y., Murray, M.B. and Baker, M.A. (2012) Managing tuberculosis in patients with 
diabetes mellitus: Why we care and what we know. Expert Review of Anti-Infective Therapy. 
doi:10.1586/eri.12.75. 
de Jesus Lopes Ribeiro, A.L., Degiacomi, G., Ewann, F., et al. (2011) Analogous 
mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium 
smegmatis. PLoS ONE. doi:10.1371/journal.pone.0026675. 
Jin, Y., Xin, Y., Zhang, W., et al. (2010) Mycobacterium tuberculosis Rv1302 and 
Mycobacterium smegmatis MSMEG___4947 have WecA function and MSMEG__4947 is 
required for the growth of M. smegmatis. FEMS Microbiology Letters. doi:10.1111/j.1574-
6968.2010.02045.x. 
Kalscheuer, R., Syson, K., Veeraraghavan, U., et al. (2010) Self-poisoning of 
Mycobacterium tuberculosis by targeting GlgE in an α-glucan pathway. Nature Chemical 
Biology. doi:10.1038/nchembio.340. 
Kaul, G., Dasgupta, A. and Chopra, S. (2018) Delpazolid. Oxazolidinone antibiotic, 
Treatment of tuberculosis. Drugs of the Future, 43 (4): 233. 
doi:10.1358/dof.2018.043.04.2795153. 
Kaur, D., Guerin, M.E., Škovierová, H., et al. (2009) Chapter 2 Biogenesis of the Cell Wall 
and Other Glycoconjugates of Mycobacterium tuberculosis. Advances in Applied 
Microbiology. doi:10.1016/S0065-2164(09)69002-X. 
Kazda, J., Falkinham, J.O., Pavlik, I., et al. (2009) The ecology of mycobacteria: Impact on 
animal’s and human’s health. doi:10.1007/978-1-4020-9413-2. 
Kim, K.J., Chen, V. and Fane, A.G. (1993) Some factors determining protein aggregation 
during ultrafiltration. Biotechnology and Bioengineering. doi:10.1002/bit.260420216. 
Chapter 7 References 
153 
 
Kim, S., Thiessen, P.A., Bolton, E.E., et al. (2016) PubChem substance and compound 
databases. Nucleic Acids Research. doi:10.1093/nar/gkv951. 
Koch, R. (1884) Die Aetiologie der Tuberkulose. Mittheilungen aus dem Kaiserlichen 
Gesundheitsamte. doi:10.1007/BF01765224. 
Koch, R. (1890) I. Weitere Mittheilungen über ein Heilmittel gegen Tuberculose. Deutsche 
Medizinische Wochenschrift. doi:10.1055/s-0029-1207546. 
Kolly, G.S., Boldrin, F., Sala, C., et al. (2014) Assessing the essentiality of the decaprenyl-
phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional 
mutants. Molecular Microbiology. doi:10.1111/mmi.12546. 
Kolly, G.S., Mukherjee, R., Kilacskovï¿½, E., et al. (2015) GtrA protein Rv3789 is required 
for arabinosylation of arabinogalactan in Mycobacterium tuberculosis. Journal of 
Bacteriology. doi:10.1128/JB.00628-15. 
Kramnik, I. and Beamer, G. (2016) Mouse models of human TB pathology: roles in the 
analysis of necrosis and the development of host-directed therapies. Seminars in 
Immunopathology. doi:10.1007/s00281-015-0538-9. 
Larrouy-Maumus, G., Skovierova, H., Dhouib, R., et al. (2012) A small multidrug 
resistance-like transporter involved in the arabinosylation of arabinogalactan and 
lipoarabinomannan in mycobacteria. J Biol Chem. doi:10.1074/jbc.M112.400986. 
Lebendiker, M., Maes, M. and Friedler, A. (2014) “A screening methodology for purifying 
proteins with aggregation problems.” In Insoluble Proteins: Methods and Protocols. 
doi:10.1007/978-1-4939-2205-5_14. 
Lee, R.E., Hurdle, J.G., Liu, J., et al. (2014) Spectinamides: A new class of semisynthetic 
antituberculosis agents that overcome native drug efflux. Nature Medicine. 
doi:10.1038/nm.3458. 
Lee, Y.-J., Han, S.K., Park, J.H., et al. (2018) The effect of metformin on culture conversion 
in tuberculosis patients with diabetes  mellitus. The Korean journal of internal medicine, 33 
(5): 933–940. doi:10.3904/kjim.2017.249. 
Leeds, J.A., Sachdeva, M., Mullin, S., et al. (2014) In vitro selection, via serial passage, of 
clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. 
Journal of Antimicrobial Chemotherapy. doi:10.1093/jac/dkt302. 
Lehmann, J. (1946) PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF 
TUBERCULOSIS. The Lancet. doi:10.1016/S0140-6736(46)91185-3. 
Levi, V. and González Flecha, F.L. (2002) Reversible fast-dimerization of bovine serum 
albumin detected by fluorescence resonance energy transfer. Biochimica et Biophysica Acta 
(BBA) - Proteins and Proteomics, 1599 (1–2): 141–148. doi:10.1016/S1570-
9639(02)00414-4. 
Li, W., Upadhyay, A., Fontes, F.L., et al. (2014) Novel insights into the mechanism of 
inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. 
Chapter 7 References 
154 
 
Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.03229-14. 
Liu, Y., Fu, X., Shen, J., et al. (2004) Periplasmic proteins of Escherichia coli are highly 
resistant to aggregation: Reappraisal for roles of molecular chaperones in periplasm. 
Biochemical and Biophysical Research Communications. doi:10.1016/j.bbrc.2004.02.125. 
Makarov, V., Lechartier, B., Zhang, M., et al. (2014) Towards a new combination therapy 
for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine. 
doi:10.1002/emmm.201303575. 
Makarov, V., Manina, G., Mikusova, K., et al. (2009) Benzothiazinones Kill Mycobacterium 
tuberculosis by blocking Arabinan synthesis. Science. doi:10.1126/science.1171583. 
Manina, G., Bellinzoni, M., Pasca, M.R., et al. (2010) Biological and structural 
characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in 
benzothiazinone resistance. Molecular Microbiology. doi:10.1111/j.1365-
2958.2010.07277.x. 
Manjunatha, U., Boshoff, H.I.M. and Barry, C.E. (2009) The mechanism of action of PA-
824: Novel insights from transcriptional profiling. Communicative & integrative biology. 
doi:10.4161/cib.2.3.7926. 
Marcinkeviciene, J.A., Magliozzo, R.S. and Blanchard, J.S. (1995) Purification and 
characterization of the Mycobacterium smegmatis catalase-peroxidase involved in isoniazid 
activation. J. Biol. Chem. doi:10.1074/jbc.270.38.22290. 
De Marco, A., Vigh, L., Diamant, S., et al. (2005) Native folding of aggregation-prone 
recombinant proteins in Escherichia coli by osmolytes, plasmid- or benzyl alcohol-
overexpressed molecular chaperones. Cell Stress and Chaperones. doi:10.1379/CSC-
139R.1. 
Marx, V. (2014) Pouring over liquid handling. Nature Methods. doi:10.1038/nmeth.2785. 
McNeil, M., Daffe, M. and Brennan, P.J. (1990) Evidence for the nature of the link between 
the arabinogalactan and peptidoglycan of mycobacterial cell walls. Journal of Biological 
Chemistry. 
Meadow, P.M., Anderson, J.S. and Strominger, J.L. (1964) Enzymatic polymerization of 
UDP-acetylmuramyl-L-ala·L-glu-L-lys-D-ala·D-alaand UDP-acetylglucosamine by a 
particulate enzyme from Staphylococcus aureus and its inhibition by antibiotics. 
Biochemical and Biophysical Research Communications. doi:10.1016/S0006-
291X(64)80014-0. 
Mikušová, K., Beláňová, M., Korduláková, J., et al. (2006) Identification of a novel 
galactosyl transferase involved in biosynthesis of the mycobacterial cell wall. Journal of 
Bacteriology. doi:10.1128/JB.00489-06. 
Mikušová, K., Huang, H., Yagi, T., et al. (2005) Decaprenylphosphoryl arabinofuranose, the 
donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-
step epimerization of decaprenylphosphoryl ribose. Journal of Bacteriology. 
doi:10.1128/JB.187.23.8020-8025.2005. 
Chapter 7 References 
155 
 
Mills, J.A., Motichka, K., Jucker, M., et al. (2004) Inactivation of the mycobacterial 
rhamnosyltransferase, which is needed for the formation of the arabinogalactan-
peptidoglycan linker, leads to irreversible loss of viability. Journal of Biological Chemistry. 
doi:10.1074/jbc.M407782200. 
Minnikin, D.E., Dobson, G. and Parlett, J.H. (1985) “Extraction and Chromatographic 
Analysis of Characteristic Mycobacterial Lipids.” In Habermehl, K.-O. (ed.). Rapid Methods 
and Automation in Microbiology and Immunology. Berlin, Heidelberg, 1985. Springer 
Berlin Heidelberg. pp. 274–282. 
Minnikin, D.E., Lee, O.Y. and Wu, H.H.T. (2015) “Pathophysiological Implications of Cell 
Envelope Structure in Mycobacterium tuberculosis and Related Taxa.” In Tuberculosis - 
Expanding Knowledge. doi:dx.doi.org/10.5772/59585. 
Mitchison, D. and Davies, G. (2012) The chemotherapy of tuberculosis: past, present and 
future. The International Journal of Tuberculosis and Lung Disease. 
doi:10.5588/ijtld.12.0083.The. 
Monin, L. and Khader, S.A. (2014) Chemokines in tuberculosis: The good, the bad and the 
ugly. Seminars in Immunology. doi:10.1016/j.smim.2014.09.004. 
Muramatsu, Y., Ishii, M.M. and Inukai, M. (2003) Studies on novel bacterial translocase I 
inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G. J Antibiot 
(Tokyo). 
Murray, J.F., Schraufnagel, D.E. and Hopewell, P.C. (2015) Treatment of tuberculosis: A 
historical perspective. Annals of the American Thoracic Society. 
doi:10.1513/AnnalsATS.201509-632PS. 
Myllymäki, H., Niskanen, M., Oksanen, K.E., et al. (2015) Animal models in tuberculosis 
research – where is the beef? Expert Opinion on Drug Discovery. 
doi:10.1517/17460441.2015.1049529. 
Neelsen, F.K.A. (1892) Grundriss der pathologisch-anatomischen Technik fur praktische 
Arzte und Studierende. 
Neres, J., Hartkoorn, R.C., Chiarelli, L.R., et al. (2015) 2-carboxyquinoxalines kill 
mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chemical 
Biology. doi:10.1021/cb5007163. 
Neres, J., Pojer, F., Molteni, E., et al. (2012) Structural basis for benzothiazinone-mediated 
killing of Mycobacterium tuberculosis. Science Translational Medicine. 
doi:10.1126/scitranslmed.3004395. 
Ojha, A.K., Baughn, A.D., Sambandan, D., et al. (2008) Growth of Mycobacterium 
tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. 
Molecular Microbiology. doi:10.1111/j.1365-2958.2008.06274.x. 
OligoAnalyzer 3.1 (n.d.). 
Ortalo-Magne, A., Dupont, M.A., Lemassu, A., et al. (1995) Molecular composition of the 
Chapter 7 References 
156 
 
outermost capsular material of the tubercle bacillus. Microbiology. doi:10.1099/13500872-
141-7-1609. 
Palucci, I. and Delogu, G. (2018) Host Directed Therapies for Tuberculosis: Futures 
Strategies for an Ancient Disease. Chemotherapy. doi:10.1159/000490478. 
Parikka, M., Hammarén, M.M., Harjula, S.K.E., et al. (2012) Mycobacterium marinum 
Causes a Latent Infection that Can Be Reactivated by Gamma Irradiation in Adult Zebrafish. 
PLoS Pathogens. doi:10.1371/journal.ppat.1002944. 
Parish, T. and Roberts, D.M. (2015) Mycobacteria protocols: Third edition. 
doi:10.1007/978-1-4939-2450-9. 
Peroutka Iii, R.J., Orcutt, S.J., Strickler, J.E., et al. (2011) SUMO fusion technology for 
enhanced protein expression and purification in prokaryotes and eukaryotes. Methods in 
molecular biology (Clifton, N.J.). doi:10.1007/978-1-61737-967-3_2. 
Pethe, K., Bifani, P., Jang, J., et al. (2013) Discovery of Q203, a potent clinical candidate 
for the treatment of tuberculosis. Nature Medicine. doi:10.1038/nm.3262. 
Piton, J., Foo, C.S.Y. and Cole, S.T. (2017) Structural studies of Mycobacterium 
tuberculosis DprE1 interacting with its inhibitors. Drug Discovery Today. 
doi:10.1016/j.drudis.2016.09.014. 
Pore, V.S., Divse, J.M., Charolkar, C.R., et al. (2015) Design and synthesis of 11α-
substituted bile acid derivatives as potential anti-tuberculosis agents. 
doi:10.1016/j.bmcl.2015.08.006. 
Porter, C.M. and Miller, B.G. (2012) Cooperativity in monomeric enzymes with single 
ligand-binding sites. Bioorganic Chemistry. doi:10.1016/j.bioorg.2011.11.001. 
PrimerX (n.d.). 
Primm, T.P. and Franzblau, S.G. (2007) Recent Advances in Methodologies for the 
Discovery of Antimycobacterial Drugs. Current Bioactive Compounds. 
doi:10.2174/157340707781695550. 
Protein Data Bank (n.d.). 
ProtParam (n.d.). 
Qiagen and Qiagen (2005) QIAGEN® Plasmid Purification Handbook. Plasmid. 
Quémard, A. (2016) New Insights into the Mycolate-Containing Compound Biosynthesis 
and Transport in Mycobacteria. Trends in Microbiology. doi:10.1016/j.tim.2016.04.009. 
Rana, A.K., Singh, A., Gurcha, S.S., et al. (2012) Ppm1-Encoded Polyprenyl 
Monophosphomannose Synthase Activity Is Essential for Lipoglycan Synthesis and 
Survival in Mycobacteria. PLoS ONE. doi:10.1371/journal.pone.0048211. 
Resh, M.D. (2015) “Lipid Modification of Proteins.” In Biochemistry of Lipids, Lipoproteins 
Chapter 7 References 
157 
 
and Membranes: Sixth Edition. doi:10.1016/B978-0-444-63438-2.00013-4. 
Sala, C. and Hartkoorn, R.C. (2011) Tuberculosis drugs: new candidates and how to find 
more. Future Microbiol. doi:10.2217/fmb.11.46. 
Salgame, P., Geadas, C., Collins, L., et al. (2015) Latent tuberculosis infection - Revisiting 
and revising concepts. Tuberculosis. doi:10.1016/j.tube.2015.04.003. 
Sambandan, D., Dao, D.N., Weinrick, B.C., et al. (2013) Keto-Mycolic acid-dependent 
pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis. mBio. 
doi:10.1128/mBio.00222-13. 
Scherman, M.S., Winans, K.A., Stern, R.J., et al. (2003) Drug targeting Mycobacterium 
tuberculosis cell wall synthesis: Development of a microtiter plate-based screen for UDP-
galactopyranose mutase and identification of an inhibitor from a uridine-based library. 
Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.47.1.378-382.2003. 
Sharma, S., Gelman, E., Narayan, C., et al. (2014) Simple and rapid method to determine 
antimycobacterial potency of compounds by using autoluminescent mycobacterium 
tuberculosis. Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.03205-14. 
Shirude, P.S., Shandil, R.K., Manjunatha, M.R., et al. (2014) Lead optimization of 1,4-
azaindoles as antimycobacterial agents. Journal of Medicinal Chemistry. 
doi:10.1021/jm500571f. 
Smith, N.H., Hewinson, R.G., Kremer, K., et al. (2009) Myths and misconceptions: The 
origin and evolution of Mycobacterium tuberculosis. Nature Reviews Microbiology. 
doi:10.1038/nrmicro2165. 
So, A.D., Gupta, N., Brahmachari, S.K., et al. (2011) “Towards new business models for 
R&D for novel antibiotics.” In Drug Resistance Updates. 2011. 
doi:10.1016/j.drup.2011.01.006. 
Soetaert, K., Rens, C., Wang, X.M., et al. (2015) Increased vancomycin susceptibility in 
mycobacteria: A new approach to identify synergistic activity against multidrug-resistant 
mycobacteria. Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.04856-14. 
Sorrell, F.J., Greenwood, G.K., Birchall, K., et al. (2010) Development of a differential 
scanning fluorimetry based high throughput screening assay for the discovery of affinity 
binders against an anthrax protein. Journal of Pharmaceutical and Biomedical Analysis. 
doi:10.1016/j.jpba.2010.02.024. 
Sridhar, S., Dash, P. and Guruprasad, K. (2016) Comparative analyses of the proteins from 
Mycobacterium tuberculosis and human genomes: Identification of potential tuberculosis 
drug targets. Gene. doi:10.1016/j.gene.2015.12.054. 
Stover, C.K., De La Cruz, V.F., Fuerst, T.R., et al. (1991) New use of BCG for recombinant 
vaccines. Nature. doi:10.1038/351456a0. 
Stover, C.K., Warrener, P., VanDevanter, D.R., et al. (2000) A small-molecule 
nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 




Taneja, N.K. and Tyagi, J.S. (2007) Resazurin reduction assays for screening of anti-
tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, 
Mycobacterium bovis BCG and Mycobacterium smegmatis. Journal of Antimicrobial 
Chemotherapy. doi:10.1093/jac/dkm207. 
Tangallapally, R., Yendapally, R., Daniels, A., et al. (2007) Nitrofurans as Novel Anti-
tuberculosis Agents: Identification, Development and Evaluation. Current Topics in 
Medicinal Chemistry. doi:10.2174/156802607780059772. 
TBfacts.org (2018) Bangladesh MDR TB treatment regimen – Francophone Study, 
STREAM. 
Telenti, A., Philipp, W.J., Sreevatsan, S., et al. (1997) The emb operon, a gene cluster of 
Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine. 
doi:10.1038/nm0597-567. 
Tiemersma, E.W., van der Werf, M.J., Borgdorff, M.W., et al. (2011) Natural history of 
tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative 
patients: A systematic review. PLoS ONE. doi:10.1371/journal.pone.0017601. 
Trefzer, C., Škovierová, H., Buroni, S., et al. (2012) Benzothiazinones are suicide inhibitors 
of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1. Journal of the 
American Chemical Society. doi:10.1021/ja211042r. 
UniProt Consortium, T. (2018) UniProt: the universal protein knowledgebase. Nucleic Acids 
Research. doi:10.1093/nar/gky092. 
Villemin, J.A. (2015) On the virulence and specificity of tuberculosis. The International 
Journal of Tuberculosis and Lung Disease, 19 (3): 256–266. doi:10.5588/ijtld.06.0636-v. 
Wang, C.K., Weeratunga, S.K., Pacheco, C.M., et al. (2012) DMAN: A java tool for analysis 
of multi-well differential scanning fluorimetry experiments. Bioinformatics. 
doi:10.1093/bioinformatics/btr664. 
Wang, F., Sambandan, D., Halder, R., et al. (2013) Identification of a small molecule with 
activity against drug-resistant and persistent tuberculosis. Proceedings of the National 
Academy of Sciences. doi:10.1073/pnas.1309171110. 
Warrier, T., Tropis, M., Werngren, J., et al. (2012) Antigen 85C inhibition restricts 
Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. 
Antimicrobial Agents and Chemotherapy. doi:10.1128/AAC.05742-11. 
Van De Weert, M. and Stella, L. (2011) Fluorescence quenching and ligand binding: A 
critical discussion of a popular methodology. Journal of Molecular Structure. 
doi:10.1016/j.molstruc.2011.05.023. 
Weston, A., Stern, R.J., Lee, R.E., et al. (1997) Biosynthetic origin of mycobacterial cell 
wall galactofuranosyl residues. Tubercle and Lung Disease. doi:10.1016/S0962-
8479(98)80005-1. 
Chapter 7 References 
159 
 
WHO (2010) “Treatment of tuberculosis: guidelines.” In 4Th Edition. 
doi:10.1164/rccm.201012-1949OC. 
WHO (2016) WHO treatment guidelines for drug-resistant tuberculosis : 2016 update. Who. 
doi:WHO/HTM/TB/2016.04. 
WHO (2017) Global Tuberculosis Report 2017. doi:10.1001/jama.2014.11450. 
Wolucka, B.A., McNeil, M.R., De Hoffmann, E., et al. (1994) Recognition of the lipid 
intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of 
action of ethambutol on mycobacteria. Journal of Biological Chemistry. 
Yano, T., Kassovska-Bratinova, S., Teh, J.S., et al. (2011) Reduction of Clofazimine by 
Mycobacterial Type 2 NADH:Quinone Oxidoreductase. Journal of Biological Chemistry. 
doi:10.1074/jbc.M110.200501. 
Yempalla, K.R., Munagala, G., Singh, S., et al. (2015) Nitrofuranyl Methyl Piperazines as 
New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. ACS 
Medicinal Chemistry Letters. doi:10.1021/acsmedchemlett.5b00141. 
Zhang, J., Chung, T. and Oldenburg, K. (1999) A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular 
screening. doi:10.1177/108705719900400206. 
Zhang, Y. and Mitchison, D. (2003) The curious characteristics of pyrazinamide: A review. 
International Journal of Tuberculosis and Lung Disease. doi:10.5588/ijtld.16.0360. 
 
  





7.1 DNA oligonucleotides 















































Chapter 7 References 
161 
 























Chapter 7 References 
162 
 
7.2 Protein sequences 
7.2.1 6xHis-Mt-DprE1 
His-tag, DprE1 uniprot ID: P9WJF1. Molecular weight: 51 775.84 Da fusion protein. 











MBP-DprE2. Features:  Xa protease recognition site, periplasmic translocation signal. 
Molecular weight: 72 350.73 Da fusion protein, MBP-tag is 40 208.69 Da, DprE2 is 


















6xHis-SUMO-DprE2. Molecular weight: 40 766 Da fusion protein, DprE2 is 27 338 Da. 








7.2.4 Tag-free Mt-DprE2 
Molecular weight: 27 469 Da. Theoretical pI: 7.78. 
MVLDAVGNPQTVLLLGGTSEIGLAICERYLHNSAARIVLACLPDDPRREDAAAAM
KQAGARSVELIDFDALDTDSHPKMIEAAFSGGDVDVAIVAFGLLGDAEELWQNQR
KAVQIAEINYTAAVSVGVLLAEKMRAQGFGQIIAMSSAAGERVRRANFVYGSTKA
GLDGFYLGLSEALREYGVRVLVIRPGQVRTRMSAHLKEAPLTVDKEYVANLAVT
ASAKGKELVWAPAAFRYVMMVLRHIPRSIFRKLPI 
